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1. Recent Advances of the Povarov Reaction 
 
1.1 Introduction 
One of the major challenges in modern organic synthesis is to develop highly selective 
methodologies affording efficient and rapid access to biologically important molecules or the 
scaffolds which are found as the privileged structure in natural product and pharmaceutical 
developments. In this regard, the Povarov reaction, which was developed in 1960s by the 
Russian Scientist L. S. Povarov, can be considered as one of the most powerful strategies for 
synthesizing a certain class of ubiquitous nitrogen heterocycles.  
Since the pioneering work of Povarov and co-workers,1–6 significant research interest was 
attracted and enormous efforts have been implicated in this particular research area to obtain 
more efficient synthetic routes to directly access tetrahydroquinolines and other interesting 
heterocyclic scaffolds employing Povarov reaction as the key step. There are a lot of publications 
coming out each year on this particular topic, providing detail mechanistic insights and 
discovering novel synthetic applications; therefore, it is justified to summarize the recent 
advances of the Povarov reaction in a definite time interval. The field was previously reviewed 
by Kouznetsov,7 covering the literature up to mid-2008, which mainly focused on the various 
applications of Povarov reaction, especially, the multi-component coupling strategy allowing a 
straightforward access to various heterocycles, giving a special attention to environment-friendly 
methodologies. In 2011, a general review was published on the chemistry of tetrahydroquinoline 
synthesis, in which some space was also devoted to the Povarov reaction as a tool for 
synthesizing tetrahydroquinolines and covered the literature up to mid-2010.8 After this period 
there have been much more advances carried out concerning especially the mechanistic aspects 
as well as the asymmetric variations of the Povarov reaction.  
In this present review, we have made an effort to briefly include the critical advances of the 
Povarov reaction from 2008 to 2012, particularly in light of the detail mechanistic studies, 
asymmetric variations using various organo-catalysts, giving a special emphasis on the 
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utilization of Povarov reaction as a key step for creating more complex and diversified molecules 
by means of choosing appropriate starting materials having multiple functionalities. 
1.2 Historical Background of the Povarov reaction 
The Povarov reaction was originally reported in 1963 as a one-pot reaction of arylaldimines 3, 
derived from condensation of aromatic aldehydes 1 and aniline 2a with electron-rich olefins, I 
particular, ethyl vinyl ether 4a or ethyl vinyl sulfide 4b in presence of BF3/OEt2 as a Lewis acid 
(LA) catalyst to obtain 2,4-disubstituted tetrahydroquinolines 5a/5b which were further oxidized 
to the corresponding quinolines 6a/6b (Scheme 1.1). The reaction can be considered as a 
powerful tool for generating three contiguous stereogenic-centers in a single step with an 
excellent regioselectivity. After almost three decades of Povarov’s original work, the reaction 
was upgraded into a one-pot, multicomponent reaction (MCR), in which the aldimine was 
generated in situ.9 
Scheme 1.1. Original Protocol of Lewis-Acid Catalyzed One-Pot Povarov Reaction 
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The Povarov reaction can be catalyzed by a variety of reagents, including LAs, Brønsted acids 
(BAs) and various metal salts. In recent years, catalytic multicomponent version of inter- and 
intramolecular Povarov reactions have emerged as potential tools in both diversity- and target-
oriented syntheses due to the time and step economic aspects. Asymmetric variants of the 
reaction have also been achieved with a great success, leading to the synthesis of 
enantiomerically pure tetrahydroquinolines in presence of chiral catalysts. Moreover, the reaction 
offers a huge variation in substrate selection with respect to the dienes and more importantly, 
various nucleophilic olefins having multiple functionalities as the dienophilic components. Now-
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a-days, syntheses of complex heterocyclic scaffolds, utilizing Povarov reaction as the key step 
have become an attractive alternative route towards the creation of novel heterocycles. 
1.3 Mechanistic Overview 
The mechanism of Povarov reaction has been debated for a long time; historically, it was 
proposed as a concerted, formal [4π+2π]-type inverse electron-demand aza-Diels-Alder reaction. 
Although, theoretical calculations show that the reaction can proceed through both concerted and 
stepwise pathways depending on the nature of the solvent10 and dienophiles used.11 When, the 
dienophile is polarized in nature, the reaction is assumed to take place in a stepwise fashion12 
through the initial formation of the imine 3 by condensation of aldehyde and aniline. Once the 
imine is activated by LA catalyst, it can readily undergo nucleophilic attack by the electron-rich 
olefin 7 via the well established Mannich-type reaction to give a cationic intermediate 8. Once 
the intermediate 8 is formed, it can be trapped by the aromatic ring of the aniline moiety via an 
intramolecular electrophilic substitution to produce the tetrahydroquinoline derivative 10 
(Scheme 1.2)13,14  
Scheme 1.2. Mechanistic Aspects of the Povarov Reaction: Stepwise Mechanism Leads over 
the Concerted One 
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Moreover, this mechanistic assumption could open up the possibility to trap the reactive cationic 
intermediate 8 by employing an external nucleophile and thus the final ring-closure step could be 
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terminated affording an acyclic compound rather than the usual cyclic tetrahydroquinoline 
scaffold. In this context, there are several recent evidences which could well demonstrate the 
reliability of this stepwise mechanism taking into account the feasible trapping of the ionic 
intermediate 8, enabling the possibility of a four component reaction,12,15a e.g., Lavilla and co-
workers elegantly exploited a LA-catalyzed four-component Povarov reaction of Aldehydes 11, 
amines 12, cyclic enol ethers 13 and alcohols 14, where the alcohol acts as an external 
nucleophile or terminator of the Povarov process, trapping the final oxocarbonium intermediate 
15, leading to the formation of a new compound 16 (Scheme 1.3).15a  
Scheme 1.3. Four-Component Povarov Reaction Using Alcohols 14 as the Terminators 
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More recently, Masson and Zhu have reported a detailed mechanistic study on three component 
Povarov reaction, where they have speculated, depending on the polarized nature of the 
enecarbamate double bond of the dienophile 18, a stepwise mechanism could be initiated by the 
Mannich-type reaction. They were able to trap the N-acyliminium intermediate generated after 
the Mannich-type reaction by an alcohol as an external nucleophile. Utilization of benzaldehyde 
17a and 4-methoxyaniline as the aldehyde and amine components respectively in presence of the 
dienophile 18 and Povarov terminator, EtOH (17 equivalent) afforded the Mannich adduct 19 in 
21% yield, together with the tetrahydroquinoline 20 (50%) as the major product. With electron-
deficient anilines such as 4-nitroaniline, they could only isolate the Mannich adduct 19 in 72% 
yield, at the expense of the Povarov product 20 (Scheme 1.4). These results provided direct 
evidence in support of a stepwise mechanism for catalytic Povarov reaction.12 In addition, Alves 
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and co-workers showed that the cycloaddition of glyoxylate imines 21 with trans-1,3-dienes 
produce only a specific diastereomer of the tetrahydroquinoline derivatives 25 with an excellent 
Scheme 1.4. Interrupted Povarov Reaction Leading to Mannich-Type Product 19 as the 
Major product 
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(10 mol%)
2
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CH2Cl2, 0 oC N
H
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R1 = NO2, 19 = 72%, 20 = 0%
R1 = OMe, 19 = 21%, 20 = 50%
18
19 20
 
regio- and stereoselectivity instead of a mixture of 23 and 24 which is also in accord with a 
stepwise reaction mechanism (Scheme 1.5).14d  
Scheme 1.5. Trans-Dienes in Povarov Reaction Affording a Single Diastereomer 25 Instead 
of 23 and 24 
LA
COOEt
N H
21 22
R1
HN
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R2
R2 R2 R2
23
 
However, there are some experimental evidences indeed, which support the concerted 
mechanism too,16 e.g., Lucchini and co-workers showed that depending on the solvent polarity 
the reaction of tetrahydrofuran and electron-poor imines in presence of BF3-Et2O, can proceed 
either through a concerted or a stepwise mechanism; as in general, an aprotic solvent allows the 
formation of a transition state and hence allows a concerted mechanism, while a protic solvent 
stabilizes an ionic intermediate and hence the reaction can proceed through a stepwise pathway.10 
In spite of the presence of a few evidences in support of concerted mechanism, exhaustive recent 
investigations strongly support only a stepwise mechanism for the Povarov-type reaction. 
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1.4 Various Catalysts Used for Povarov Reaction 
1.4.1 Lewis Acid (LA)-Catalyzed Povarov Reaction 
Since the pioneering work of Povarov, who used BF3/Et2O as the catalyst, several other LAs 
have been used for the Povarov reaction till to date. However, many of them are not fully 
satisfactory with regard to operational simplicity, isolated yields and restricted to mainly specific 
substrates. In 1967, Hagihara showed that quinoline derivatives could be synthesized utilizing 
dicobalt octacarbonyl as the catalyst instead of BF3/Et2O.17 Remarkably, Kobayashi and co-
workers introduced lanthanide(III)  triflates as excellent catalysts for three-component Povarov 
reaction between N-aryl aldimines and alkenes,18 potentially replacing the stoichiometric use of 
other LAs. Due to the smaller ionic radii of lanthanide(III) triflates they are more effective 
towards Lewis bases such as imines. Moreover, the formation of the reactive adduct (LA-imine) 
between lanthanide(III) and Lewis base becomes more facile due to strong electron withdrawing 
power of triflate counter anions. However, Xia and Lu recently showed that molecular iodine can 
also be used as an inexpensive and readily available catalyst for the one-pot Povarov reaction.19 
This might be considered as a pivotal advancement from the point of view of toxic-metal free 
catalyst developement. Muthusubramanian and co-workers reported an efficient, one-pot 
synthesis of a range of azaindole substituted quinoline derivatives 28 by Povarov reaction in 
good yields and diastereoselectivity using inexpensive and readily available SnCl2 as a Lewis 
acid catalyst (Scheme 1.6).20 The reaction has been found to be chemo- and regioselective with 
good atom economy. 
Scheme 1.6. SnCl2-Ctalyzed Three-Component Povarov Reaction 
N N
O
SO2Ph
NH2
R1
R2C6H4 H
SnCl2, CH3CN,
80 oC, 12 h N N
N
R2
R1
SO2Ph26 2
27
28  
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Use of TMSCl (20 mol%)21 and commercially available, inexpensive phosphomolybdic acid 
(PMA, H3PMo12O40)22 as catalysts also provide an access to various furo- or pyranoquinolines 
with aliphatic, furyl- or thionyl-moieties in excellent yields. Masaki and coworkers developed a 
polymer-supported π-acid (poly-DCKA-1) catalyst for the two- and three-component imino DA 
reactions to give pyrano[3,2-c]quinolines at room temperature in water.23 Thus use of water as a 
solvent from the point of view of green chemistry shows promising development for certain 
substrates and further development of solid-supported catalyst brings possibility of easy catalyst 
handing and reuses. Recently, Menéndez et al. reported CAN-catalyzed reaction of 3,5-
disubstituted anilines, vinyl ethers and aromatic aldehydes leading to  trans-2-aryl-4-
arylaminotetrahydroquinolines.24 In many cases, Povarov reaction is followed by an oxidation 
step to form the corresponding quinoline derivatives. This important oxidation step involves a 
formal removal of four hydrogen atoms from the tetrahydroquinoline intermediate. In general, 
harsh conditions or large amounts (e.g., MnO2) of expensive (e.g., Pd-based) or toxic oxidants 
(e.g., DDQ, nitrobenzene, etc.) are required to successfully furnish this conversion. As a result, 
introduction of more efficient and environmentally benign oxidants for this transformation is 
highly desirable. In this context, synthesis of quinolines 34 from N-alkyl anilines 29 and olefins 
30 via a one-pot Povarov reaction followed by oxidation reaction using a TEMPO salt (T+BF4-) 
(31) as a highly efficient, mild and nontoxic oxidant is important (Scheme 1.7).25  
Scheme 1.7. TEMPO Oxonium Salt (31)-Mediated Povarov Reaction 
H
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H
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This reaction can also be considered as an alternative method for preparing N-aryl iminium 
cation 32 via TEMPO-mediated dehydrogenative coupling reaction. The main advantage of 
using this catalytic system is its moisture tolerance and hence the reaction can be performed 
under aerobic conditions maintaining the same level of efficiency.  
1.4.2 Brønsted Acid-Catalyzed Povarov Reaction 
In addition to LAs, several Brønsted acids are also known to catalyze the Povarov reactions, e.g.; 
the three component reaction of aromatic aldehydes 17, anilines 2 and enynes 35 to synthesize 4-
substituted quinolines 36, reported by Zhao and Liu is noteworthy (Scheme 1.8).26 Legros et al. 
reported the use of fluorinated alcohols e.g. trifluoroethanol, TFE or hexafluoroisopropanol 
(HFIP) as both solvent as well as catalyst for three-component Povarov reaction.27  
Scheme 1.8. Brønsted Acid-Catalyzed Three Component Povarov Reaction: Application of 
Ethynyl Ketene-S,S-Acetals as Highly Electron-Rich Dienophiles 
NH2
CH2Cl2
rt, 5 min
57-72%
CF3SO3H N
R1
R2
R2R1
O
CO2Et
SS
CO2Et
S
S
17 2 35 36
 
1.4.3 Base-Catalyzed Povarov Reaction 
Although, the Povarov cycloaddition reaction is well-established as an acid-catalyzed 
cycloaddition reaction of electron-rich dienophiles and N-arylimines, Sun et al. reported an 
unprecedented microwave (MW)-assisted base-catalyzed Povarov reaction of electron-deficient 
alkylpropiolates 39 followed by a [1,3]sigmatropic rearrangement to produce a small library of 
dihydropyrimido[1,2-a]benzimidazole 41 (Scheme 1.9).28a  
 
 
Chapter	1																																													Recent	Advances	of	the	Povarov	Reaction	 						2012	
 
9 
 
Scheme 1.9. Syntheses of Dihydropyrimidobenzimidazoles 41 via Base-Catalyzed Povarov 
Reaction 
N
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N
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1.4.4 Green Catalysts Used for Povarov Reaction 
As we discussed, many of the previous methods utilizes metals or other undesired chemical 
species into the “environment” during the course of the reaction. Now-a-days, the concept of 
green chemistry29 encourages chemists to develop new synthetic method using a safer and non-
waste-producing alternative catalyst. Solid acid catalysts are not only environment-friendly but 
also have many economic advantages.30 Acidic cation-exchange resins have been used as solid 
acid catalysts in many fields,31 including the Povarov reaction, e.g.; in 2003, Li et al. reported  an 
acidic cation-exchange resin (AG® 50W-X2)-catalyzed Povarov reaction of aromatic amines 
and 3,4-dihydro-2H-pyran for the synthesis of tetrahydroquinoline derivatives in water. In all the 
cases they obtained a mixture of cis- and trans-diastereomers but, unlike the reactions using LA 
catalysts, which produce heavy metal or acid pollution, the use of the solid, AG®50W-X2 resin 
as the catalyst gave rise to a cleaner recyclable procedure.32 Another interesting approach in this 
regard is the utilization of natural biopolymers, e.g.; cellulose and starch as solid supported 
catalysts from renewable resources. The unique biodegradability and cost-effectiveness 
accomplish these materials as effective catalysts when converted to their sulfonic acid deriva- 
tives. In this regard, utilization of cellulose sulphuric acid as an efficient eco-friendly, reusable 
catalyst for the diversity oriented synthesis of anti-tubercular tetrahydroquinolines via Povarov 
reaction presents an alternative environment-friendly procedure.33 The products were obtained as 
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a mixture of cis- and trans-isomers with a preference to the trans-isomer 43, but interestingly, 
when the reaction was carried out in aqueous medium the cis-isomer 44 became the major 
product (Scheme 1.10). 
Scheme 1.10. Sulfonated Cellulose-Catalyzed Multi-Component Povarov Reaction 
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1.4.5 Use of Heterogeneous Catalysis for the Povarov Reaction 
Although, homogeneous catalysts are much more reactive compared to the traditional 
heterogeneous catalysts, the major drawback of homogeneous catalysis is the difficulty of their 
recovery from the reaction medium. Recovery of the homogeneous catalyst often needs energy 
consuming precipitation or distillation of the products which may lead to the deactivation of the 
catalyst. In this regard, the use of heterogeneous catalysts is always advantageous from both 
environmental and economical points of view due to its efficient recycling and easy handling. 
However, there are only a few reports of Povarov MCR using heterogeneous catalysts known till 
date. For example, Sartori et al. reported a one-pot three component reaction of aromatic 
aldehydes 17, aromatic amines 2 and cyclopentadiene 45 in the presence of acid clays as 
catalysts for the synthesis of cyclopentanetrahydroquinolines 46 in good yields (85–98%) 
(Scheme 1.11).34  
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Scheme 1.11. Solid Supported Bentonite-Catalyzed Three Component Povarov Reaction 
NH2
O
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40 oC
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HN
H
H
46
R1
R2
 
Montmorillonite KSF, acid Bentonite Bieliaca, and Hectorite are efficient catalysts to carry out 
this one-pot approach, Bentonite Bieliaca being the most efficient catalyst which could be used 
for five consecutive runs without reducing its efficiency. In all cases the reactions were regio- 
and stereospecific yielding exclusively the endo-product. Kobayashi et al. reported efficient 
synthesis of various tetrahydroquinoline derivatives 48 in 65-99% yield using a polymer 
supported scandium catalyst, [(polyallyl)scandium trifylamide ditriflate], (PA-Sc-TAD) (Scheme 
1.12).35  
Scheme 1.12. Solid Supported Sc-Catalyzed Three Component Povarov Reaction 
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The method is especially useful for the construction of a library of quinoline derivatives due to 
the high efficiency and simplicity of the process. Recently, it has been reported that Brønsted and 
solid Lewis acids such as antimony chloride doped on hydroxyapatite (SbCl3-HAP),36 perchloric 
acid adsorbed on silica gel (HClO4–SiO2)37 Fe3+–K10 Montmorillonite clay and HY zeolite38 are 
highly efficient and diastereoselective solid acid catalysts for the one-pot synthesis of pyrano- 
and furanoquinolines by coupling the three components, benzaldehydes, anilines and 3,4-
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dihydro-2H-pyran or 3,4-dihydro-2H-furan. Although, all of these methods are apparently 
exciting but often suffer from tedious multi-filtration processes.  
 
1.5 Enantioselective Three-Component Povarov Reactions 
Despite of the high potential of constructing functionalized, enantioenriched six-membered 
cyclic compounds from relatively simple substrates, only a handful of examples describing 
catalytic asymmetric Povarov reactions have been reported.39-41 Most of the available methods 
make use of vinylethers or cyclopentadiene (Grieco cycloaddition) as dienophiles, often in 
combination with chelating N-2-hydroxyphenyl imines activated by chiral Lewis or Brønsted 
acids.40a-40c The limited range of dienophiles, together with the requirement of a specific aryl 
group at the imine nitrogen in some cases, pose serious limitations to the structural variety of 
accessible 1,2,3,4-tetrahydroquinolines. Only very recently, the range of dienophilic components 
was extended to enecarbamates, in a very efficient way. In 1996, the first catalytic asymmetric 
IEDDA reaction was reported by Kobayashi and Ishitani using chiral binaphthol–ytterbium 
complexes.42a Subsequently, aminodiol–titanium complexes42b and chiral phosphoric acids43,41 
have been developed for the stereoselective IEDDA reactions. Although, there are a lot of 
examples of enantioselective transition metal-catalyzed MC Povarov reactions, metal 
contamination being highly undesirable for drug synthesis; the application of organocatalysis is 
highly recommended. Use of chiral phosphoric acids as the efficient catalysts for numerous 
enantioselective transformation including the Povarov-type reaction was first introduced by the 
group of Akiyama and Terada,44 These bifunctional catalysts are generally known to 
cooperatively activate both the electrophilic imine and the nucleophileic olefin via H-bonding to 
introduce high enantioselectivities. The first chiral Brønsted acid (51)-catalyzed enantioselective 
Povarov reaction of azabutadiene 49 and electron-rich alkenes 50 was reported by Akiyama et 
al., leading to tetrahydroquinolines 53 with high enantioselectivity (Scheme 1.13).43a They 
proposed that the reaction proceed through the formation of a nine-membered cyclic transition 
state 52, wherein the phosphoryl- oxygen forms a hydrogen bond with the hydrogen of the imine 
OH moiety, allowing the nucleophilic attack, preferentially from the re-face of the imine and 
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hence a concerted mechanism was proposed in turn. Great breakthroughs in reactivity and 
enantioselectivity has also been acheived with vinylethers,41 vinylindoles45 and enecarbamates12 
as dienophiles.  
Scheme 1.13. Chiral Phosphoric Acid (51)-Catalyzed Povarov Reaction of Aldimines 6 with 
Vinyl Ethers 50 
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 In 2011, Masson and Zhu reported chiral phosphoric acid (55)-catalyzed, highly enantioselective 
three-component Povarov reaction with a reversal of enantiofacial selectivity (via the transition 
state 56) (Scheme 1.14) relative to Akiyama’s catalytic system.12  
BINOL-phosphoric acid catalysts have been extensively used for Povarov reactions using 
imines. Because of the generality of this catalyst, it is highly desirable to rationalize the facts 
behind its mechanism of action. Recently, Simón and Goodmann developed a model, based on 
DFT calculations for describing the degree and nature of enantioselectivity of BINOL-phosphate 
catalyzed reactions. Apparently the model works well for a huge number of reactions and 
requires only the E/Z- configuration of the transition state and the orientation of the Dienophile.46 
Although, a wide variety of dienophiles such as enol ethers, enecarbamates, and 
cyclopentadienes have been successfully employed in enantioselective Povarov reactions, the use 
of simple acyclic alkenes as dienophiles with limited success. 
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Scheme 1.14. Asymmetric Three-Component Povarov Reaction Using Chiral Phosphoric 
Acid 55 
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In this context, Ricci et al.45 reported the first two-component Povarov reaction using 
vinylindoles as alkene dienophiles catalyzed by a chiral phosphoric acid. Utilization of 
unsymmetrical β-substituted alkenes as the dienophile input for the three-component chiral 
phosphoric acid-catalyzed asymmetric Povarov reaction has been presented for the first time by 
Masson and co-workers (Scheme 1.15).47  
Scheme 1.15. Chiral Phosphoric Acid-Catalyzed Povarov Reaction with Unsymmetrical 
Alkenes 58 as the Dienophile Input 
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They used isoeugenol derivatives 58 bearing a free phenol functional group as dienophiles. The 
chiral catalyst 59, with a bulky 2,4,6-triisopropyl phenyl group in the 3,30-position of (R)-
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BINOL, furnished the tetrahydroquinoline 60 with excellent enantioselectivity but with a lower 
yield which was further improved by using DCE as the solvent.47 
Recently, Jacobsen et al. reported cooperative Brønsted acid catalyzed synthesis of 
tetrahydroquinolines 64 using chiral thiourea 63 in very good yields and excellent 
enantioselectivity (Scheme 1.16).48 The enantioselectivity is achieved in this case via formation 
of a highly reactive cationic intermediate through specific weak H-bonding interactions. 
Scheme 1.16. Chiral Thiourea-Catalyzed Asymmetric Povarov Reaction 
Ph
N
H
O
NBSA
(10 mol%)
chiral thiourea catalyst
(10 mol%)
toluene, 48h, 4oC
trans:cis upto 4:1
ee: upto > 91%
HN O
H
HPh
F3C
CF3
N
H
N
H
O
HN
S
t-Bu
O
61 62 64 63
 
Jørgensen et al. reported an efficient organocatalytic (67), one-pot procedure to access 
enantiomerically pure polycyclic hexahydrocyclopenta[b]quinoline derivatives 70 with five 
stereogenic centers in high yields. The reaction proceeds through an initial organocatalytic 
Michael addition of a δ,ε-unsaturated aldehyde 65 and nitroalkene 66, followed by the 
subsequent Povarov-type cycloaddition of the Michael adduct 68 to give rise to functionalized- 
polycyclic compound 70 in presence of a Brønsted acid (TsOH). The system provides great 
tolerance toward different aldehydes, anilines, and nitroalkenes (Scheme 1.17).49 
Scheme 1.17. Asymmetric Organocatalytic syntheses of Cyclopenta[b]quinoline Derivatives 
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Recently, Gong et al. established an efficient organocatalytic asymmetric Povarov reaction of 2-
hydroxystyrenes 71. The protocol combines the merits of both organocatalysis and 
multicomponent reactions, tolerating a wide range of aldehydes, anilines and styrenes to furnish 
structurally diverse cis-tetrahydroquinolines in high stereoselectivities of up to > 99:1 dr and 
97% ee using 10 mol% of the chiral phosphoric acid 72. The current protocol not only provides a 
facile access to tetrahydroquinolines 73 with chiral quaternary stereocenters upon using α-alkyl 
2-hydroxystyrenes as substrates, but also furnishes an efficient method to synthesize cis-
disubstituted tetrahydroquinolines with high enantioselectivity (Scheme 1.18).50 
Scheme 1.18. Asymmetric Povarov Reaction with 2⁸Hydroxystyrenes 75 
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1.6 Applications of Povarov Reaction 
1.6.1 Application in Total Synthesis 
Natural products have played an important role in the identification of several medicines. 
Although, many strategies have been invented by chemists in order to facilitate the synthesis of 
various complex natural products, most of them are time-consuming, impractical and in some 
cases might also lack structural variability. Following nature’s efficiency of multiple bond 
formation between various substrates, development of novel MCRs in order to achieve diversity 
oriented molecules in a relatively simpler way is highly desirable. In this context, Povarov 
reaction can be considered as a potential tool for the total syntheses of several 
tetrahydroquinoline containing natural products. Among them, the most promising are 
guanidine-containing alkaloids martinelline 79a and martinellic acid 79b. As the first example of 
biomimetic Povarov reaction, Batey and co-workers synthesized the unprecedented heterocyclic 
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core of these attractive natural products via an intermolecular 2:1 multicomponent coupling of a 
substituted aniline 75 with two equivalents of an endocyclic enamine 76 (Scheme 1.19).51  
Scheme 1.19. Total Syntheses of Martinellin and Martinelinc Acid. 
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The use of lanthanide(III) salts resulted in the formation of the ‘wrong’ endo-product in 92% 
yield with 85:15 diastereomeric ratio in favor of the endo-diastereomer. However, 5 mol% of 
camphor sulfonic acid (CSA) afforded the desired exo-diastereomer 78 in 74% yield after 48 h. 
Povarov approach (Scheme 1.20).52 Bodwell and co-workers recently reported an intramolecular 
Povarov reaction using 3-aminocoumarins and o-cinnamylsalicylaldehydes to synthesize a series 
of pentacyclic heterocycles with high yields and trans, trans relative stereochemistry.53  
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Scheme 1.20. Intramolecular Povarov Reaction for the Synthesis of Luotonin A, 82 
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1.6.2 Application in the Syntheses of Various Complex Heterocycles 
Functionalized benzo-fused oxabicyclooctanes and nonanes are unique heterocyclic scaffolds 
and their use in molecular design is still restricted. In this context, TiCl4 catalyzed syntheses of 
substituted benzo-fused 9-oxabicyclo[4.2.1]nonane ring systems 85 in good yields and 
diastereoselectivity is noteworthy (Scheme 1.21).54  Due to the high reactivity of TiCl4 the 
reaction was carried out at low temperature (-78 to -50 °C) to control the selectivity. The reaction 
proceeds via an initial Povarov-type reaction followed by an intramolecular Friedel-Crafts 
annulation with electron-rich aromatic system.  
Scheme 1.21. TiCl4-Ctalyzed  Syntheses of Benzo-Fused Oxabicyclononanes, 85 
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O
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H83 84 85  
Gillaizeau et al. developed a simple triflic acid-catalyzed, one-pot strategy for an efficient 
diastereoselective synthesis of polyfunctionalized nitrogen-fused tetrahydroquinoline scaffolds 
91 via a domino reaction under mild conditions starting from readily available enamides 86 and 
benzyl azides 87 (Scheme 1.22).55 The proton catalyzed elimination of N2 from 87 leads to the 
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rearranged iminium intermediate 89 which afterwards follows a Povarov type reaction sequence 
to yield 91 as a desired product. 
Scheme 1.22. Syntheses of Nitrogrn-Fused Tetrahydroquinolines 91 via the Reaction of 
Enamides 86 and Substituted Benzyl Azides 87. 
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In 2012, Lavilla et al. reported the stereoselective syntheses of cyclic amidines utilizing 
geometrically or electronically restricted imines in Povarov-type reactions. Normally, in Povarov 
process, the olefin forms bonds with the imine carbon and one of the un-substituted ortho- 
position of the aniline ring. When one of these positions is blocked, after the Mannich process, 
instead of formation of the Povarov product, the reaction could follow a sequential Ritter step, 
provided a third component 97 is introduced as an amphiphilic reactant. The reaction sequence 
could be completed by amidine formation through intramolecular trapping of the nitrilium ion by 
the secondary nitrogen centre of 98, affording the three-component adduct 99 in a highly 
stereoselective manner (Scheme 1.23).56 
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Scheme 1.23. Forbidden Povarov Process Opens Up the Possibility of New Heterocycle (99) 
Formation 
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1.7 Scope of Various Electron-Rich Olefins as the Dienophiles 
In general, the Povarov reaction is extremely useful with a broad set of anilines and carbonyl 
derivatives. It is important to state at this point that not only aromatic Schiff bases like N-
benzylidenaniline, but also N-alkyl aldimines can be utilized as the aza-dienes in this type of 
reactions.57,58 However, the addition reaction towards these aldimines is difficult to develop, 
because of their tendency to easy hydrolysis and polymerization under acidic conditions. In 
2003, Batey and Menéndez independently showed that aliphatic aldehydes or aldehyde 
equivalents can be successfully employed under appropriate conditions. They showed that slow 
Chapter	1																																													Recent	Advances	of	the	Povarov	Reaction	 						2012	
 
21 
 
addition of reactants in presence of a mild Lewis acid,57,58 can minimize the above mentioned 
trends. It was further smoothened by carrying out the reaction in fluorous solvents.59  However, 
further efforts have also been extensively devoted to expand the range of activated olefin input 
for this reaction. Initially, Cyclic enol ethers, e.g. 2,3-dihydrofuran 10060 and 3,4-2H-
dihydropyran 101 were used as more popular dienophiles. Utilization of these enol ethers afford 
the corresponding cis-fused furo[3,2-c]- and pyrano[3,2-c]quinoline derivatives 102 and 103. 
Among the other dienophiles, vinyl enol ethers, vinyl sulfides, silyl enol ethers and their 
analogues were significantly used in the cycloaddition of N-aryl aldimines to obtain 2,4-
substituted tetrahydroquinolines. Later on, the introduction of enamine-type functional groups 
has also been successfully explored.61 In this context, cyclic enamides (104) are specially 
appealing since they allow access to a new set of functionalized tetrahydropyrroloquinolines 105 
(Scheme 1.24).  
Scheme 1.24. Multicomponent Povarov Reaction with Different Electron-Rich Dienophiles 
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Significantly, the development of this chemistry by Batey and co-workers has allowed a 
straightforward path for the total synthesis of Martinelline and Martinellic acid.62a Lavilla and 
co-workers reported an excellent example of Povarov-type MCR utilizing dihydropyridines 
(DHPs) as the dienophiles,63a,64 which are very good substrates due to their straightforward 
preparation from commercially available pyridines and the rich chemistry of the enamine 
products that can be exploited further in different ways. As a continuation of this work, recently 
they have reported the syntheses of novel tetrahydroquinoline scaffolds with attractive 
functionalization patterns (108, 109), utilizing unsaturated lactams 106 as synthetically useful 
substrates for Povarov MCRs (Scheme 1.25).65  
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Scheme 1.25. Unsaturated Lactams as New Olefin Imputs for Povarov MCR 
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These adducts are readily converted to a variety of quinoline derivatives in a straightforward 
manner. The introduction of a fourth component to trap the final iminium ion intermediate 
(Scheme 1.2, intermediate 8) and the spatial-temporal control of this MCR to functionalize 
microelectrodes63 are also noteworthy. Cyclic alkenes like cyclopentadiene and indene are also 
common dienophiles for the study on catalytic activity of some acids in the imino DA 
cycloaddition reaction.66,67 Recently, Liu and co-workers reported a triflic acid catalyzed 
Povarov-type cycloaddition reaction of alkenyldiazo compounds and aldimines to synthesize 
diazo-containing cycloadducts in a stereoselective manner. The resulting cycloadducts provide 
access to various six- and seven-membered azacycles, by either the generation of metal carbenes 
or the functionalization of the diazo group present.68 In general, as we discussed previously, the 
Povarov reaction is limited to electron-rich alkenes. However, Batey and co-workers showed that 
the introduction of ring strain in the dienophile, as with moderately strained 
bicyclo[2.2.1]heptenes 110, enables three-component Povarov reaction with in situ formed N-
arylimines under LA catalyzed conditions (BF3-OEt2). The reactions proceed efficiently with a 
diverse set of commercially available anilines and benzaldehydes, as well as a variety of 
substituted norbornenes. The corresponding tetrahydroquinolines 111 are formed with high 
complexity in a multicomponent fashion and are obtained in good yield and high 
diastereoselectivity (Scheme 1.26).69 
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Scheme 1.26. Utilization of Strained Norbornene-Derived Dienophiles 110 in Three-
Component Povarov Reaction 
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1.8 Cyclic Enamines Bearing Reactive Donor-Acceptor (D-A) Substituted 
Cyclopropane Moiety as the New Olefin Input for Povarov-Type Reactions 
Although, the Povarov reaction has been established to be quite general with respect to its 
broader substrate scope, the reactivity of the electron-rich olefin in presence of additional 
functionality, especially in presence of Donor-Acceptor (D-A) substituted cyclopropanes is still 
to be explored.  
D-A substituted cyclopropanes have proven to be of great utility in synthetic organic chemistry70 
and the presence of the cyclopropane group as an additional functionality could give rise to 
further scopes in terms of further reactivity of the Povarov adducts in diversity oriented 
synthesis. In this context, recently Reiser et al.  reported an efficient Lewis acid catalyzed 
multicomponent reaction for the stereoselective syntheses of cis-4,5-disubstituted pyrrolidinones 
116 in high yields, based on monocyclopropanated N-Boc-protected pyrrole 112 (Boc = tert-
butoxycarbonyl).71 Initially a set of Povarov products were synthesized by a three component 
reaction of benzaldehyde 17a, aniline 2a and the bicyclic compound 112, utilizing 5 mol% of 
Sc(OTf)3 as a catalyst in presence of 4 Å molecular sieves (MS) at room temperature, under N2 
atmosphere; the desired cycloaddition products 113a and 114a were obtained with moderate 
diastereoselectivity in favor of the endo isomer 113a (Scheme 1.27). Application of heterocyclic 
aldehydes in the three-component reaction under the optimized reaction conditions also 
proceeded smoothly, giving rise to the desired products in good yields and comparable 
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diastereoselectivity. Phenyl substitution in 5-position of thiophene and 2-furancarbaldehydes 
were also tolerated well, although the reaction time was considerably higher. 
Scheme 1.27. Multicomponent Povarov Reaction Using Tert-butyl methyl 2-azabicyclo[3. 1. 
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Sc(OTf)3-catalyzed multicomponent assembly of furan-2-carbaldehydes 17l, aniline 2a and 
cyclopropanated N-Bocpyrrole 112, smoothly afforded synthetically challenging cis-4,5-disubsti-
tuted pyrrolidinone 115a with an improved yield of 82% and excellent stereoselectivity. Among 
a large number of Lewis acids screened, 40 mol% of Sc(OTf)3 was emerged as the best catalyst 
under above mentioned refluxing condition. However, catalyst loading was finally reduced by 
eight fold (5 mol%) under microwave (MW) irradiation which became best suited for the same 
goal. Thus, the overall process combined a Povarov reaction, D-A induced cyclopropane ring 
opening, 1,4-furan ring migration and quinoline formation, involving the formation and breaking 
of one C-O, four C-N and five C-C bonds. Using readily available furancarbaldehydes 17 and 
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aromatic amines 2; a broad range of cis-4,5-disubstituted pyrrolidinones 115 could be 
synthesized with complete chirality transfer from 112 in high yields (Scheme 1.28). 
Scheme 1.28. Sc(OTf)3-Catalyzed Synthesis of Substituted Pyrrolidinones 115 
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1.9 Conclusion 
Since the historical development of so-called inverse electron demand aza-DA reaction or the 
Povarov reaction in 1963, a huge amount of research interest was attracted during the last few 
decades in order to achieve more detailed mechanistic proofs as well as interesting heterocyclic 
scaffolds. The major developments in this field mainly constitute, utilization of various catalysts, 
enantioselective variations, including chiral organocatalysts and more promisingly, construction 
of diverse heterocycles by manipulating Povarov reaction as the key step, employing 
multifunctional dienophiles and hence, expansion of substrate scope towards many directions. 
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Replacement of usual organic solvents by water has also been achieved as a greener approach. 
Although a lot of efforts have been devoted to gain detail mechanistic insights of the reaction and 
development of catalytic enantioselective variations, only a few successful reactions have been 
published till now which implicate the importance of the Povarov reaction in light of 
synthesizing numerous heterocyclic scaffolds other than the tetrahydroquinolines.  
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2. Aim of this Work 
It has recently been realized that highly efficient synthetic methods with a strong focus on 
multiple bond formation in a single step are required which could be obtained through rational 
designing of novel multicomponent reactions (MCRs). Due to the operational simplicity and 
high atom economy, MCRs with subsequent transformations, including cyclization and re-
functionalization have emerged as the complementary and powerful alternatives to conventional 
strategies for the synthesis of complex molecules having relevant applications in both 
combinatorial chemistry and DOS (Figure 2.1).1,2,3 The aim of this work was to develop efficient 
and novel multicomponent approaches, based on a bi-functional compound and utilizing the 
Povarov reaction as the key step for creating complex heterocyclic molecular scaffolds, which 
could be utilized for various screening processes.  
FG2
FG1
3 CR cyclization
or
FG3
E
A B
C
D F
 
Figure 2.1. Construction of complex heterocycles E or F via a three component reaction 
followed by cyclization of D. 
 
2.1 Utilization of D-A-Substituted Cyclopropane Ring Containing Electron-
Rich Olefin for the Povarov Reaction 
The Povarov reaction was vastly exploited for the constructions of tetrahydroquinoline moieties 
by the reaction of aldimins and a huge range of electron rich olefins. On the contrary, utilization 
of olefins containing D-A substituted cyclopropane ring as an additional functionality was 
unprecedented till now. In this context, our aim was to introduce for the first time the bicyclic 
compound, tert-butyl methyl 2-azabicyclo[3.1.0]hex-3-ene-2, 6-dicarboxylate 6 as an electron 
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rich, bi-functional olefinic component for the Povarov reaction to access 
tetrahydropyrroloquinolines in a stereoselective manner.  
 
2.2 Utilization of Povarov Reaction as the Key step for Developing Novel 
Synthetic Strategies to Access Diversified Heterocyclic Scaffolds  
It was also intringuing to us whether it is possible to develop synthetic routes to access 
diversified heteroccyles, e.g., tetrahydropyrroloquinolines (G), polycyclic imines (H), 
funtionalized pyrroles (I), pyrrolidinones (J) and functionalized pyrazolidines (k) in stereo-and 
regioselective manner following multicomponent-one-pot strategy. Most often, multicomponent 
reaction produces multiple products and suffers from low yield and selectivity. Thus it was 
challenging for us to develope proper reaction conditions which could give only the desired 
product in good yield and selectivity (Figure 2.2).  
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Figure 2.2. Strategy for synthesizing various heterocycles utilizing the Povarov reaction as the 
key step.  
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Although, most of the already established MCRs do not require a catalyst, the quest for novel 
and more efficient MCRs has resulted in an intensified effort to find suitable catalysts in order to 
obtain diversified products in broader perspective. In this context, we have chosen mainly metal 
triflates as catalyst due to their inherene afinities towards the non bonding electron pair to form 
reactive adducts as important intermediates. 
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3. A Catalytic Multicomponent Approach for the Syntheses of 
Biologically Relevant Tetrahydropyrrolo[3,2-c]quinoline Derivatives 
 
3.1 Tetrahydropyrroloquinolines as Pharmaceutically Relevant Molecules  
Ring-fused tetrahydropyrroloquinolines and relative derivatives constitute the ubiquitous class of 
nitrogen heterocycles in the nature and have found potential applications as pharmaceuticals and 
agrochemicals.1 In 1995, scientists at Merck, first reported the isolation of two novel guanidine 
alkaloids, martinelline (1) and martinellic acid (2) from the root extracts of a family of tropical 
plants, Martinella iquitosensis vine, which have long been used by indigenous people for 
medicinal purposes.2 Later, these  Martinella alkaloids were observed to possess not only strong 
affinity for adrenergic, muscarinic and bradykinin receptors3 but also moderate antibacterial4 and 
potent cytotoxic5 activities. The unique hexahydropyrrolo[3,2-c]quinoline (3) moiety (Figure 
3.1), present in these molecules is assumed to be responsible for showing such therapeutic 
applications. Consequently, development of efficient methodologies for the synthesis of such 
tetrahydropyrroloquinoline framework continues to be an important goal of synthetic organic 
chemists. One of the most powerful strategies for synthesizing this interesting heterocyclic 
compound is the Povarov reaction, which has already been thoroughly discussed in the previous 
chapter in light of the historical background and recent synthetic developments. 
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Figure 3.1. Martinella alkaloids from Martinella iquitosensis vine. 
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Our contribution to the aforementioned research area will be elaborated in the present and the 
following chapters with respect to a new olefin input as well as development of novel 
methodologies, utilizing Povarov reaction as the key step for creation of various heterocycles. 
 
3.2 Cyclic Enamines Bearing Reactive Donor-Acceptor (D-A) Substituted 
Cyclopropane Moiety as the New Olefin Input for Povarov-Type Reactions 
Although, the Povarov reaction has been proved to be quite general with respect to the broader 
substrate scope, the reactivity of an electron-rich olefin in presence of additional functionality, 
especially in presence of Donor-Acceptor (D-A) substituted cyclopropanes is still unexplored. 
The D-A substituted cyclopropanes have proven of great utility in synthetic organic chemistry;6 
our group is focused for long time on the development of new D-A substituted cyclopropane 
derivatives and exploring their unique reactivity for the syntheses of various pharmaceutically 
relevant molecules.7 As a continuation of this work, the diastereoselective syntheses of tert-butyl 
methyl 2-azabicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 has already been well established 
(Scheme 3.1)8c  
Scheme 3.1. Synthesis of Tert-butyl methyl 2-azabicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 
H
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In quest for constructing novel heterocycles by utilizing Povarov reaction as the key step, we 
envisioned that the enamine moiety present in 6 could lead to the Povarov-type reaction in 
presence of N-aryl imines, affording functionalized tetrahydropyrroloquinoline derivatives 
(Figure 3.2). Consequently, we investigated the scope of 6 as a new olefin input for the Povarov 
reaction. 
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Figure 3.2. Electron-rich enamine 6 bearing additional D-A cyclopropane moiety as a promising 
olefin input for the Povarov reaction. 
Our initial experiments were performed based on the preformed Schiff’s base 9a (via the 
condensation of benzaldehyde 7a and aniline 8a) and the bicyclic compound 6 utilizing 20 mol% 
of BF3/OEt2 as a catalyst in presence 4 Å molecular sieves (MS) under N2 atmosphere at 0 °C to 
room temperature; gratifyingly we obtained the desired cycloaddition products 10a and 11a as 
expected after 48 h with moderate diastereoselectivity of 6:1 in favor of the endo isomer 10a 
(Scheme 3.2).  
Scheme 3.2. One-Pot Povarov Reaction Using Tert-butyl methyl 2-azabicyclo[3.1.0]hex-3-
ene-2, 6-dicarboxylate 6 
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The isolated yield of the major diastereomer 10a was 45%. Next, we focused on carrying out the 
reaction in a multicomponent one-pot fashion which was highly desirable over the multistep 
procedure with respect to atom-economic transformation of easily available starting materials 
into complex organic building blocks. To our delight, we obtained comparable results when we 
set up a three-component reaction of benzaldehyde 7a, anilines 8a and the electron-rich olefin 6 
under similar Lewis acid catalysis (Scheme 3.3).  
	Chapter	2																																										Synthesis	of	Tetrahydropyrroloquinolines		 2012	
 
37 
 
Scheme 3.3. Multicomponent Povarov Reaction Using Tert-butyl methyl 2-azabicyclo[3. 1. 
0]hex-3-ene-2, 6-dicarboxylate 6 
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Next, we turned our attention to optimize the reaction condition in order to decrease the catalyst 
loading and reaction time. In this regard, several Brønsted and Lewis acid catalysts were 
screened based on the preliminary reaction of benzaldehyde 7a, aniline 8a and olefin 6 and the 
results are summarized in Table 3.1. When 20 mol% of triflic acid was used as a catalyst, we 
obtained a completely different diastereoselectivity of 1:6 in favor of the exo-isomer 11a in a 
much improved isolated yield of 71% after 36 h (Table 3.1, entry 1).  
Since, lanthanide metal salts are already proved to be efficient LA catalysts for this type of 
reaction; we also investigated our system using different lanthanide triflates (Table 3.1, entries 3-
6). Although, in all of these cases the time of the reaction decreased significantly but the 
diastereomeric ratio became much lower. Finally 1 mol% of Cu(OTf)2 was found to be the best 
catalyst of choice, considering both reaction time as well as diastereoselectivity of the 
cycloaddition products (Table 3.1, entry 8). 
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Table 3.1. Catalyst Screening at Room Temperaturea 
N
Boc
CO2Me
H
H
NH2
CH2Cl2
rt, MS 4 Å
catalyst (x mol%) HN N
Boc
CO2Me
H
H
H
H
O
HN N
Boc
CO2Me
H
H
H
H
10a7a 8a 6 11a  
entry catalyst x mol% conversion
(%)b
yield
(%)c
time
 (h)
1
2
3
4
5
6
BF3-Et2O 20 60 48 45
TfOH 20 7190 36
Yb(OTf)3 20 100 08 48
Yb(OTf)3 5 100 12 65
Sc(OTf)3 5 100 08 72
Sc(OTf)3 1 100 09 72
7
8
Cu(OTf)2 5 100 12 79
Cu(OTf)2 1 100 16 80
drd
6:1
1:6
1:1
2:1
2.5:1
2.5:1
4:1
4.5:1
 
a Reaction conditions: 0.835 mmol 7a, 0.835 mmol 8a, 0.334 mmol 6, catalyst (x mol%) and DCM (2 mL). b  
Determined by 1H NMR.c Yields of isolated major diastereomer 10a. d Determined by 1H NMR. 
With this optimized reaction condition in hand, next we examined the scope of the reaction with 
respect to different aldehydes and anilines (Table 3.2). The aniline input showed appropriate 
reactivity, ranging from activated to deactivated systems affording the desired products in good 
yields and moderate diastereoselectivity (Table 3.2, entries 2-6). When different aldehydes were 
involved, the more electron-deficient nature of the aldehyde 7 appeared to have a positive effect 
on the yield of the Povarov products (Table 3.2, entries 8-11). This observation indicates that the 
electron withdrawing substituent on either aldehyde or aniline part lowers the energy barrier of 
the reaction and thus resulting in a shorter reaction time and higher yield as expected. 
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Table 3.2. Scope of Povarov Reaction with Different Aldehydes, Anilines and New Olefin 
Inputa 
N
Boc
CO2Me
H
H
NH2
CH2Cl2
rt, MS 4 Å
Cu(OTf)2 (1 mol%) HN N
Boc
CO2Me
H
H
H
H
O
HN N
Boc
CO2Me
H
H
H
H
107 8 6 11
R2R1
R1 R1
R2 R2
 
entry time  (h)
isolated yield 
        (%)b
1
2
4
18 80
16 79
18 70
3 12 72
endo/exoc
4.5:1
4:1
3:1
3:1HN
N
H H
CO2Me
H
H
Boc
Cl
HN
N
H H
CO2Me
H
H
Boc
CF3
HN
N
H H
CO2Me
H
H
Boc
F
HN
N
H H
CO2Me
H
H
Boc
R1 R2
H H
H 4-F
H
H
4-CF3
4-Cl
major diastereomer
10a
10b
10c
10d
5 22 55 4:1HN
N
H H
CO2Me
H
H
Boc
4-MeH
10e
 
Table Continued.. 
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entry major diastereomer time  (h)
isolated yield 
        (%)b
endo/exocR1 R2
7 18 69 4:1
HN
N
H H
CO2Me
H
H
Boc
3-FH
11 12 78 4:1HN
N
H H
CO2Me
H
H
Boc
H4-NO2C6H4
O2N
10g
10k
10 16 77 4:1HN
N
H H
CO2Me
H
H
Boc
H4-CF3
F3C
10j
F
8 18 75 4.5:1
HN
N
H H
CO2Me
H
H
Boc
H4-Cl
Cl
10h
9 18 73 4:1
HN
N
H H
CO2Me
H
H
Boc
H4-Br
Br
10i
6 30 49 4:1HN
N
H H
CO2Me
H
H
Boc
3,5-(Me)2H
10f
 
a Reaction conditions: 0.835 mmol 7, 0.835 mmol 8, 0.334 mmol 6, 0.00334 mmol catalyst (1 mol%) and DCM (2 
mL). b Yields of isolated major diastereomer 10. c Determined by 1H NMR. 
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The relative stereochemistry of the products 10a and 10k (Table 3.2, entries 1 and 11) were 
unambiguously established by single crystal X-ray analysis (Figure 3.3). 
                   
Figure 3.3. X-ray crystal structures of compounds 10a and 10k. 
Application of heterocyclic aldehydes in the three-component reaction under the optimized 
reaction conditions also proceeded smoothly, giving rise to the desired products in good yields 
and comparable diastereoselectivity (Table 3.3).  
Table 3.3. Scope of Povarov Reaction with Different Heteroaromatic Aldehydesa 
entry major diastereomer time 
 (h)
isolated yield 
        (%)b
endo/exocR1 R2
1
3
18 68
12 72
2 20 54
4:1
2.5:1
3.5:1
HN
N
H H
CO2Me
H
H
Boc
HN
N
H H
CO2Me
H
H
Boc
2-thiophenyl H
5-Ph-2-thiophenyl
2-furayl
H
H
S
HN
N
H H
CO2Me
H
H
Boc
S
Ph
10l
10m
10n
O
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entry major diastereomer time 
 (h)
isolated yield 
        (%)b
endo/exocR1 R2
3:1
2.5:1
8 75
14 73
HN
N
H H
CO2Me
H
H
Boc
F
4-NO2
4-OMe
3-OMe
4-F
2.5:114 75
HN
N
H H
CO2Me
H
H
Boc
O
3:19 78HN
N
H H
CO2Me
H
H
Boc
NO2
HN
N
H H
CO2Me
H
H
Boc
O
4
5
6
7
2-furayl
2-furayl
2-furayl
2-furayl
2.5:116 65
13
4
2:1
2.7:1
63
70
HN
N
H H
CO2Me
H
H
Boc
HN
N
H H
CO2Me
H
H
Boc
HN
N
H H
CO2Me
H
H
Boc
F
1-napthyl
3-F,4-Me
3,5-(Me)28
9
10
2-furayl
2-furayl
2-furayl
10o
10p
10q
10r
10s
10t
10u
O
O
O
O
O
O
O
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entry products time  (h)
isolated yield 
        (%)b
endo/exocR1 R2
H
3,4-(Me)2
4-OMe
6624 2.5:1HN
N
H H
CO2Me
H
H
Boc
6021 2:1HN
N
H H
CO2Me
H
H
Boc
6922 3:1HN
N
H H
CO2Me
H
H
Boc
O
11
12
13
5-Ph-2-furayl
5-Ph-2-furayl
5-Ph-2-furayl
10v
10w
10x
O
O
O
Ph
Ph
Ph
 
a Reaction conditions: 0.835 mmol 7, 0.835 mmol 8, 0.334 mmol 6, 0.00334 mmol catalyst Cu(OTf)2 (1 mol%) 
and DCM (2 mL). b Yields of isolated major diastereomer 10. c Determined by 1H NMR. 
In this context, furan-2-carbaldehydes were also tolerated well, although the reaction time was 
considerably increased in those cases (Table 3.3, entries 2, 11, 12, 13). Replacement of anilines 
with 1-napthylamine resulted in the corresponding tetrahydrobenzo[h]quinoline 10u in 65% 
yield (Table 3.3, entry 10). The relative stereochemistry of the product 10n (Table 3.3, entry 3) 
was unambiguously established by single crystal X-ray analysis (Figure 3.4). 
 
Figure 3.4. X-ray crystal structure of compound 10n. 
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3.3 Asymmetric Povarov Reaction Using Chiral Thiourea Catalyst 
As already discussed in Chapter 1, Section 2.5, the catalytic enantioselective Povarov reaction of 
electron-rich olefins with aldimines is an extremely powerful strategy for the construction of 
tetrahydroquinolines with high enantiopurity. Inspired by the recent work of Jacobsen et al.9 we 
decided to investigate the effect of chiral thiourea mediated Brønsted acid (BA) catalysis on our 
reaction system. Initial optimization studies with triflic acid showed a reversal in the trend of 
general diastereoselectivity of the products and the exo-diastereomers were found to be the major 
product (Scheme 3.4).  
Scheme 3.4. LA- and BA-Catalyzed Povarov Reaction: Effect on Diastereoselectivity 
HN N
Boc
CO2Me
N
H
endo (cis-)
major
exo (trans-)
major
BF3 - OEt2 TfOH
H
H
H
H
HN N
Boc
CO2Me
H
H
H
H
N
Boc
H
H
CO2Me
diisopropyl ether
0 oC - rt
toluene
0 oC - rt
9a 610a 11a
 
Next, we turned our attention towards combining the BA with the bifunctional sulfinamido 
thiourea derivative 17 in order to obtain enantiomerically pure tetrahydropyrroloquinoline 11. 
The thiourea catalyst 17 was prepared by literature known procedure and after purification on 
silica, employed for the subsequent optimization studies (Scheme 3.5).10  
Initial experiments were performed with the benzylidine aniline 9a and the racemic-bicyclic 
cyclopropanated compound 6 in presence of 10 mol% of each of TfOH and the thiourea catalyst 
17. When the reaction was carried out at room temperature, the desired product was formed as a 
recemic mixture after 48 h in 75% of isolated yield with a diastereoselectivity of 8:1 in favor of 
the exo-isomer (Table 3.4, entry 1). In order to achieve enantioselectivity, the temperature was 
then reduced to -55 oC as reported by Jacobsen et al. But unfortunately, we obtained only a trace 
amount of the product (<10%) (Table 3.3, entry 4).  
 
	Chapter	2																																										Synthesis	of	Tetrahydropyrroloquinolines		 2012	
 
45 
 
Scheme 3.5. Synthesis of Jacobsen’s Thiourea Catalyst 
H2N
NH2
HCl
Et2O H2N
NH3Clrt
CF3
F3C N
0o C
CF3
F3C NH
N
H
S
NH2
C S
tert-butylsulfinyl chloride
DIPEA/DMAP
rt, overnight
CF3
F3C NH
N
H
S
HN
S
t-Bu
O
CF3
F3C NH
N
H
S
HN
S
t-Bu
O
12 13
14
15
16 17
 
In order to have a better conversion, we then slightly increased the temperature to -45 oC, but 
after 48 h we could get only 12% of the product 11 with excellent diastereoselectivity of 99:1 in 
favor of the exo-isomer 11 in very good enantiomeric excess; ee = 96% (Table 3.4, entry 6). 
Encouraged by this result, next we decided to increase the BA loading to 12 mol% in order to 
have better conversion. Several conditions were screened, altering also the BA-thiourea ratio and 
finally, we obtained the desired product 11 with excellent diastereo- and enantioselectivity 
(Table 3.4, entry 10) but only with a moderate yield of 25%. It is important to mention at this 
point that since, we initiated our studies with a racemic mixture of 6, the maximum yield of the 
enantiomerically pure product 11 could be as high as 50% only. Considering the above 
observations, we concluded that our effort towards the efficient enantioselective syntheses of 
tetrahydropyrroloquinolines via chiral thiourea mediated BA-catalysis might not be a suitable 
route to achieve our goal. Therefore, we decided to plan for an alternative methodology utilizing 
organocatalysis and the process is still under investigation. 
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Table 3.4. Brønsted Acid/Thiourea-Catalyzed Asymmetric Povarov Reaction 
N
H
TfOH (x mol%)
thiourea (y mol%)
dry toluene, MS 4Å
N
Boc
CO2Me
H
H
6
HN N
Boc
CO2Me
H
H
H
H
9a 11  
entry TfOH 
(mol %)
thiourea 
(mol %) yield (%)
a dr
(exo:endo)b
ee (%)
exo isomerc
3 5 10 -55 no reaction - -
4 10 10 -55 very little
 product
- -
1 10 10 RT 75 8:1 rac.
2 15 10 RT 86 6:1 rac.
5 10 10 -50 10 99:1 52
6 10 10 -45 12 99:1  96
7 10 5 -45 12 1:1 rac.
8 12 10 -40 16 99:1  98
9 15 10 -40 21 99:1 26
10 12 10 -30 25 49:1 >99
temp
(o C)
 
a Major diastereomer, separated by column chromatography. b Determined by 1H NMR. c Determined by chiral 
HPLC analysis after 48 h. 
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3.4. CuFe2O4 Nanoparticles as an Efficient Magnetically Recoverable Catalyst 
for the Povarov MCR 
In recent years, the use of magnetic nanoparticles has become more and more attractive due to 
their numerous applications in synthesis and catalysis.11 Catalyst recycling via magnetic 
separation is a promising alternative to filtration or centrifugation as it potentially prevents loss 
of catalyst and hence much more suitable for industrial applications. Although, various catalysts 
have been used for the Povarov-type reaction till date but only a few of them were recyclable. In 
this context, the use of heterogeneous catalysis, especially the use of magnetic Cu–Fe spinel 
catalyst (CuFe2O4) for this type of reaction is highly fascinating. Our aim was to exploit 
magnetically separable CuFe2O4 nanoparticles as a reusable catalyst for the synthesis of 
tetrahydropyrroloquinolines (10 and 11) from easily available starting materials (Scheme 3.6). 
Scheme 3.6. Magnetically Recoverable CuFe2O4-Nanoparticle Catalyzed Povarov Reaction 
R2
N
Boc
CO2Me
H
H
NH2
CH2Cl2, rt
CuFe2O4 (5 mol%) HN N
Boc
CO2Me
H
H
H
H
O
HN N
Boc
CO2Me
H
H
H
H
107 8 6 11
dr = 4:1
R1
R1
R2
R1
R2
 
To test the catalytic property with respect to the Povarov reaction, CuFe2O4 nanoparticles were 
prepared by literature known procedure.12 Initial studies were performed using benzaldehyde 7a, 
aniline 8a and the electron rich olefin 6 in presence of different mol% of the catalyst and finally 
5 mol% of CuFe2O4 was found to be the best considering both time as well as diastereoselectivity 
of the products (Table 3.5).  
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Table 3.5. Optimization of Reaction Condition with CuFe2O4 Nanoparticles as Catalysta 
N
Boc
CO2Me
H
H
NH2
CH2Cl2, rt, 
16 h
CuFe2O4 (5 mol%) HN N
Boc
CO2Me
H
H
H
H
O
HN N
Boc
CO2Me
H
H
H
H
10a7a 8a 6 11a
dr = 4:1
 
entry x mol% conversion
(%)b
yield
(%)c
time
 (h)
1
2
3
4
5
6
15 100 12 72
20 72100 12
10 100 15 70
5 100 16 75
2 85 24 61
1 80 24 58
drd
3:1
3:1
3:1
4:1
4:1
4:1
 
a Reaction conditions: 0.835 mmol 7a, 0.835 mmol 8a, 0.334 mmol 6, Catalyst (x mol%) and DCM (2 mL). b 
Determined by 1H NMR. c Yields of isolated major diastereomer 10a. d Determined by 1H NMR. 
To check the recyclability of the catalyst, after the reaction was complete, the catalyst was 
separated from the reaction mixture by magnetic decantation, washed with methanol and CH2Cl2, 
dried under vacuum and reused for the next cycle. The catalyst was found to be highly active up 
to 3 runs after which the reaction time was significantly increased for quantitative conversion of 
the olefin 6 (Table 3.6).  
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Table 3.6. Povarov Reaction Using CuFe2O4 Nanoparticles as Catalyst: Recycling 
Experimenta 
entry run yield
(%)b
time
 (h)
1
2
3
4
2 16 73
1 7516
3 16 74
4 24 66
drc
4:1
4:1
4:1
4:1
 
a Reaction conditions: 0.835 mmol 7a, 0.835 mmol 8a, 0.334 mmol 6, 0.0167 mmol Catalyst (5 mol%) 
and DCM (2 mL). b Yields of isolated major diastereomer 10a. c Determined by 1 H NMR. 
 
3.5 Conclusion 
In summary, we have successfully introduced a cyclopropanated enamine as a new olefin input 
for Cu(OTf)2 catalyzed three component Povarov reaction affording a convenient way to 
synthesize pharmaceutically relevant tetrahydropyrroloquinoline scaffolds with novel 
connectivity and functionalization in very good yields and moderate diastereoselectivity. We 
have also focused to develop an efficient route to synthesize enantiomarically pure 
tetrahydropyrroloquinoline using a previously reported chiral thiourea catalyst and the process is 
still under investigation. Utilization of magnetically separable CuFe2O4-nanoparticles as the 
catalyst under mild reaction conditions is an additional sustainable contribution to this method. 
The catalyst was successfully recovered after completion of the reaction and reused for up to 
three consecutive cycles with high efficiency. Further extension of this work in light of the 
utilization of magnetic nanoparticles as the reusable catalyst and screening of some of the 
Povarov products for biological activities is ongoing. 
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4. A Catalytic Multicomponent Approach for the Stereoselective 
Syntheses of Cis-4,5-Disubstituted Pyrrolidinones 
 
4.1 Cis-4,5-Disubstituted Pyrrolidinones as Pharmaceutically Relevant 
Molecules  
Pyrrolidinones are more commonly known as γ-lactams 19, which represent the widespread 
structural features of many natural and designed biologically active molecules. A careful look at 
the structure of these five-membered heterocycles reveals that they are closely related to the 
folded conformation of γ-Amino-Butyric Acid (GABA) 18 (Figure 1), which is the dominant 
inhibitory neurotransmitter present in the mammalian central nervous system and seems to play a 
key role in the transportation of GABA  across the membranes into different nerve tissues.1 
OOC NH3 OOC H3N HN
O
18 19
R1
 
Figure 1. Structural resemblance of pyrrolidinones 19 with γ-amino-butyric acid 18. 
Consequently, pyrrolidinones have found profound applications in pharmaceutical development.2 
They are the core structures of nootropics or the so-called ‘smart drugs’ which are reported to 
improve several mental functions such as cognition, memory, concentration etc. Rolipram (20) is 
one of the examples of the nootropics which is a potent PDE4-inhibitor and hence, acts as an 
anti-inflammatory drug (Figure 2).3  
N
O
S
HO
N
O
O
O N
O
Ar
Ar
O
NHR2
20 21 22  
Figure 2. Pharmaceutically important pyrrolidinones. 
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Especially relevant for our study, Bayer Healthcare has identified cis-4,5-disubstituted 
pyrrolidinones containing aromatic and heteroaromatic groups (21) as lead structures for 
inhibition of type II 17β-hydroxysteroid dehydrogenase; being implicated in the treatment of 
osteoporosis.2a Likewise, cis-4,5-diarylated pyrrolidinones (22) have been reported to inhibit 
transcription factor HOXA13, a regulator of mammalian development of certain cancer types 
(Figure 2).2c  
4.2 Syntheses of Cis-4,5-Disubstituted Pyrrolidinones  
Because of the prevalence in pharmaceutical development and natural products, methods for the 
efficient stereoselective synthesis of substituted pyrrolidinones are on great demand.4 Although, 
considerable efforts have been directed to a great number of synthetic approaches to these 
biologically important nitrogen-heterocycles, mainly based on Pd-catalyzed cyclization,5 Ni-
catalyzed reductive coupling of aldimines and activated alkenes (Scheme 4.1),6 Rh-catalyzed 
intramolecular C-H insertion of diazo derivatives,7 addition of homoenolates to imines,8 N-
heterocyclic carbene catalyzed addition of enals to imines,9 ring expansion of β-lactams10 and 
several cycloaddition strategies10; surprisingly, only a few methods exist related to cis-4,5-
disubstituted pyrrolidinones,5a,9a-b,10,13a-c moreover, methods employing multicomponent 
reactions (MCR) are scarce in general.[11a,d]  
Scheme 4.1. Regioselective Synthesis of Pyrrolidinones 25 by Nickel-Catalyzed Reductive  
Coupling of Aldimines 23 and Activated Alkenes 24 
N
R1
R2
R3
OMe
O
1. [NiBr2(Phen)], Zn
CH3CN, H2O, 80 °C
2. toluene, PTSA, reflux
NR
2
R1
O
R323 24 25up to 87% yield  
In this context, Bode et al. described the efficient synthesis of  pyrrolidinones 32 via direct 
annulations of enals 26 and N-sulfonylimines 27 using in situ-generated, protonated N-
heterocyclic carbene salt 28 as catalyst (Scheme 4.2).9  
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Scheme 4.2. Synthesis of Pyrrolidinones via Direct Annulation of Enals and N-
Sulfonylimines 
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More recently, Scheidt et al. reported the stereoselective synthesis of substituted pyrrolidinones 
37 from amideenolate 33, acylsilane 34 and N-phosphenyl imine 35 in presence of LDA. 
Mechanistically, the reaction proceeds via the intermediate formation of a β-
silyloxyhomoenolate equivalent (Scheme 4.3).8  
Scheme 4.3. Stereoselective Synthesis of Substituted Pyrrolidinones 37 from Acylsilanes 34 
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However, all of these processes suffer from lack of operational simplicity; hence development of 
alternative methodologies to access these valuable heterocycles by exploring new chemical 
building blocks is of great significance. In this context, utilization of multicomponent 
approaches, involving highly strained, functionalized D-A cyclopropane, bearing both 
electrophilic and nucleophilic centers to access pyrrolidinones is novel. As a continuation of our 
ongoing research, investigations into the unique chemistry of Lewis acid (LA) promoted 
cyclopropane ring-opening of the Povarov products revealed novel reactivity; especially, with a 
typical furyl substitution on the aldehyde part (10n and 11n). As discussed in the previous 
chapter, a three-component reaction of furan-2-carbaldehyde 7i, anilines 8a and the 
cyclopropanated olefin 6 smoothly afforded the Povarov products 10n and 11n as a 3.5:1 
diastereomeric mixture in favor of the endo-isomer 10n, in presence of 1 mol% of Cu(OTf)2 as a 
catalyst (Scheme 4.4). The two diastereomers obtained, can easily be separated on silica.  
Scheme 4.4. Multicomponent Povarov Reaction Using Cu(OTf)2 as Catalyst 
CH2Cl2
rt, MS 4 Å
Cu(OTf)2 (1 mol%) HN N
Boc
CO2Me
H
H
H
H
HN N
Boc
CO2Me
H
H
H
H
10n 11n
N
Boc
CO2Me
H
H
6
O O
NH2
7i 8
O O
93% overall yield  
Upon addition of one equivalent of Yb(OTf)3 to 10n (major diastereomer) in CH3CN under 
reflux condition, surprisingly afforded the cis-4,5-disubstituted pyrrolidinone 38a; an unusual, 
rearranged product as a single diastereomer in 79% of isolated yield (Table 4.1, entry 4). 
Lowering in the catalyst loading reduced the conversion as well as the yield of the product 38a 
with an increased reaction time (Table 4.1, entry 3), a lowered catalyst loading of 50 mol% of 
Yb(OTf)3 gave only a little conversion, indicating very weak substrate-metal binding (Table 4.1, 
entries 1 and 2). No reaction was observed in absence of the catalyst, revealing the necessity of 
the catalyst for the generation of the 1,3-dipole (Table 4.1, entry 14). In order to avoid 
stoichiometric catalyst loading, a variety of other LAs were screened and finally 40 mol% of 
Sc(OTf)3 was emerged as the catalyst of choice, ensuing a clean reaction, giving the same 
rearranged product 38a after 12 h as a single diastereomer in 80% of isolated yield (Table 4.1, 
entry 7).  
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Table 4.1. Optimization of Metal-Triflate Catalyzed Rearrangement of the Povarov 
Product 10na 
HN
N Boc
CO2Me
O
CH3CN, MS 4 Å  
reflux
LA (x mol%)
H H
H
H
10n 38a
HN
N
O
O
 
entry catalyst x mol% conversion
b
(%)
isolated yield
(%)
time
(h)
5
6
Sc(OTf)3
Sc(OTf)3
20
30
36
36
80
91
50
69
7 Sc(OTf)3 40 12100 80
1
2
Yb(OTf)3
Yb(OTf)3
40
50
--
--
--
--
0
0
3 Yb(OTf)3 75 3680 55
4 Yb(OTf)3 100 24100 79
8
9
Y(OTf)3
Y(OTf)3 30
20 48
40
50
50
45
45
10 Y(OTf)3 40 3665 60
11
12
Gd(OTf)3
Gd(OTf)3
20
40
36
48
40 21
50 35
13 40Cu(OTf)2
no
reaction -- --
14 --Blank noreaction -- --
 
a Reaction conditions: 0.5 mmol 10n, Catalyst (x mol%) and MeCN (2 mL), b Determined by 1H NMR. 
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The higher oxophilicity and smaller ionic radius of Sc(OTf)3, compared to the other lanthanide 
triflates presumably helps in its more effective binding to the substrate and hence, Sc(OTf)3 
behaves as a more active catalyst in this case. When the catalyst loading was decreased to 20 
mol%, the desired product 38a was obtained with only 50% yield and increased reaction time of 
36 h (Table 4.1, entry 5). The relatively higher catalyst loading prompted us to look for better 
alternatives. In this context, microwave (MW)-assisted organic synthesis has demonstrated itself 
to be superior in many instances when compared to reactions carried out using conventional 
thermal conditions.12 The use of MW irradiation often helps to reduce reaction time, minimize 
side products and also to improve yields. Based on these facts, we examined the effect of 
microwave heating on our reaction system. Gratifyingly, a much lower (eight times) loading of 
only 5 mol% Sc(OTf)3 afforded the same desired product 38a in 99% of isolated yield, when the 
reaction mixture was irradiated in a microwave at 125 °C for 2.5 h (Scheme 4.5) in absence of 
molecular sieves. Next, we turned our attention to synthesize the cis-pyrrolidinones 38 in a 
multicomponent (MCR) one-pot fashion to overcome the time consuming as well as expensive 
purification methods of the stepwise procedure.13-16  
Scheme 4.5. Microwave-Assisted Rearrangement of 10n. 
HN
N Boc
CO2Me
O H
H
H H
HN
N
O(5 mol%)
MeCN, 125 oC
MW, 2.5 h O
Sc(OTf)3
10n 38a
yield > 99%
 
To our delight, Sc(OTf)3-catalyzed multicomponent assembly of furan-2-carbaldehydes 7i, 
aniline 8a and cyclopropanated N-Bocpyrrole 6, smoothly afforded synthetically challenging cis-
4,5-disubstituted pyrrolidinone 38a in high yield (82%) with excellent stereoselectivity (Table 
4.2, entry 15). Among a number of Lewis acids which were screened, we found that 5 mol% of 
Sc(OTf)3) under microwave (MW) irradiation is best suited for this process which combines a 
Povarov reaction,17 donor-acceptor induced cyclopropane ring opening, a 1,4-furan ring 
migration and quinoline formation, involving the formation and breaking of one C-O, four C-N 
and five C-C bonds. 
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Table 4.2. Optimization of Metal-Triflate Catalyzed Multicomponent Reaction of 7, 8 and 
6a 
HN
N
O
R2
N
Boc
CO2Me O
H
H
6 38
O O
NH2
R2
7 8
R1
R1 catalyst (x mol%)
 
entry catalyst x mol% conversion
%b
yield
of 38 (%)c time (h)condition
Cu(OTf)21 only 10n
was obtained
---- reflux20
2
3
Yb(OTf)3
Yb(OTf)3
40
50
--
--
--
--
4 Yb(OTf)3 75 3680 55
5 Yb(OTf)3 100 24100 79
6
7
Y(OTf)3
Y(OTf)3 30
20 48
40
50
50
45
45
reflux
reflux
reflux
reflux
reflux
reflux
only 10n
was obtained
only 10n
was obtained
8 Gd(OTf)3 40 4850 35
9 Y(NO3)3 40 7240 36
reflux
reflux
10 Sc(OTf)3 40
12100 85 refluxMW
11 Sc(OTf)3 30 3690 79 reflux
12 Sc(OTf)3 20
36100 82 reflux
MW
13 Sc(OTf)3 5 6100 82 MW
2
2.5
 
a Reaction conditions: 0.4 mmol 7, 0.4 mmol 8, 0.334 mmol 6, Catalyst (x mol%) and MeCN (2 mL),  b  
Determined by 1H NMR.c Yields of isolated product 38. 
Using readily available furancarbaldehydes 7 and aromatic amines 8; a broad range of cis-4,5- 
disubstituted pyrrolidinones could be synthesized with complete chirality transfer from 6 in high 
yields. For the majority of transformations investigated (rac)-6 was employed, nevertheless, 
employing enantiopure (+)-6 (Table 4.3, entry 1) gives rise to 38a with no erosion of 
stereochemistry.  
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Table 4.3. Sc(OTf)3  catalyzed one-pot reaction of 7, 8 and 6a 
HN
N
O
R2
N
Boc
CO2Me O
H
H
6 38
O O
NH2
R2
7 8
MW
rt to 125 oC
R1
R1
Sc(OTf)3 (5 mol%)
 
entry product time (h) yield (%)
b
1
HN
N
O
O
826.0
R1 R2
H H
2
HN
N
O
O
765.0H F F
35
38a
38b
HN
N
O
O
3
OMe
5.5H 4-OMe 7538c
 
Table continued.. 
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entry product time (h) yield (%)
b
8
HN
N
O
O
HN
N
O
O
NO2
83
77
7
HN
N
O
O
F
4 4.0
5.5
HN
N
O
O
655
OMe
5.5
4.5 84
R1 R2
H
H
H
H
9 715.5Ph
4-NO2
3-OMe
1-napthyl
3-F,4-Me
H
HN
N
O
O
386 6.0H 3,5-(Me)2
10
HN
N
O
O
69
Ph
5.5Ph 3,4-(Me)2
11
HN
N
O
O
74
Ph
5.5Ph 4-OMe O
38
38d
38e
38f
38g
38h
38i
38j
38k
HN
N
O
O
Ph
 
a Reaction conditions: 0.4 mmol 7, 0.4 mmol 8, 0.334 mmol 6, Sc(OTf)3 (5 mol%), 1.5 h room temp., 3-4.5 h 125 
oC, MW. b Yield of isolated product. 
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Both electron withdrawing and donating substituents on aniline are tolerated well, allowing the 
generation of a variety of quinoline moieties in 4-position of the pyrrolidinone (Table 4.3, entries 
2-7, 10-11). Out of the two regioisomers possible when 3-substituted anilines are employed 
(Table 4.3, entries 5-7), only the sterically less hindered quinoline placing that group in 7- rather 
than 5-position is formed. When the sterically more crowded 5-position cannot be avoided, yield 
of the product significantly decreases as 1-napthylamine resulted in the corresponding 
benzo[h]quinoline moiety instead of a quinoline (Table 4.3, entry 8). Also, phenyl substitution in 
5-position of furans is tolerated well (Table 4.3, entries 9-11).  
The structural assignment of pyrrolidinones 38 (Table 4.3, entries 1 and 10) was confirmed 
unambiguously by single-crystal X-ray analysis of 38a and 38j (Figure 4.3). 
                                
Figure 4.3. X-ray crystal structures of 38a and 38j in Table 4.3. 
 
4.3 Proposed Mechanism 
A plausible mechanism for the synthesis of 38 (Scheme 4.6) involves the initial Povarov reaction 
(sequence of Mannich reaction and intramolecular electrophilic substitution)18 of aldimine 9i 
onto enamide 6 at its exo-face. Interestingly, the bicyclic structure of 6 must also control the 
stereochemistry of the furan group, which is found on the endo-face of the bicyclo[4.3.0] ring 
system, being opposite as found in Povarov reactions with simple 2,3-dihydrofuran or 2,3-
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dihydro-1H-pyrroles.18a As a consequence of this stereochemical outcome, the cis-configured 
aldimine 9i rather than the trans-isomer must undergo the cycloaddition.  
Scheme 6. Plausible Mechanism for the Synthesis of Substituted Pyrrolidinones 38 
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Subsequent formation of iminium ion 39n by Sc(OTf)3-mediated cyclopropane ring opening 
followed by furan migration via a spiroannulated intermediate19 40n could lead to 41n, which 
undergoes rearomatization that requires an unusual C-N-bond  cleavage to give rise to 42n that 
finally collapses to the pyrrolidinone 38a upon N-Boc hydrolysis and lactamization. Indeed, as 
we discussed earlier, the Povarov products 10n and 11n could be obtained by carrying out the 
reaction at ambient temperature rather than at reflux condition. Notable, both endo- and exo-
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diastereomers with respect to the stereochemistry of the furan substituent, being readily 
separated on silica, could be obtained. While endo-10n was still the major stereoisomer formed, 
under these reaction conditions more of exo-11n must have formed compared to the reaction 
conditions for the one-step process to pyrrolidinones 38 described above. 
Subjecting endo-10n and exo-11n individually to those conditions, endo-10n cleanly rearranged 
to the previously obtained pyrrolidinone 38a, while exo-11n yielded the ring-opened polycyclic 
imine 43a indicating that the specific conformational arrangement of the endo-10n is optimal for 
the rearrangement to proceed. In the case of exo-11n, the migration of the furan moiety to the 
iminium-centre through the formation of crucial spiro-intermediate is presumably blocked by the 
H-atom on the ring C-atom next to the furan (Scheme 4.7). 
Scheme 4.7. Cycloaddition of 9i, 6 and Subsequent Rearrangement. 
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When other aromatic aldehydes but furans were employed, stable polycyclic imines 43 and 44 
were obtained as a diastereomeric mixture in very good overall yields (Table 4.4), suggesting 
that the furan moiety is unique for the observed 1,4-migration.  
Table 4.4. Synthesis of Policyclic Imine Derivatives 43a 
43 (major)
N
Boc
CO2Me
H
H
6
NH2
7 8a
MW
rt to 125 oC
Sc(OTf)3 (5 mol%)
ArCHO
HN
N
CO2Me
H
H
Ar
HN
N
CO2Me
H
H
Ar
MeCN
44 (minor)  
productb,c time (h)  yield (%)dentry
1
2
Ar
HN
N
CO2Me
HN
N
CO2Me
3.5
3.0
64
69
H
H
H
H
Ar 43
Ph
4-ClC6H4
43a
43b
dre
2:1
Ar
2.5:1
3
Ar
HN
N
CO2Me
3.0 61
H
H4-MeC6H4 43c 2:1
 
Table continued.. 
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productb,c time (h)  yield (%)dentry
5 2.5 65
7
Ar
HN
N
CO2Me
1.0 53
H
H
Ar
HN
N
CO2Me
H
H 702.0
Ar 43
4-NO2C6H4
1-napthyl
2-thionyl
6
43e
43f
43g
dre
2:1
2.6:1
1.5:1
4
Ar
HN
N
CO2Me
3.0 60
H
H4-OMeC6H4 43d 2:1
Ar
HN
N
CO2Me
H
H
 
a Reaction conditions: Aromatic aldehyde 7 (0.40 mmol), aniline 8 (0.40 mmol) and tert-butyl methyl 2-aza-
bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6  (0.334 mmol) in 4 mL, 5 mol% Sc(OTf)3 (0.016 mmol)  acetonitrile, 
1.5 h at room temp., 1-3.5 h at 125 oC, MW. b Major diastereomer, separated by column chromatography. c 
Stereochemistry determined by analogy to entry 1, Table 2. d Isolated yield of major isomers. e Determined by 1H 
NMR. 
The structure of 43a (Table 4.4, entry 1) was unequivocally established by single-crystal X-ray 
analysis (Figure 4.4). 
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Figure 4.4.  X-ray crystal structures of 43a in Table 4.4. 
This observation opens up the opportunity for a four component reaction by introducing suitable 
external nucleophile that could add to the imine functionality in 43. Indeed, Sc(OTf)3 catalyzed 
MCR between benzaldehyde 7a, aniline 8a, enamide 6 and pyrrole 45 resulted in the formation 
of a polycyclic compound 46 as a mixture of four diastereomers (4.5:2.5:2:1) with 42% of 
isolated yield of the major diastereomer (Scheme 4.8). 
Scheme 4.8. Functionalization of 43 via Intermolecular Trapping of Iminium Ion 
reflux
N
H
46
MeCN, MS 4 Å
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(20 mol%)N
Boc
CO2Me
H
H
6
NH2
7a 8a
PhCHO
45
HN
NH
CO2Me
H
H
NH
42% yield
(major diastereomer)  
 
4.4 Properties of the Cis-Pyrrolidinones 
As an initial effort towards studying biological activities, we measured the fluorescence spectra 
of some of the cis-pyrrolidinones and interestingly compounds 38a and 38h showed a strong 
fluorescent property, which could make them potentially useful as biomarkers (Figures 4.5 and 
4.6). Some more studies are still under investigation. 
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Figure 4.5. Excitation (left) and Emission (right) spectra of compound 38a (0.2 µM solution in 
acetonitrile) with their indicated maxima. 
 
 
 
 
 
 
Figure 4.6. Excitation (left) and Emission (right) spectra of compound 38h (0.2 µM solution in 
acetonitrile) with their indicated maxima. 
 
4.5 Conclusion 
In conclusion, we have developed an unprecedented, catalytic three component reaction, based 
on the readily available donor-acceptor substituted cyclopropane adduct of N-Boc-pyrrole 6 to 
access a range of functionalized cis-4,5-disubstituted pyrrolidinones 38 in a stereoselective 
manner with high yield. The use of chiral cyclopropane derivative in the initial step affords the 
HN
N
O
O
38a
HN
N
O
O
38h
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pyrrolidinones in high enantiomeric excess. Finally, systematic multi-step syntheses were 
performed to establish the plausible mechanism for the stero-specific nature of this MCR which 
shows that Sc(OTf)3 catalyzed opening of cyclopropane ring leads to the formation of iminium 
cation as a common and key intermediate which was further trapped employing external 
nucleophile. Furan containing endo-Povarov product can undergo a facile 1,4 furan migration 
through a spiro-intermediate leading to stereo-selective synthesis of cis-lactam, while its exo-
analogue cannot afford such migration due to the steric hindrance by it neighboring H-atom and 
thus results in the formation of the polycyclic imine. Moreover, other non-furan aromatic 
analogues give rise to similar polycyclic imines as they presumably lack the formation of 
important spiro-intermediate for such long distance 1,4 migration. Since, cis-pyrrolidinones are 
ubiquitous structural constituents in pharmacologically important molecules with many 
interesting applications; the operational simplicity and excellent yields, combined with lower 
amount of catalyst loading, time and step economic aspects should make this new heterocycle 
synthetic strategy highly attractive and promising in the development of new functionalized 
molecules. 
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5. A Catalytic Multicomponent Approach for the Efficient Syntheses of 
Tetrahydro-, Dihydro- and 1H-Pyrazoles  
 
5.1 Biological Importance 
Five-membered aza-heterocycles containing two ring nitrogen atoms, e.g., tetrahydro-, dihydro- 
and 1H-pyrazoles are found as core structural components of a few complex natural products and 
numerous synthetically designed bioactive molecules including agrochemicals1 and important 
drugs such as Celebrex2 and Viagra.3 Most of these heterocyclic compounds not only 
demonstrate high potential as antidepressants,4 analgesics,5 anticonvulsants,6 but also possess 
many other therapeutic applications (Figure 5.1).7-9 As a consequence, these aza-heterocycles 
have become attractive synthetic targets, demanding the development of new/alternative 
chemical reactions for their easy access from readily available starting materials. 
N N
N
O
N
OH
Cl
NC
L
      
N
H
N
R3
R2
R1
H
H
M
          
N NNH
S
Et
O
N  
Figure 5.1. Compound L is used for treating and/or preventing renal injury, cardiovascular 
diseases, especially hypertension, and/or endocrine diseases; Compound M is a potent anti-
proliferative agent;10 Compound N shows antidepressant activity. 
 
5.2 Literature Precedence on the Syntheses of Tetrahydro-, Dihydro- and 1H-
Pyrazoles 
Cyclocondensation of 1,3-dicarbonyl compounds 48 with hydrazine derivatives 49 represents 
one of the simplest and most general approaches for the construction of pyrazole derivatives 
(Scheme 5.1, route A).11 A serious drawback of this cycloaddition method is the lack of 
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selectivity; products are obtained as a mixture of different regioisomers, if the reactivity of the 
two carbonyl groups is not profoundly different. Replacement of 1,3-dicarbonyl compounds with 
α,β-ethynyl ketones or esters could afford regioselectivity, depending on specific substrates.12 
However, if a diversity-oriented synthesis of pyrazoles is desired, these methods become 
cumbersome as each 1,3-diketone must be purified prior to use, since they are often obtained as a 
mixture of condensation products. Furthermore, the presence of electron-withdrawing functional 
groups on 48, such as aldehydes, nitriles, esters and alkyl halides, prevent the required 
transformation to access the desired pyrazole 47. Another increasingly utilized approach is the 
functionalization at N-1 of the preformed tri-substituted pyrazole 50 by either nucleophilic 
substitution or transition metal catalyzed C-N bond formation reaction (Scheme 5.1, route B).13 
Scheme 5.1. General Approaches for the Syntheses of Substituted Pyrazoles 
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47
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O
R4
O
R3
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B
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N
N
R1 R4
R3
R4
NHN
R2
R3
R1 X
48 49 52 53
50 51  
Arguably, the most popular and potential approach for the synthesis of substituted pyrazoles is 
the 1,3-dipolar cycloaddition of azomethine imines 52 with multiple-bond containing systems 53 
under thermal or strongly acidic conditions (Scheme 5.1, route C).14-16  
Reaction of N-monosubstituted hydrazones 54 with electron-deficient nitroolefins 55 to afford 
substituted pyrazoles 57 in a regioselective manner under catalyst free condition, can be 
considered as a significant alternative to the previously mentioned harsh reaction conditions 
(Scheme 5.2).17  
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Scheme 5.2. Reaction of N-Monosubstituted Hydrazones 54 with Nitro-Olefins 55   
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Methods have also been developed for the enantioselective synthesis of these valuable 
heterocycles. In this regard, Leighton and co-workers reported an asymmetric intermolecular 
[3+2] cycloaddition of benzoylhydrazone 58 and acyclic enol ether 59 using 1.2 equivalents of a 
chiral pseudoephedrine-derived silane Lewis acid 60 to afford the corresponding enantiopure 
tetrahydropyrazoles 61 in good yields and diastereoselectivity (Scheme 5.3).18  
Scheme 5.3. Chiral Silicon Lewis Acid Catalyzed [3+2] Cycloaddition of Acylhydrazone 58 
and Enol Ether 59 
R H
N
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toluene, 23 oC,
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yield = up to 93%
dr = up to>99:1
ee = up to 99%
58 59
60
61
 
In 2009 Müller and List showed that chiral Brønsted acids (63) can efficiently catalyze the 
cycloisomerization of α,β-unsaturated hydrazones 62 to produce pyrazolines or dihydropyrazoles 
64 in high yields and enantiomeric excess (Scheme 5.4).19  
 
Chapter	4																			Syntheses	of	Tetrahydro‐,	Dihydro‐	and	1H‐Pyrazoles	 							2012	
 
74 
 
Scheme 5.4. Chiral Phosphoric Acid-Catalyzed Intramolecular 6π-Electrocyclization of α-
β-Unsaturated Arylhydrazones 62 
N
H
N N N
R1
R2
R1
R2
chlorobenzene,
30 oC, 75-96 h
63 (10 mol%)
62 64
O O
P
HO O
63
yield = up to 99%
ee = up to >96%  
Recently, Tsogoeva et al. reported an in situ-generated silicon Lewis acid-derived chiral 
Brønsted acid (67) catalyzed [3+2] cycloaddition of preformed acylhydrazone 65 and 
cyclopentadiene 66 for the enantioselective synthesis of pyrazolidines or the so called 
tetrahydropyrazoles 68 (Scheme 5.5).20 
Scheme 5.5. [3+2] Cycloaddition of Acylhydrazone 65 and Cyclopentadiene 66 Using 
BINOL Phosphate/Ph2SiCl2 67 as a Catalytic System. 
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5.3 Cu(OTf)2-Ctalyzed Multicomponent (AAB-Type) Approach for the 
Syntheses of Tetrahydro-, Dihydro- and 1H-Pyrazoles 
Although, the use of various Lewis acids allows the cycloaddition to proceed under milder 
condition with improved diastereoselectivity compared to the conventional methods,21-23 many 
available methods for synthesizing aza-heterocycles are limited to intramolecular versions24a,b 
and/or the substrates are mainly restricted to preformed acylhydrazones25 and acyclic enol 
ethers24c or silyl enol ethers, confined by several drawbacks such as unsatisfactory yields, poor 
chemo- and/or stereoselectivity, etc. Electron-deficient olefins, such as nitroolefins are usually 
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known to undergo this type of cycloaddition, mainly with N-monosubstituted hydrazones17 or 
diazo compounds26. Therefore, the development of more general strategies for the syntheses of 
these structurally diverse heterocyclic compounds with multiple functionalities is highly 
desirable. Till to date, there are no such reports where enamides and cyclic enol ethers are 
employed as electron-rich olefins for synthesizing pyrazoles and related five-membered 
heterocycles. Moreover, utilization of in situ-derived N-hydroxymethyl hydrazones 73 from 
readily available aldehydes and N-monosubstituted hydrazines in a one-pot multicomponent 
fashion (AAB-type), instead of using preformed hydrazones 70 is novel. As a continuation of our 
ongoing interest in exploring the scope of LA-catalyzed cycloaddition reactions,27 we envisioned 
the possibility of generating a 1,3-dipol on the in situ-generated α-hydroxy-N-
aminomethylphenylhydrazone 73 by the condensation of two equivalents of aldehyde and one 
equivalent of N-methyl hydrazine, which could then undergo a cycloaddition reaction with 
various electron-rich olefins 71 affording functionalized five-membered aza-heterocycles 74 
(Scheme 5.6).  
Scheme 5.6. Strategy for the Syntheses of Five-Membered Aza-Heterocycles 74a,b 
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a X = N-Boc, O; n = 1, 2. b When one equiv of aldehyde 7 was used, the corresponding hydrazone 70 was obtained, 
but the desired cycloaddition product 72 was not observed upon addition of the olefin 71. 
In this scenario, a few challenges had to be encountered: (1) the hydrazine 69 should not 
deactivate the LA catalyst; (2) the catalyst should preferentially coordinate to the active 
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intermediate 73 to introduce regioselectivity but not with the azomethine imine 70 which might 
form first during the course of the reaction; (3) the reaction should proceed through a concerted 
pathway in order to achieve diastereoselectivity.  
We initiated our studies by investigating a one-pot, three component (AAB-type) reaction of two 
equivalents of benzaldehyde 7a, one equivalent of N-methyl hydrazine 69a and tert-butyl 2,3-
dihydropyrrole-1-carboxylate 71a in presence of various LA catalysts and the results are 
summarized in Table 5.1.  
Table 5.1. Optimization of Lewis Acid Catalyzed [3+2] Cycloaddition Reactiona 
DCM, rt, air
Cu(OTf)2 (20 mol%)
O
H
N N
NH2
Boc
7a 69a 71a
NHN
N
Boc
H
H
74a
(2 equiv)  
entry catalyst x mol% yield
b
 (%)
time 
(h)
5
6
Cu(OTf)2
Cu(OTf)2
10
15
12
12
45
56
7 Cu(OTf)2 20 665
8
9
Yb(OTf)3
Yb(OTf)3
10
20
12
12
>10
25
condition
rt
rt
rt
rt
rt
4 CuI 20 rt
1 Blank -- rt
2 Blank reflux
3 Blank
--
-- MW, 
125 °C
24
24
2
24
--
--
--
--
 
                                                                                                         Table continued.. 
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entry catalyst x mol% yield
b
 (%)
time 
(h)
10 Sc(OTf)3 15 1455
11 Sc(OTf)3 20 964
c
condition
rt
rt
 
aReaction conditions: 0.94 mmol 7a (2.0 equiv), 0.47 mmol 69a (1.0 equiv), 0.47 mmol 71a (1.0 equiv), 
Catalyst (x mol%) and DCM (2 mL). bYields of isolated product 74a. c1:1 mixture of two diastereomers. 
To our delight, the desired cycloaddition occurred at room temperature affording 
tetrahydropyrrolo[2,3-c]pyrazole 74a after 6 h in 65% yield as a single diastereomer in presence 
of 20 mol% of Cu(OTf)2 as the best suited catalyst (Table 5.1, entry 7). Lowering in the catalyst 
loading resulted in decreased yield of 74a in parallel with an increased reaction time (Table 5.1, 
entries 5 and 6). Among the other Lewis acids, 20 mol% of Sc(OTf)3 was also found to produce 
comparable result with a significant loss of diastereoselectivity of the products (dr 1:1). Further 
optimization studies revealed that the aforementioned reaction does not occur under N2 
atmosphere; initial exposure of the reaction vessel to air for 15-30 minutes is necessary to have a 
specific control over formation of the desired products. To investigate the role of areal oxygen, 
we carried out a reaction in O2 atmosphere, which failed to produce the desired products. A 
complex mixture of products was formed in this case which could not be characterized. This 
observation led us to conclude that the role of moderate amount of aerial O2 was presumably 
crucial to regenerate Cu(II), the active catalyst; since, Cu(II) ions of Cu(OTf)2 are known to be 
reduced to Cu(I) ions by hydrazine28. No product formation was observed, when the reaction was 
carried out in presence of cupper iodide, proving that Cu(I) ion was unable to catalyze this 
reaction. When the reaction was continued for longer time in air, the corresponding 
dihydropyrazole 75a was isolated instead of 74a after 10 h in 65% yield. A prolonged reaction 
time of 24 h resulted in the corresponding 1H-pyrazole 76a as a single regioisomer in 83% yield 
(Table 5.2, entry 1). With these optimized reaction conditions in hand, we next investigated the 
scope of cycloaddition using a variety of other electron-rich olefins 71 (Table 5.2). The reaction 
was well tolerated with various cyclic and acyclic enamines and enol ethers to afford 74-76 
depending upon the time of reaction in moderate to good yields with excellent regio- and 
stereoselectivity. 
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Table 5.2. Substrate Scope with Different Olefinsa 
DCM, rt, air
Cu(OTf)2 (20 mol%)
O
H
N
NHN
XX
n
[X = N-Boc, O]
n
NH2
[n = 1, 2]
NN
X
n
NN
X
n
[O] [O]
7a
69a
71
74 75 76
 
N
O
3
NN
N
O
NN
N
O
(24 h, 88%)(6 h, 85%)
--
71c 75c 76b
4
NN
5
NHNO O
O
OH
6
NNO
O
H
H
7
OSiMe3Ph
NN
Ph
(10 h, 65%)
(16 h, 60%)
(12 h, 55%)
(10 h, 95%)
--
--
NN
O
H
(30 h, 61%)
----
NN
OH
(28 h, 67%)71d
71e
71f
71g
74c
75d
75e
75f
76c
76e
NN
O
(30 h, 63%)76d
--
entry dihdropyrazole
b,c
1
olefin
2
NN
N
NHN
N
Boc
N
Boc
Boc
N
BocH
H
tetrahydropyrazole 1H-pyrazoleb,c
NHN
N
Boc
H
H
(6 h, 65%) (24 h, 83%)
(12 h, 75%)
NN
N
Boc
H
(30 h, 77%)
71a
71b
71 74 75 76
74a
74b 75b
76a
--
NN
N
Boc
(10 h, 65%)75a
H
 
aReaction conditions: 0.94 mmol 7 (2.0 equiv), 0.47 mmol 69 (1.0 equiv), 0.47 mmol 71 (1.0 equiv), 
Cu(OTf)2 (20 mol%) and DCM (2 mL) in air at room temperature. bTime of reaction and yield of isolated 
products are in the parenthesis. cReactons were performed in separate vessels for longer time. 
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The formation of a mixture of compounds 74, 75 and 76 was never encountered due to well 
resolved reaction time under the provided reaction conditions (see experimental part and Table 
5.3). Six-membered cyclic enamine 71b afforded 74b as a single diastereomer in 75% yield after 
12 h. When the reaction was carried out for 30 h, 75b was obtained in 77% as a single 
diastereomer (Table 5.2, entry 3). In this case, we could not obtain the corresponding 1H-
pyrazole even after carrying out the reaction for 2 days in air. Moreover, no pyrazole formation 
was observed even after treating the dihydropyrazole 75b with Pd/C in air or with the oxidizing 
reagent DDQ, which caused presumably due to the resistance towards the generation of two 
adjacent exo-cyclic double bonds to the six membered hydrocarbon back bone. The acyclic 
enamide 71c afforded the desired products 75c and 76b in excellent yields and selectivity in a 
much shorter reaction time (Table 5.2, entry 3). In this case we could not isolate the 
corresponding tetrahydropyrazole, presumably due to faster conversion of tetrahydro-analogue to 
dihydro-analogue 75c. However, when enamines were replaced by enol ethers, the latter were 
found to be less reactive as expected and increased reaction time was required to produce the 
desired products (Table 5.2, entries 4, 5 and 6). In case of five-membered cyclic enol ether 71d 
the cycloaddition resulted in the formation of ring-opened product 75d as a mixture of two 
inseparable diastereomers (dr 1:1). The structural assignment of 75c and 75d (Table 5.1, entry 3 
and 4) were confirmed unambiguously by single-crystal X-ray analysis (Figure 5.2).  
         
Figure 5.2. X-ray crystal structure of compounds 75c and 75d in Table 5.2. 
Six-membered enol ether, 3,4-dihydro-2H-pyran 71e afforded the corresponding tetrahydro- and 
dihydro pyrazoles (74c and 75e) in moderate yields, however, corresponding pyrazole was not 
obtained even after 2 days, similar to the case of 71b. Next, we examined the substrate generality 
with respect to aldehydes 7 and N-monosubstituted hydrazines 69 and the results are summarized 
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in Table 5.3. In this context, it is important to mention that in all the cases, three different types 
of products were isolated separately from different reaction vessels based on the controlled 
reaction times provided before quenching the catalyst. Both electron withdrawing and donating 
substituents on aldehyde are tolerated well. 
Table 5.3. Scope of the Aldehydes and N-Mono-substituted Hydrazinesa  
DCM, rt, air
Cu(OTf)2 (20 mol%)
R1
O
R2
H
N
R1
NHN
XX
n
[X = N-Boc, O]
n
NH2
[n = 1, 2]
R2
R1
NN
X
n
R2
R1
NN
X
n
R2
[O] [O]
7
69
71
74 75 76
 
entry 76c
time (h), 
yield(%)b
olefin
5 74g
(10, 75)
R1
NN
N
NHN
N
Boc
N
Boc
Boc
N
Boc
11 76m
(24, 69)
R1
NNO
OH
R1 R2
Ph
4-NO2C6H4 Me
4-MeC6H4 Me
1
2
3
4-BrC6H4 Ph
Me6
R1
2-FC6H4 Me
76h
(18, 70)
76f
(10, 87)
76g
(15, 79)
74h
(16, 64)
N
O
7 4-ClC6H4 Me
i-Bu Me8
R2
R2
R2
(15, 88)
76j
(18, 59)
H
H
NN
N
R2
O
R1
4 74f
(15, 51)
i-Bu Me
NN
N
Boc
R2
12 76n(30, 47)i-Pr Me
R1
NN
OH
R2
2-OMeC6H4
2-OMeC6H4
74 75c
NN
N
R2
O
R1
R1
H
--
--
--
R1
NHN
N Boc
R2
H
H
time (h), 
yield(%)b
time (h), 
yield(%)b
--
74d
(8, 76)
74e
(10, 75)
75i
(26, 71)
75j
(32, 60)
75h
(30, 55)
(6, 86)
75l
(12, 55)
75m
(10, 65)
75n
(15, 45)
--
75g
(8, 85)
--
--
--
--
--
--
--
--
R1
NN
N
Boc
R2
H
Me9 76k
(15, 89)
--
4-OMe Me10 76l
(24, 80)
--
75q
(20, 70)
R1
NHN
O
O
4-ClC6H4 Me
Ph
Me
13
14
15
75o
(30, 71)
75p
(24, 73)
R2
2-FC6H4
4-NO2C6H4
H
H
R1
NN
O
R2
H
--
74k
(12, 70)
74i
(14, 69)
74j
(12, 70
--
--
--
2-F --
--
71
71a
71b
71c
71d
71e
75k 76i
 
Table continued.. 
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entry 76c
time (h), 
yield(%)b
olefinR1 R2 74 75c
time (h), 
yield(%)b
time (h), 
yield(%)b71
16 76o
(18, 65)
NN
O O2-FC6H4 Me
F
17 76p
(24, 88)
4-OMeC6H4 Me
OSiMe3 NN
75r
(10, 64)
--
NN
O
F
--
NN
H
75s
(16, 85)----
71f
71h MeO MeO  
a Reaction conditions: 0.94 mmol 7 (2.0 equiv), 0.47 mmol 69 (1.0 equiv), 0.47 mmol 71 (1.0 equiv), Cu(OTf)2 (20 
mol%) and DCM (2 mL) in air at room temperature. b Time of reaction and yield of isolated products are in the 
parenthesis. c Reactions were performed in separate vessels for longer time. 
Electron withdrawing groups on ortho- or para- positions of aldehyde increased the yield of the 
products with a shortened reaction time (Table 5.3, entries 1, 5, 7, 11, 13, 14, 15 and 16). Six 
membered cyclic enamide, tert-butyl 3,4-dihydropyridine-1(2H)-carboxylate (71b) and enol 
ether, 3,4-dihydro-2H-pyran (71e) did not afford any pyrazole, but only the corresponding 
tetrahydro- and dihydro pyrazoles were obtained due to the lack of an appropriate orientation for 
the final dehydrogenation step. The silyl enol ethers were also suitable substrates (Table 5.2, 
entry 7 and Table 5.3, entry 17), resulting in 76e and 76p in 95% and 88% yields respectively.29 
 
5.4 Mechanistic Investigation 
To clarify the reaction mechanism (Schemes 5.7-5.9), we performed a step wise reaction 
sequence, initially with one equivalent of aldehyde 7. Addition of olefin 71c to hydrazone 70a, 
formed by the condensation of one equivalent of benzaldehyde 7a and methylhydrazine 69a in 
presence of 20 mol% of Cu(OTf)2 failed to produce the desired product 76b (Scheme 5.7). All 
the starting materials were recovered after 24 h. This experiment proved that for this particular 
system, addition of electron-rich olefins to normal N-methylhydrazone does not take place in a 
normal [3+2] cycloaddition mode.  
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Scheme 5.7. Stepwise Reaction Sequence Using One Equivalent of Benzaldehyde 7a. 
O
H
N
NH2 N
H
N
N
H
N
DCM, rt, air
Cu(OTf)2 (20 mol%) No Reaction
DCM or neat
N
O
7a 69a 70a
70a 71c
1.5 h, reflux
Isolated
 
Next, we introduced two equivalents of aldehyde in a sequential manner. The preformed 
hydrazone 70a was added to a pre-stirred (30 minutes) solution of 20 mol% of Cu(OTf)2 and one 
equivalent of benzaldehyde 7a, stirred for another 15 minutes to form the aminoalcohol 
intermediate 73a which was isolated and characterized by NMR spectroscopy. The addition of 
olefin 71c to the α-hydroxymethyl hydrazone 73a resulted in the formation of the desired 
product 76b after 24 h in 88% of isolated yield (Scheme 5.8).  
Scheme 5.8. Cu(OTf)2-Catalyzed Syntheses of Pyrazoles 76 in a Sequential Manner with 
Two Equivalents of Aldehyde 7a. 
NN
N
O
O
N
H
N
DCM, rt, air
Cu(OTf)2 (20 mol%)
OH
N
N
-PhCHO (7a)7a 70a 76b (24 h, 88%)
DCM, rt
73a
71c
 
Introduction of a different aldehyde 7k instead of 7a at the second step of the previously 
mentioned reaction sequence afforded the pyrazole 76l having para-methoxyphenyl substitution 
at the five position which corresponds to the aldehyde 7k (Scheme 5.9).  
Scheme 5.9. Cu(OTf)2-Catalyzed Syntheses of Pyrazoles 76 in a Sequential Manner with 
Two Equivalents of Different Aldehydes 7a and 7k. 
NN
N
O
O
N
H
N
DCM, rt, air
Cu(OTf)2 (20 mol%)
OH
N
N
-PhCHO (7a)
O O O
obtained
instead of 76b
7k 70a
76l (26 h, 80 %)
DCM, rt
71c
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Based on these observations, a plausible mechanism is proposed for the current multicomponent 
reaction (Scheme 5.10), involving the initial formation of mono-phenyl substituted-N-
methylhydrazone (azomethine imine, 70a), which consequently undergoes nucleophilic attack at 
the carbonyl-C of aldehyde by the sec-amine center of 70a to form the active intermediate, α-
phenyl-N-hydroxymethyl-N-methylhydrazone 73a, which could also be formed even in the 
absence of Cu(II) ions but could not afford the desired products upon addition of electron rich 
olefins. However, utilization of 20 mol% of Cu(OTf)2 smoothly afforded 77a through the 
chelation of 73a to Cu(II) ion, utilizing the α-hydroxy and imine N-atom of Ph-CH(OH)-NMe-
N=CH-Ph (73a) as chelating arms. The Cu(II) ions also promote the assembling process through 
further binding to the hetero-atom of electron rich olefin which subsequently undergoes 
nucleophilic substitution at the carbon center bearing the hydroxyl group in a concerted fashion 
and a much shortened reaction time was required in this case. In some cases (mainly for five 
membered cyclic enol-ether, Table 5.3, entry 11) presumably, the cationic intermediate Ph-
HC=N+(Me)-N=CH-Ph (78a) is formed first as a consequence the OH- group being transferred to 
Cu(II) ion from the intermediate 73a, resulting in the formation of 1:1 diastereomeric mixture of 
the products. Thus Cu(II) ion promotes C-OH bond activation as an important step. 
Scheme 5.10. Plausible Mechanism for the Syntheses of Aza-Heterocycles and Model for 
Stereoselection 
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The corresponding cationic species (iminum or olefinium ion 77a) undergoes ring closer to form 
the desired cationic five-membered aza-heterocycle (78a) which then undergoes hydrolysis 
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producing tetrahydropyrazole (74c) with the removal of a molecule of benzaldehyde. In most of 
the cases, the tetrahydropyrazoles 74c undergo subsequent aerial oxidation to their corresponding 
dihydro- and/or 1H-pyrazole analogues. In terms of regio- and stereoselectivity, the formation of 
70a through the protection of -NH2 group of hydrazine and substitution of OH- group of 73a in a 
concerted pathway are the crucial steps. The mechanism is also supported by the complete 
consumption of aldehyde at the beginning and then regeneration of aldehyde at the completion of 
the reaction, observed on the TLC and monitored by IR studies (Scheme 5.11).  
The IR spectra revealed initial decrease in the relative intensity of the previous carbonyl 
stretching at 1699 cm-1 (Figure 5.3, B), after 1 h of addition of 69a the sharp band at 1699 cm-1 
had almost disappeared (Figure 5.3, C). The IR spectra, recorded after addition of olefin 71c 
showed the reappearance of the sharp peak at 1699 cm-1 (Figure 5.3, D). After 6 h, the relative 
intensity of the aldehyde peak was significantly increased (Figure 5.3, E) supporting the removal 
of a molecule of aldehyde 7a.  
Scheme 5.11. Mechanistic Proof: IR Studies Showing the Consumption and Regeneration 
of Benzaldehydea 
DCM, rt, air
Cu(OTf)2 (20 mol%)
O
H
N
NH2
NHN
H
H
(2 equiv)
O
O
7a 69a 71e 76c
 
a  Reaction conditions: 0.4 mmol benzaldehyde 7a (2.0 equiv), 0.235 mmol methylhydrazine 
69a (1.2 equiv), 0.4 mmol 3,4-dihydro-2H-pyran 71e (1.0 equiv), Cu(OTf)2 (20 mol%) and 
DCM (2 mL); 
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Figure 5.3. (A) Benzaldehyde + Cu(OTf)2 in DCM (0.5 mL); (B) After addition of 
methylhydrazine; (C) After 1 h of addition of methylhydrazine; (D) After 2 h of addition of 
olefin; (E) After 6 h of addition of olefin. 
Moreover, the active intermediate α-phenyl-N-hydroxymethyl-N-methylhydrazone 73a was 
isolated and characterized by NMR and Mass spectrometric methods. The mass spectrum of 73a 
shows M+/z value of 223.12 of the corresponding cation Ph-HC=N+(Me)-N=CH-Ph (80a) upon 
loss of OH- anion. In absence of any olefin, 73a undergoes aerial oxidation into the 
corresponding amidohydrazone 81a which was isolated and well characterized by NMR30 and 
Mass-spectroscopic methods after 24 h. The similar oxidized product can also be quantitatively 
obtained using 5 mol% of anhydrous FeCl3 instead of 20 mol% of Cu(OTf)2, after 3 h in 
presence of air (Scheme 5.12).  
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Scheme 5.12. FeCl3 Catalyzed Oxidation of Intermediate 73a to the Corresponding Amide 
81a 
O
N
HN+
OH
N
N
Ph
Ph
O
N
N
Ph
FeCl3 (5 mol%)
rt, air
2 h
Isolated and
characterized
Isolated, readily 
gets oxidised
[O]
N
N
Ph
Presence of this cation was determined
from the peak at 223.12 Mass spectroscopy
7a 70a 73a
80a
81a
rt
 
 
5.5 Conclusion 
In summary, we have developed a Cu(II)-catalyzed multicomponent, regio- and stereoselective 
syntheses of pharmaceutically relevant aza-heterocycles via a [3+2]-type cycloaddition based on 
the in situ-derived α-hydroxy-aminomethyl-phenylhydrazone (73) in good to excellent yields. 
The regio- and stereoselectivity come into play through the protection of –NH2 group of mono 
substituted hydrazine and Cu(II) catalyzed substitution of OH- group of 73 in a concerted 
pathway. Functionalized pyrazoles were thus synthesized from readily available aldehydes, 
hydrazines and olefins. The broad chemistry and good substrates scope are further attractive 
aspects of this novel methodology. 
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6.1 Summary 
This Ph.D thesis describes the development of a number of novel multicomponent synthetic 
methodologies for making various biologically and pharmaceutically relevant heterocyclic 
compounds in good yields and excellent selectivity under appropriate conditions, which are 
briefly summarized in Figure 6.1.  
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Figure 6.1. Syntheses of various nitrogen-heterocycles, utilizing the Povarov-type reaction as the 
key step. 
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In Chapter 1, we have given a brief overview on the recent advancements of the Povarov 
reaction. Several trends have been shown, how important heterocyclic scaffolds other than 
tetrahydroquinolines could be synthesized utilizing the Povarov reaction as a key step. 
In Chapter 2, we have introduced the monocyclopropanated N-Boc-protected pyrrole 6 (Boc = 
tert-butoxycarbonyl) as an electron-rich olefinic component, keeping in mind the plethora of 
chemistry of the D-A substituted cyclopropane derivatives. We have successfully synthesized a 
range of functionalized tetrahydropyrroloquinolines 10 and 11. Both endo- and exo-
diastereomers (10 and 11 respectively) have been isolated in good yields, following a LA-
catalyzed MC Povarov reaction. Several substituted aromatic aldehydes and anilines have been 
well tolerated for the reaction. The presence of electron withdrawing groups on either aldehyde 
or aniline part has shown positive impacts on both yield and reaction time. We have found 
Cu(OTf)2 as the best catalyst among all other metal-triflates examined, presumably due to its 
strongest binding to N-atom of in situ-generated N-arylaldimines. Lewis acids have 
predominantly produced the endo-product 10, while, the trend have been found to be reversed 
when the system is tuned by replacing Lewis Acids [M(OTf)x] by Brønsted acids (TfOH). 
Moreover, we have demonstrated the utilization of magnetically separable CuFe2O4-
nanoparticles as a reusable heterogeneous catalyst for the Povarov reaction with the efficient 
recycling of the catalyst up to three consecutive cycles. The syntheses of enantiopure 
pyrroloquinolines have also been carried out utilizing Jacobsen´s chiral thiourea catalyst which 
has been previously examined by the group of Jacobsen for the Povarov reaction with different 
substrates.  
In Chapter 3, we have shown that furyl substituted endo-tetrahydropyrroloquonolines (10n to 
10x) (Ar1 = 2-furyl or 2-C6H5-furyl) can further undergo an unprecedented rearrangement to 
produce cis-4,5-disubstituted pyrrolidinones (38) in very good yields with excellent 
stereoselectivity, when refluxed for 12 hours in the presence of 40 mol% of Sc(OTf)3. The 
catalyst loading has been successfully reduced by eight times (5 mol%) with an increased yield 
of 99%, when irradiated under microwave at 125 °C. A plausible mechanism has been proposed 
for the aforementioned rearrangement, initiated by the generation of Sc(OTf)3-mediated iminium 
ion as a key intermediate through the cyclopropane ring-opening, followed by a 1,4-furan 
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migration via a spiroannulated intermediate. The formation of the spiroannular intermediate has 
been proposed as the critical step for the rearrangement to occur, which once formed; undergo a 
1,4-furan migration followed by rearomatization at the expense of an unusual C-N-bond 
cleavage giving rise to the cis-pyrrolidinone (38) upon N-Boc hydrolysis and lactamization. On 
the contrary, the exo-diastereomers 11n (Ar1 = 2-furyl or 2-C6H5-furyl) has been found to 
undergo a simple cyclopropane ring-opening reaction to form the polycyclic imines (43), failing 
to undergo 1,4-furane migration due to the steric hindrance, created by the H-atom, connected to 
the next C-atom of –CH(NHR)-2-furyl centre. For non-furan aromatic aldehydes, both the exo- 
and endo-diastereomers (10 and 11 with Ar1 = other than furan or substituted furan) have 
resulted in similar polycyclic imines (43), due to lack of long distance 1,4-migration of non furan 
aromatic rings. As a partial proof of the proposed reaction mechanism, the iminium intermediate 
has been trapped (as functionalized pyrrole 46) by introducing an external nucleophile, e.g., 
pyrrole. Finally, we have optimized the reaction condition for synthesizing the cis-pyrrolidinones 
(38) as a one-pot, multicomponent reaction under MW irradiation. When a mixture of furan-2-
aldehydes 7i, anilines 8 and 6 has been irradiated under MW, in the presence of 5 mol% of 
Sc(OTf)3, initially at room temperature (to minimize the formation of the exo-isomer) and then at 
a higher temperature of 125 °C for 4.5-6 h, similar pyrrolidinones (38) are obtained in good 
yields.  
In Chapter 4, we have described a Cu(OTf)2 catalyzed MCR (AAB-type) of aldehydes, electron 
rich olefins and N-monosubstituted hydrazines. The chemistry has followed its own way and 
produced functionalized tetrahydropyrazoles (74). The preformed hydrazone did not react with 
electron rich olefins in the presence of LA [Cu(OTf)2]. The systematic investigations showed 
that the first equivalent of aldehyde was utilized for the in situ-generation of the hydrozone, 
which further reacted with the second equivalent of the aldehyde to give an α-
hydroxyaminomethylhydrazone as the key intermediate, followed by the Cu(II) catalyzed 
nucleophilic -OH substitution by olefin in a concerted way in order to produce functionalized 
tetrahydropyrazoles in regio- and stereoselective manner. The tetrahydropyrazole can be further 
oxidized to the corresponding dihydro- (75) and 1H-pyrazoles (76) depending upon the substrate 
as well as the reaction time. The reaction sequence was monitored by IR studies and cross-
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aldehyde experiments. Moreover, the critical α-hydroxyaminomethylhydrazone intermediated 
was isolated as the corresponding amide and well-characterized by spectroscopic methods. 
6.2 Future Prospective 
We have made a plenty of functionally diverse heterocyclic compounds by utilizing novel 
synthetic approaches. Some of these compounds had been sent to the Kansas University, USA, 
which will be finally sent to NIH, USA for screening after a thorough purification tests. At the 
moment, eighteen compounds have successfully passed through the purity-test and their 
screening processes are still under investigation.  
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7. Experimental Part 
 
7.1 General Information 
1H NMR-Spectra were recorded on Bruker Avance 300, Bruker Avance 400, Bruker Avance 
600, Varian Inova 600, Bruker DRX-400 with a H/C/P/F QNP gradient probe and Bruker 
Avance 500 with a dual carbon/proton CPDUL cryoprobe. The chemical shift δ is given in 
[ppm], calibration was set on chloroform-d1 (7.26 ppm) or tetramethylsilane (0.00 ppm) as 
internal standard. The spectra were evaluated in 1st order and the coupling constants are given in 
Hertz [Hz]. The following abbreviations for the spin multiplicity were used: s = singlet, d = 
doublet, t = triplet, q = quartet, qt = quintet, m = multiplet, dt = doublet of a triplet, dd = double 
doublet, ddd = doublet of a double doublet, sept = septet. The used deuterated solvents are given 
separately.  
13C NMR-Spectra were recorded on Bruker Avance 300, Bruker Avance 400, Bruker Avance 
600, Varian Inova, Bruker DRX-400 with a H/C/P/F QNP gradient probe and Bruker Avance 
500 with a dual carbon/proton CPDUL cryoprobe. The chemical shift δ is given in [ppm], 
calibration was set on chloroform-d1 (77.16 ppm), or tetramethylsilane (0.00 ppm) as internal 
standard. The multiplicity of the signals were detected by DEPT 135 and 90 (DEPT = 
distortionless enhancement by polarization transfer) 
Masspectrometry was performed on Varian MAT 311A, Finnigan MAT 95, Thermoquest 
Finnigan TSQ 7000, Nermag quadrupoles, VG ZAB high-resolution double-focusing and VG 
Autospec-Q tandem hybrid with EBEqQ configuration. The percentage set in brackets gives the 
peak intensity related to the basic peak (I = 100%). High resolution mass spectrometry (HRMS): 
The molecular formula was proven by the calculated precise mass. 
Thin layer chromatography (TLC) was prepared on TLC-aluminium sheets (Merck, silica gel 
60 F254, 0.2 mm). Detection in UV-light l = 254 nm, staining with I2, Mostain, 
molybdatophosphoric-acid (5% in ethanol), KMnO4 solution or vanillin-sulfuric acid. 
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Column chromatography was performed in glass columns (G2 or G3). As a stationary phase 
silica gel Merck-Geduran 60 (0.063-0.200 mm) or flash silica gel Merck 60 (0.040-0.063 mm) 
was used. 
Solvents: Abs. solvents were prepared according to usual lab procedures or taken from the MB-
SPS solvent purification system. Ethylacetate, hexanes (40-60 °C) and dichloromethane were 
purified by distillation before use. Further solvents and reagents were of p.a. quality. 
Reactions with oxygen- and moisture sensitive reactants were performed in oven dried and in 
vacuo heated reaction flasks under a pre-dried inert gas (nitrogen or argon) atmosphere. For 
cooling to temperatures < -40 °C a cryostat Haake EK 90 or dry ice/iso-propanol mixture was 
used. 
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7.2 General Procedure for BF3-OEt2-Catalyzed Syntheses of Povarov-Type 
Products 10a and 11a. 
 
7.2a General Procedure A1 
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Aldimine 6a was prepared by condensation of benzaldehyde 7a (0.833 mmol) and aniline 8a 
(0.833 mol) in ethanol under refluxing condition, re-crystallized from hexane, dried under 
vacuum and used for the next step. A mixture of aldimine 9a (0.833 mmol) and tert-butyl methyl 
2-aza-bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (0.334 mmol) in 4 mL dichloromethane was 
placed in a dry Schlenck tube and the mixture was degassed by sparging with nitrogen. The 
reaction mixture was then cooled to 0 oC. A solution of BF3-OEt2 (20 mol%) in dry 
dichloromethane (0.5 mL) was then added dropwise under N2 and the tube was sealed with a 
teflon lined cap at once. This mixture was then allowed to warm to room temperature and stirred 
for 48 hours or until complete consumption of the starting material as indicated by TLC or by 1H 
NMR. The reaction mixture was then quenched with Et3N, concentrated in vacuo, extracted with 
chloroform and washed with distilled water. The organic layer was dried over anhydrous Na2SO4 
and concentrated under reduced pressure. The crude product was purified using column 
chromatography (2-15% ethylacetate in hexane) to yield the desired products 10a and 11a. 
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7.2b General Procedure A2 
N
Boc
CO2Me
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NH2
CH2Cl2
rt, MS 4 Å
BF3-OEt2 (20 mol%) HN N
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CO2Me
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H
H
H
O
HN N
Boc
CO2Me
H
H
H
H
10a7a 8a 6 11a
 
To a 25 mL dry round bottom flask was added a solution of aromatic benzaldehyde 7a (0.833 
mmol), aniline 8a (0.833 mmol) and tert-butyl methyl 2-aza-bicyclo[3.1.0]hex-3-ene-2,6-
dicarboxylate 6 (0.334 mmol) in 4 mL DCM under N2 atmosphere, Cu(OTf)2 (20 mol%). This 
mixture was then allowed to warm to room temperature and stirred for 48 hours or until complete 
consumption of the starting material as indicated by TLC or by 1H NMR. The reaction mixture 
was then concentrated in vacuo, extracted with ethylacetate and washed with distilled water. The 
organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure and 
purified on silica to afford the desired tetrahydropyrroloquinolines 10a and 11a. 
 
7.3 General Procedure for Cu(OTf)2-Catalyzed Three-Component Syntheses 
of Povarov-Type Products 10a and 11a. 
 
7.3a General Procedure A3 
 
To a 25 mL dry round bottom flask was added a solution of aromatic aldehyde 7 (0.833 mmol), 
substituted aniline 8 (0.833 mmol) and tert-butyl methyl 2-aza-bicyclo[3.1.0]hex-3-ene-2,6-
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dicarboxylate 6 (0.334 mmol) in 4 mL DCM under N2 atmosphere, Cu(OTf)2 (20 mol%). This 
mixture was then allowed to warm to room temperature and stirred for 48 hours or until complete 
consumption of the starting material as indicated by TLC or by 1H NMR. The reaction mixture 
was then concentrated in vacuo, extracted with ethylacetate and washed with distilled water. The 
organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure and 
purified on silica to afford the desired tetrahydropyrroloquinolines 10 and 11. 
 
7.4 Characterization Data of Compounds 10 and 11. 
Compound 10a: Synthesized according to General Procedure A3 using benzaldehyde 7a (85  
μL), aniline 8a (76 μL) and tert-butyl methyl 2-aza-bicyclo[3.1.0]hex-
3-ene-2,6-dicarboxylate 6 (80 mg). The product was purified by 
column chromatography (2-15% ethylacetate in hexane) to afford 112 
mg (Yield: 80%) of a white solid 10a, mp = 68-71 oC.  
1H NMR (300 MHz, CDCl3, ppm) δ: 7.51 – 7.46 (m, 2H), 7.44 – 7.38 (m, 2H), 7.37 – 7.32 (m, 
2H), 7.15 – 7.07 (m, 1H), 6.84 (t, J = 5.3 Hz, 1H), 6.68 – 6.64 (m, 1H), 5.44 (t, J = 16.7 Hz, 1H), 
4.50 (d, J = 2.6 Hz, 1H), 3.91 (s, 1H), 3.65 (s, 1H), 3.60 – 3.52 (m, 3H), 3.34 (t, J = 15.5 Hz, 
1H), 2.75 (dt, J = 7.1, 2.4 Hz, 1H), 2.46 – 2.38 (m, 1H), 1.52 – 1.41 (m, 9H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 170.62, 156.33, 145.74, 142.39, 140.39, 129.04, 128.89, 
128.26, 127.92, 126.93, 126.52, 122.05, 119.20, 114.26, 80.48, 77.48, 77.05, 76.63, 59.17, 51.80, 
51.67, 48.61, 44.65, 28.44, 27.02, 23.25. 
HR-EIMS (C25H28N2O4): calculated: 420.2, found: 420.2049. 
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Compound 10b: Synthesized according to General Procedure A3 using benzaldehyde 7a  
(85 μL), 4-fluoroaniline 8b (80 μL) and tert-butyl methyl 2-aza-
bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The product was 
purified by column chromatography (2-15% ethylacetate in hexane) to 
afford 115 mg (Yield: 79%) of a white solid 10b, mp = 83-85 oC. 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.51 – 7.37 (m, 4H), 7.37 – 7.33 (m, 1H), 7.34 – 7.29 (m, 
1H), 6.83 (td, J = 8.4, 2.6 Hz, 1H), 6.60 (dd, J = 8.8, 4.7 Hz, 1H), 5.37 (t, J = 18.8 Hz, 1H), 4.45 
(d, J = 2.2 Hz, 1H), 3.82 (s, 1H), 3.57 (s, 3H), 3.33 (t, J = 11.1 Hz, 1H), 2.74 (d, J = 7.4 Hz, 1H), 
2.44 – 2.36 (m, 1H), 1.58 (s, 3H), 1.54 (d, 1H), 1.47 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ: 170.13, 150.59, 141.97, 140.78, 128.98, 128.89, 127.99, 127.06, 
126.15, 116.37, 115.07, 80.47, 59.58, 51.40, 44.77, 44.49, 44.23, 28.23, 26.62. 
19F NMR (282 MHz, CDCl3, ppm) δ: -124.56.  
HR-EIMS (C25H27FN2O4): calculated: 438.20, found: 438.1960. 
 
Compound 10d: Synthesized according to General Procedure A3 using benzaldehyde 7a  
(85 μL), 4-chloroaniline 8d (74 μL) and tert-butyl methyl 2-aza-
bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The product was 
purified by column chromatography (2-15% ethylacetate in hexane) to 
afford 106 mg (Yield: 70%) of a dirty-white solid 10d, mp = 80-82 oC.  
1H NMR (300 MHz, CDCl3, ppm) δ: 7.57 (d, J = 2.3 Hz, 1H), 7.44 (dd, J = 4.8, 0.9 Hz, 2H), 
7.40 (d, J = 7.6 Hz, 2H), 7.35 (dt, J = 6.1, 2.4 Hz, 1H), 7.05 (dd, J = 8.5, 2.4 Hz, 1H), 6.59 (d, J 
= 8.6 Hz, 1H), 5.35 (d, J = 28.6 Hz, 1H), 4.46 (d, J = 2.0 Hz, 1H), 3.92 (s, 1H), 3.57 (s, 3H), 3.38 
(dd, J = 17.0, 14.2 Hz, 1H), 2.74 (s, 1H), 2.43 – 2.34 (m, 1H), 1.57 (d, J = 4.8 Hz, 1H), 1.51 (s, 
9H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 170.15, 155.52, 144.29, 144.29, 139.99, 129.09, 128.29, 
128.29, 128.06, 126.44, 126.44, 116.76, 80.10, 57.74, 51.69, 46.19, 44.56, 28.41, 27.00. 
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HR-EIMS (C25H27ClN2O4): calculated: 454.17, found: 454.1660. 
Compound 10e: Synthesized according General Procedure A3 using benzaldehyde 7a (85 μL),  
4-methylaniline 8e (89 mg) and tert-butyl methyl 2-aza-
bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The product was 
purified by column chromatography (2-10% ethylacetate in hexane) to 
afford 79 mg (Yield: 55%) of a white solid 10e, mp = 63-65 oC.  
1H NMR (300 MHz, CDCl3, ppm) δ: 7.48 (d, J = 7.4 Hz, 2H), 7.42 – 7.37 (m, 2H), 7.34 (t, J = 
4.8 Hz, 1H), 7.16 (t, J = 7.9 Hz, 1H), 6.92 (d, J = 8.1 Hz, 1H), 6.58 (d, J = 8.1 Hz, 1H), 5.38 (dd, 
J = 36.9, 8.4 Hz, 1H), 4.45 (d, J = 2.0 Hz, 1H), 3.77 (s, 1H), 3.53 (s, 3H), 3.31 (d, J = 6.0 Hz, 
1H), 2.73 (d, J = 5.9 Hz, 1H), 2.42 (s, 1H), 2.24 (s, 3H), 1.74 (dd, J = 14.9, 11.2 Hz, 1H), 1.51 (s, 
9H). 
13C NMR (151 MHz, CDCl3, ppm) δ: 170.07, 150.77, 147.03, 139.23, 129.32, 129.00, 128.49, 
127.44, 126.30, 124.56, 122.57, 114.98, 81.07, 60.38, 57.05, 53.40, 51.78, 44.20, 28.38, 26.85, 
25.39, 21.03. 
HR-EIMS (C26H30N2O4): calculated: 434.22, found: 434.2205. 
 
Compound 10f: Synthesized according to General Procedure A3 using benzaldehyde 7a (85  
μL), 3,5-dimethylaniline 8f (104 μL) and tert-butyl methyl 2-aza-
bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The product was 
purified by column chromatography (2-10% ethylacetate in hexane) to 
afford 73 mg (Yield: 49%) of a white sticky solid 10f.  
 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.47 (d, J = 7.3 Hz, 2H), 7.40 (t, J = 7.3 Hz, 2H), 7.33 (dd, 
J = 6.2, 3.6 Hz, 1H), 6.51 (s, 1H), 6.37 (s, 1H), 5.50 (d, J = 5.8 Hz, 1H), 4.46 (d, J = 1.3 Hz, 1H), 
3.84 (s, 1H), 3.58 (s, 3H), 3.21 (d, J = 6.6 Hz, 1H), 2.66 – 2.57 (m, 2H), 2.29 (s, 3H), 2.23 (s, 
3H), 1.55 (s, 1H), 1.46 (s, 9H). 
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13C NMR (151 MHz, CDCl3, ppm) δ: 170.40, 156.15, 146.77, 141.21, 140.34, 137.83, 129.11, 
128.94, 128.54, 127.77, 126.36, 123.32, 117.36, 114.17, 80.09, 64.35, 56.87, 52.09, 51.60, 49.74, 
44.84, 37.20, 29.68, 29.08, 28.30, 28.17, 21.85, 20.86, 20.39, 18.53. 
HR-EIMS (C27H32N2O4): calculated: 448.24, found: 448.2361. 
 
Compound 10g: Synthesized according to General Procedure A3 using benzaldehyde 7a (85  
μL), 3-fluoroaniline 8g (80 μL) and tert-butyl methyl 2-aza-
bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The product was 
purified by column chromatography (2-10% ethylacetate in hexane) to 
afford 101 mg (Yield: 69%) of a white solid 10g.  
 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.47 (d, J = 8.2 Hz, 1H), 7.44 – 7.35 (m, 1H), 7.35 – 7.27 
(m, 4H), 6.48 (td, J = 8.6, 2.5 Hz, 1H), 6.32 (dd, J = 10.2, 2.4 Hz, 1H), 4.75 (d, J = 7.4 Hz, 1H), 
4.29 – 4.19 (m, 2H), 3.65 (s, 3H), 3.52 (dd, J = 6.8, 1.4 Hz, 1H), 2.78 (dd, J = 12.4, 4.8 Hz, 1H), 
2.24 (ddd, J = 6.6, 3.7, 1.9 Hz, 1H), 1.79 (dd, J = 3.6, 1.4 Hz, 1H), 1.50 (s, 9H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 170.65, 156.34, 142.00, 128.95, 127.78, 126.77, 126.15, 
117.21, 105.69, 100.46, 80.48, 58.37, 51.85, 46.15, 45.77, 44.15, 28.42, 27.01, 21.27. 
19F NMR (282 MHz, CDCl3, ppm) δ: -114.64. 
HR-EIMS (C25H27FN2O4): calculated: 438.2, found: 438.1957. 
 
Compound 10h: Synthesized according to General Procedure A3 using 4-chlorobenzaldehyde  
7b (117 mg), aniline 8a (76 μL) and tert-butyl methyl 2-aza-
bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The product 
was purified by column chromatography (2-10% ethylacetate in 
hexane) to afford 113 mg (Yield: 75%) of a white solid 10h.  
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1H NMR (300 MHz, CDCl3, ppm) δ: 7.57 (s, 1H), 7.40 (td, J = 8.6, 4.3 Hz, 4H), 7.15 – 7.07 (m, 
1H), 6.84 (dd, J = 10.9, 4.1 Hz, 1H), 6.66 (d, J = 8.0 Hz, 1H), 5.44 (s, 1H), 4.48 (d, J = 2.6 Hz, 
1H), 3.84 (s, 1H), 3.58 (s, 3H), 3.31 (s, 1H), 2.73 – 2.65 (m, 1H), 2.39 – 2.30 (m, 1H), 1.72 – 
1.61 (m, 1H), 1.55 (s, 3H), 1.47 (s, 6H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 170.13, 153.11, 145.37, 139.41, 133.66, 129.22, 128.32, 
127.82, 123.22, 119.98, 115.49, 80.08, 57.16, 56.76, 51.71, 46.16, 44.17, 35.99, 28.44. 
HR-EIMS (C25H27ClN2O4): calculated: 454.17, found: 454.1654. 
 
Compound 10i: Synthesized according to General Procedure A3 using 4-bromobenzaldehyde 7c  
(154 mg), aniline 8a (76 μL) and tert-butyl methyl 2-aza-
bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The product 
was purified by column chromatography (2-10% ethylacetate in 
hexane) to afford 121 mg (Yield: 73%) of a white solid 10i, mp = 
85-89 oC.  
1H NMR (300 MHz, CDCl3, ppm) δ: 7.62 – 7.50 (m, 3H), 7.37 (d, J = 8.4 Hz, 2H), 7.10 (dd, J = 
11.0, 4.2 Hz, 1H), 6.84 (t, J = 7.5 Hz, 1H), 6.66 (d, J = 8.0 Hz, 1H), 5.37 (d, J = 42.4 Hz, 1H), 
4.46 (d, J = 2.5 Hz, 1H), 3.83 (s, 1H), 3.58 (s, 3H), 3.31 (d, J = 3.2 Hz, 1H), 2.73 – 2.65 (m, 1H), 
2.37 – 2.30 (m, 1H), 1.58 (s, 3H), 1.47 (s, 6H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 174.28, 145.32, 139.58, 137.58, 131.83, 130.59, 127.80, 
121.63, 119.99, 81.27, 57.16, 52.71, 51.90, 40.82, 28.22, 27.01, 21.65. 
HR-EIMS (C25H27BrN2O4): calculated: 498.11, found: 498.1153. 
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Compound 10j: Synthesized according to General Procedure A3 using 4-trifluoromethylbenzal 
-dehyde 7d (114 μL), aniline 8a (76 μL) and tert-butyl methyl 2-
aza-bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The 
product was purified by column chromatography (2-10% 
ethylacetate in hexane) to afford 115 mg (Yield: 77%) of a white 
solid 10j, mp = 93-95 oC. 
1H NMR (600 MHz, CDCl3, ppm) δ: 7.68 (d, J = 8.2 Hz, 2H), 7.62 (d, J = 8.2 Hz, 2H), 7.12 (t, J 
= 7.4 Hz, 1H), 6.86 (t, J = 7.4 Hz, 1H), 6.68 (d, J = 7.9 Hz, 1H), 5.43 (d, J = 64.0 Hz, 1H), 4.57 
(d, J = 2.1 Hz, 1H), 3.88 (s, 1H), 3.58 (s, 3H), 3.41 – 3.27 (m, 1H), 2.74 (dt, J = 7.2, 2.7 Hz, 1H), 
2.36 – 2.32 (m, 1H), 1.77 – 1.64 (m, 2H), 1.56 (s, 3H), 1.47 (s, 6H). 
13C NMR (151 MHz, CDCl3, ppm) δ: 170.16, 155.36, 145.06, 144.78, 130.58, 128.14, 126.77, 
124.85, 123.49, 123.00, 120.21, 115.44, 79.94, 57.23, 51.73, 48.29, 45.23, 44.12, 29.72, 28.40, 
26.92, 21.49. 
HR-EIMS (C26H27FN3O4): calculated: 488.19, found: 488.1918. 
 
Compound 10k: Synthesized according to General Procedure A3 using 4-nitrobenzaldehyde 7e  
(126 mg), aniline 8a (76 μL) and tert-butyl methyl 2-aza-
bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The product 
was purified by column chromatography (2-15% ethylacetate in 
hexane) to afford 121 mg (Yield: 78%) of a white solid 10k. 
1H NMR (300 MHz, CDCl3, ppm) δ: 8.25 (d, J = 8.7 Hz, 2H), 7.68 (d, J = 8.7 Hz, 2H), 7.59 (d, J 
= 6.0 Hz, 1H), 7.17 – 7.09 (m, 1H), 6.93 – 6.84 (m, 1H), 6.73 – 6.65 (m, 1H), 5.48 (s, 1H), 4.62 
(d, J = 2.6 Hz, 1H), 4.02 – 3.90 (m, 1H), 3.54 (d, J = 15.7 Hz, 3H), 3.29 (s, 1H), 2.74 (dd, J = 
5.0, 2.1 Hz, 1H), 2.34 – 2.27 (m, 1H), 1.65 (d, J = 12.0 Hz, 1H), 1.56 (s, 3H), 1.47 (s, 6H). 
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13C NMR (75 MHz, CDCl3, ppm) δ: 170.16, 152.19, 148.18, 147.67, 144.80, 128.49, 127.40, 
124.32, 120.40, 115.47, 82.89, 77.46, 77.04, 76.61, 57.16, 51.81, 48.20, 45.75, 44.17, 35.59, 
28.43, 26.60, 25.39. 
HR-EIMS (C25H27N3O6): calculated: 465.19, found: 465.1900. 
 
Compound 10kʹ: Synthesized according to General Procedure A3 using 3-methoxybenzaldehy 
-de 7f (101 μL), aniline 8a (76 μL) and tert-butyl methyl 2-aza-
bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The product was 
purified by column chromatography (2-15% ethylacetate in hexane) to 
afford 88 mg (Yield: 59%) of a white solid 10kʹ. 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.33 (t, J = 7.9 Hz, 1H), 7.08 (t, J = 6.8 Hz, 2H), 7.02 (s, 
1H), 6.92 – 6.78 (m, 3H), 6.66 (d, J = 7.8 Hz, 1H), 5.39 (dd, J = 37.9, 13.2 Hz, 1H), 4.47 (d, J = 
2.5 Hz, 1H), 3.88 (s, 1H), 3.84 (s, 3H), 3.56 (d, J = 7.8 Hz, 3H), 3.31 (d, J = 6.2 Hz, 1H), 2.78 – 
2.71 (m, 1H), 2.58 (q, J = 7.2 Hz, 1H), 2.45 – 2.38 (m, 1H), 1.49 (s, 3H), 1.47 (s, 6H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 170.15, 160.06, 154.31, 145.72, 132.61, 130.08, 128.18, 
118.69, 115.46, 113.20, 112.21, 81.27, 57.58, 55.33, 51.66, 45.78, 44.56, 28.44, 27.00, 24.18. 
HR-EIMS (C26H30N2O5): calculated: 450.22, found: 450.2155. 
 
Compound 10l: Synthesized according to General Procedure A3 using thiophene-2-carboxal- 
dehyde 7g (77 μL), aniline 8a (76 μL) and tert-butyl methyl 2-aza-
bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The product was 
purified by column chromatography (2-20% ethylacetate in hexane) to 
afford 96 mg (Yield: 68%) of a white solid 10l. 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.61 – 7.48 (m, 1H), 7.29 (dd, J = 5.1, 1.2 Hz, 1H), 7.14 (d, 
J = 3.4 Hz, 1H), 7.12 – 7.07 (m, 1H), 7.04 (dd, J = 5.1, 3.5 Hz, 1H), 6.85 (t, J = 7.1 Hz, 1H), 
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6.68 – 6.62 (m, 1H), 5.41 (t, J = 16.9 Hz, 1H), 4.76 (d, J = 2.6 Hz, 1H), 3.99 (s, 1H), 3.62 (s, 
3H), 3.32 (d, J = 6.7 Hz, 1H), 2.76 (dt, J = 7.2, 2.7 Hz, 1H), 2.65 – 2.54 (m, 1H), 1.67 (d, J = 
21.7 Hz, 1H), 1.57 (s, 3H), 1.49 (s, 6H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 170.66, 145.07, 143.91, 130.64, 127.01, 124.76, 124.49, 
120.01, 115.06, 80.06, 53.99, 51.74, 49.01, 44.17, 28.43, 27.81, 26.59. 
HR-EIMS (C23H26N2O4S): calculated: 426.16, found: 426.1603. 
 
Compound 10m: Synthesized according to General Procedure A3 using 5-phenylthiophene-2- 
carbaldehyde 7h (157 mg), aniline 8a (76 μL) and tert-butyl methyl 
2-aza-bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The 
product was purified by column chromatography (2-20% 
ethylacetate in hexane) to afford 90 mg (Yield: 54%) of a white solid 
10m. 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.65 – 7.50 (m, 3H), 7.43 – 7.35 (m, 2H), 7.33 – 7.28 (m, 
1H), 7.23 (d, J = 3.7 Hz, 1H), 7.16 – 7.11 (m, 1H), 7.10 – 7.08 (m, 1H), 6.85 (dd, J = 10.9, 4.0 
Hz, 1H), 6.67 (d, J = 7.7 Hz, 1H), 5.42 (t, J = 16.0 Hz, 1H), 4.73 (d, J = 2.5 Hz, 1H), 4.03 (s, 
1H), 3.61 (s, 3H), 3.33 (d, J = 6.6 Hz, 1H), 2.82 – 2.74 (m, 1H), 2.63 (d, J = 2.9 Hz, 1H), 1.78 – 
1.62 (m, 1H), 1.56 (d, J = 2.3 Hz, 3H), 1.51 (s, 6H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 170.44, 155.60, 145.05, 143.66, 143.22, 134.08, 130.66, 
128.98, 128.30, 127.70, 125.75, 125.38, 123.57, 122.87, 120.38, 115.53, 80.27, 54.20, 51.76, 
49.07, 44.46, 28.45, 27.93, 23.68. 
HR-EIMS (C29H30N2O4S): calculated: 502.19, found: 502.1919. 
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Compound 10n: Synthesized according to General Procedure A3 using furan-2-carbaldehyde 7i  
(69 μL), aniline 8a (76 μL) and tert-butyl methyl 2-aza-
bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The product was 
purified by column chromatography (2% to 10% EtOAc/hexanes) to 
afford 98 mg (Yield: 72%) of a white solid 10n, mp = 73-75 oC. 
1H NMR (600 MHz, CDCl3, ppm, signal doubling because of rotamers) δ: 7.59 (dd, J = 6.2, 3.2 
Hz, 1H), 7.42 (d, J = 1.0 Hz, 1H), 7.10 (t, J = 7.4 Hz, 1H), 6.83 (t, J = 7.4 Hz, 1H), 6.65 (d, J = 
7.9 Hz, 1H), 6.36 (dd, J = 1.7, 3.1 Hz, 2H), 5.42 (d, J = 6.2 Hz) and 5.30 (s)[1H], 4.50 (d, J = 2.3 
Hz, 1H), 4.02 (br s, 1H), 3.38 (s) and 3.33 (d, J = 5.4 Hz)[1H], 2.88 (dd, J = 2.4, 4.8 Hz, 1H), 
2.50 (s, 1H), 1.69 (d, J = 14.5, 1H), 1.57 and 1.48 (s, 9H), 1.28 (d, J = 17.3 Hz, 1H). 
13C NMR (150 MHz, CDCl3, ppm, signal doubling because of rotamers) δ: 170.4 and 170.3, 
155.5, 153.6, 144.8, 142.1, 130.6, 128.3 and 128.3, 128.2, 123.5, 120.1, 115.3, 110.4, 106.2, 
80.1, 62.8, 51.9 and 51.6, 45.4, 44.4, 35.7, 31.3, 30.2 and 30.1, 28.3. 
FT-IR (neat): 3367, 3116, 3059, 2975, 2927, 2852, 1726, 1695, 1605, 1480, 1441, 1390, 1366, 
1335, 1289, 1250, 1167, 1121, 1068, 1009, 978, 945, 880, 851, 750, 595 cm-1. 
HR-EIMS (C23H26N2O5): calculated: 410.1842, found: 410.1835. 
 
Compound 11n: Synthesized according to General Procedure A3 Yield: 27%; Yellow solid, 70-
71 oC. 
1H NMR (600 MHz, CDCl3, ppm) δ: 7.45 (d, J = 7.6 Hz, 1H), 7.29 (d, J 
= 1.0 Hz, 1H), 7.07 (J = 8.0 Hz, 1H), 6.76 (t, J = 7.8 Hz, 1H), 6.60 (d, J 
= 7.8 Hz, 1H), 6.22 (dd, J= 1.8, 3.1 Hz, 1H), 6.05 (d, J = 3.2 Hz, 1H), 
5.05 (d, J = 7.5 Hz, 1H), 4.48 (d, J = 3.8 Hz, 1H), 4.15 (s, 1H), 3.67 (s, 
3H), 3.46 (dd, J = 1.3, 6.9 Hz, 1H), 3.00-2.97 (m, 1H), 2.40-2.38 (m, 
1H), 1.81 (dd, J = 1.3, 3.4 Hz, 1H), 1.50 (s, 9H). 
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13C NMR (150 MHz, CDCl3, ppm) δ: 170.4, 155.0, 143.1, 141.9, 129.9, 128.2, 122.7, 119.4, 
114.9, 110.2, 106.4, 80.4, 60.2, 52.0, 51.7, 44.6, 44.2, 35.1, 31.4, 31.0, 30.1, 29.6, 28.4,22.6. 
FT-IR (neat): 3377, 2963, 2926, 1727, 1696, 1606, 1494, 1441, 1393, 1317, 1254, 1165, 1125, 
1009, 750, 596 cm-1. 
HR-ESI-MS exact mass calculated for C23H26N2O5: m/z 411.1914 [M+H]+, found: m/z 411.1922 
[M+H]+. 
 
Compound 10o: Synthesized according to General Procedure A3 using furan-2-carbaldehyde 7i  
(69 μL), 4-fluoroaniline 8b (80 μL) and tert-butyl methyl 2-aza-
bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The product was 
purified by column chromatography (2% to 12% EtOAc/hexanes) to 
afford 107 mg (Yield: 75%) of a pale yellow solid 10o, mp = 90-93 
oC. 
1H NMR (300 MHz, CDCl3, ppm, signal doubling because of rotamers) δ: 7.40 (d, J = 1.2 Hz, 
1H), 7.30 (d, J = 8.8 Hz, 1H), 6.81 (td, J = 2.8, 11.1 Hz, 1H), 6.59 (dd, J = 4.7, 8.7 Hz, 1H), 6.37 
(dd, J = 1.8, 3.2 Hz, 1H), 6.34 (d, 3.2 Hz, 1H), 5.33 (d, 25.5 Hz, 1H), 4.44 (d, J = 2.4 Hz, 1H), 
3.98 (s, 1H), 3.62 (s, 3H), 3.32 (d, J = 16.0 Hz, 1H), 2.87 (d, J = 6.9 Hz, 1H), 2.47 (d. J = 2.6 
Hz, 1H), 1.68 (d, J = 20.4 Hz, 1H), 1.56 and 1.47 (s, 9H). 
13C NMR (300 MHz, CDCl3, ppm, signal doubling because of rotamers) δ: 170.3, 158.5, 158.5, 
155.5, 153.4, 142.2, 141.1, 124.7 and 124.7, 124.0, 116.6, 116.4, 116.3, 116.3, 115.6, 115.3, 
110.4, 106.3, 80.4, 62.8, 52.2 and 51.7, 45.9, 45.2, 44.3 and 44.1, 44.1, 35.7 and 35.4, 28.4 .  
FT-IR (neat): 3416, 2978, 2933, 2865, 1726, 1698, 1505, 1477, 1440, 1389, 1338, 1299, 
1272, 1251, 1233, 1168, 1121, 1011, 930, 884, 816, 735, 599, 547, 463 cm-1. 
HR-ESMS exact mass calculated for C23H25FN2O5: m/z 429.1820 [M+H]+, found: m/z 429.1821 
[M+H]+. 
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Compound 10p: Synthesized according to General Procedure A3 using furan-2-carbaldehyde 7i 
(69 μL), 4-methoxyaniline 8h (103 mg) and tert-butyl methyl 2-
aza-bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The 
product was purified by column chromatography (2% to 15% 
EtOAc/hexanes) to afford 110 mg (Yield: 75%) of a white sticky 
solid 10p. 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.41 (s, 1H), 7.22 (d, J = 35.5 Hz, 1H), 6.71 (dd, J = 2.5, 
8.6 Hz, 1H), 6.62 (d, J = 8.7 Hz, 1H), 6.35 (d, J = 8.6 Hz, 2H), 5.37 (dd, J = 7.1, 33.5 Hz, 1H), 
4.44 (s, 1H), 3.82 (br s, 1H), 3.73 (s, 3H), 3.63 (s, 3H), 3.41-3.33 (m, 1H), 2.91-2.86 (m, 1H), 
2.49 (s, 1H), 1.75-1.69 (m, 1H), 1.57 (d, J = 6.3 Hz, 3H), 1.47 (s, 6H). 
13C NMR (150 MHz, CDCl3, ppm) δ: 170.45, 155.5, 153.8, 153.7, 142.1, 138.7, 124.3, 116.5, 
115.9, 113.7, 110.4, 106.1, 80.2, 63.0, 55.5, 51.7, 45.4, 44.4, 35.6, 28.4, 28.3, 28.1. 
FT-IR (neat): 3432, 2962, 2931, 2848, 1728, 1695, 1620, 1509, 1441, 1392, 1335, 1239, 1164, 
1112, 1044, 952, 882, 809, 467 cm-1. 
HR-ESMS exact mass calculated for C24H28N2O6: m/z 441.2020  [M+H]+, found: m/z 441.2026 
[M+H]+. 
 
Compound 10r: Synthesized according to General Procedure A3 using furan-2-carbaldehyde 7i  
(69 μL), 3-methoxyaniline 8j (94 μL) and tert-butyl methyl 2-aza-
bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The product was 
purified by column chromatography (4% to 16% EtOAc/hexanes) to 
afford 107 mg (Yield: 73%) of a white sticky solid 10r. 
 
1H NMR (300 MHz, CDCl3, ppm, signal doubling because of rotamers) δ: 7.40 (d, J = 1.9 Hz, 
1H), 7.07-6.98 (m, 1H), 6.44-6.19 (m, 5H), 5.45 (dd, J = 6.7, 29.6 Hz, 1H), 4.47 (s, 1H), 4.05 (s, 
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1H), 3.76 and 3.75 (s, 3H), 3.62 (s, 3H), 2.86-2.72 (m, 1H), 2.59-2.54 (m, 1H), 1.69 (dd, J = 1.3, 
3.6 Hz, 1H), 1.48 and 1.42 (s, 9H). 
13C NMR (75 MHz, CDCl3, ppm, signal doubling because of rotamers) δ: 170.8 and 170.5, 
160.1, 154.9, 153.9, 146.6, 146.0, 144.4, 142.2 and 142.1, 141.9, 128.9 and 128.8, 110.4, 108.2, 
107.6, 106.3, 101.5, 100.6, 79.4, 55.1, 51.7 and 51.2, 44.7, 43.9 and 42.9, 36.7, 29.6, 28.3 . 
FT-IR (neat): 3007, 2978, 2934, 1695, 1604, 1495, 1478, 1438, 1365, 1268, 1248, 1163, 1268, 
1248, 1163, 1113, 1007, 944, 896, 696, 667, 598 cm-1. 
HR-ESMS exact mass calculated for C24H28N2O6: m/z 441.2020  [M+H]+, found: m/z 441.2021 
[M+H]+. 
 
Compound 10s: Synthesized according to General Procedure A3 using furan-2-carbaldehyde 7i  
(69 μL), 3,5-dimethylaniline 8f (104 μL) and tert-butyl methyl 2-aza-
bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The product was 
purified by column chromatography (2% to 14% EtOAc/hexanes) to 
afford 92 mg (Yield: 63%) of a white solid 10s, mp = 88-90 oC. 
 
1H NMR (600 MHz, CDCl3, ppm) δ: 7.40 (d, J = 1.6 Hz, 1H), 6.50 (s, 1H), 6.38 (d, J = 1.8, 3.2 
Hz, 1H), 6.42 (s, 1H), 6.33 (d, J = 3.2 Hz, 1H), 5.45 (br s, 1H), 4.46 (s, 1H), 3.97 (br s, 1H), 3.64 
(s, 3H), 3.23 (d, J = 5.6 Hz, 1H), 2.76 (d, J = 2.6 Hz, 1H), 2.86-2.66 (m, 1H), 2.28 (s, 3H); 2.22 
(s, 3H), 1.70 (br s, 1H), 1.54(s, 9H). 
13C NMR (150 MHz, CDCl3, ppm, signal doubling because of rotamers) δ: 170.2, 156.0, 153.9, 
145.8, 142.0, 140.2, 137.7, 123.3, 114.0, 110.3, 105.9, 80.0, 63.4 and 63.4, 51.6 and 51.6, 46.2 
and 46.1, 44.7 and 44.7, 37.1 and 37.1, 30.2, 28.2, 21.2, 20.7, 20.3 
FT-IR (neat): 3000, 2977, 2919, 1690, 1616, 1582, 1469, 1439, 1356, 1333, 1295, 1266, 1164, 
1113, 1013, 947, 834, 679, 667, 597 cm-1.  
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HR-ESMS exact mass calculated for C25H30N2O5: m/z 439.2227  [M+H]+, found: m/z 439.2227 
[M+H]+. 
 
Compound 11s: Synthesized according to General Procedure A3; Yield: 18%; White solid. 
1H NMR (600 MHz, CDCl3, ppm) δ: 7.28 (d, J = 1.1 Hz, 1H), 6.40 (s, 
1H), 6.26 (s, 1H), 6.21 (dd, J = 1.8, 3.1 Hz, 1H), 6.04 (d, J = 3.1 Hz, 
1H), 4.99 (d, J = 5.8 Hz, 1H), 4.46 (d, J = 3.9 Hz, 1H), 4.09 (br s, 1H), 
3.67 (s, 3H), 3.46 (d, J = 6.4 Hz, 1H), 2.75-2.73 (m, 1H), 2.49-2.47 (m, 
1H), 2.20 (s, 3H), 2.18 (s, 3H), 1.90 (d, J = 2.2 Hz, 1H), 1.43 (s, 9H). 
13C NMR (150 MHz, CDCl3, ppm) δ: 170.5, 155.7, 155.2, 143.6, 141.8, 140.0, 137.8, 122.6, 
113.4, 110.1, 106.2, 80.1, 64.2, 59.3, 51.7, 50.6, 44.1, 44.0, 28.2, 20.9, 20.2.  
FT-IR (neat): 3000, 2977, 2919, 1690, 1616, 1582, 1469, 1439, 1356, 1333, 1295, 1266, 1164, 
1113, 1013, 947, 834, 679, 667, 597 cm-1.  
HR-ESMS exact mass calculated for C25H30N2O5: m/z 439.2227  [M+H]+, found: m/z 439.2225 
[M+H]+. 
 
Compound 10sʹ: Synthesized according to General Procedure A3 using furan-2-carbaldehyde 7i  
(69 μL), 4-methoxyaniline 8h (103 mg) and tert-butyl methyl 2-aza-
bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The product was 
purified by column chromatography (4% to 16% EtOAc/hexanes) to 
afford 103 mg (Yield: 70%) of a white sticky solid 10sʹ. 
1H NMR (600 MHz, CDCl3, ppm, signal doubling because of rotamers) δ: 7.41 (d, J = 1.1 Hz, 
1H), 7.36 (d, J = 7.8 Hz, 1H), 6.38 (dd, J = 1.8, 3.2 Hz, 1H), 6.34 (d, J = 3.2 Hz, 1H), 6.32 (d, J 
= 10.7 Hz, 1H), 5.33 (d, J = 5.8 Hz) and 5.22 (s)[1H], 4.45 (d, J = 2.3 Hz, 1H), 3.96 (s, 1H), 3.63 
(s, 3H), 3.38 (s) and 3.32 (d, J = 4.9 Hz) [1H], 2.85 (br s, 1H), 2.47 (d, J = 2.6 Hz, 1H), 2.15 (s, 
3H), 1.75  and 1.67 (s, 1H), 1.57 and 1.48 (s, 9H). 
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13C NMR (600 MHz, CDCl3, ppm, signal doubling because of rotamers) δ: 170.3, 161.7, 160.0, 
155.5, 155.5, 153.3, 144.1, 144.1, 142.2, 133.1, 133.1, 119.1, 110.4, 106.3, 101.6, 101.5, 80.3, 
62.5, 51.7, 45.3, 44.2, 35.7,  28.3, 13.8 and 13.8 . 
19F NMR (300 MHz, CDCl3, ppm) δ: -118.5 and 118.5. 
FT-IR (neat): 3392, 2968, 2956, 2926, 1721, 1688, 1632, 1507, 1439, 1389, 1303, 1261, 1243, 
1169, 1121, 1009, 945, 877, 834, 747, 541 cm-1. 
HR-ESMS exact mass calculated for C24H27FN2O5: m/z 443.1977 [M+H]+, found: m/z 443.1976 
[M+H]+. 
 
Compound 10u: Synthesized according to General Procedure A3 using furan-2-carbaldehyde 7i  
(69 μL), 1-napthylaniline 8l (183 mg) and tert-butyl methyl 2-aza-
bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The product was 
purified by column chromatography (4% to 16% EtOAc/hexanes) to 
afford 99 mg (Yield: 65%) of a white solid 10u, mp = 195-196 oC. 
 
1H NMR (300 MHz, CDCl3, ppm, signal doubling because of rotamers) δ: 7.82-7.77 (m, 2H), 
7.66 (d, J = 8.5 Hz, 1H), 7.49 (d, J = 7.2 Hz, 3H), 7.36 (d, J = 8.5 Hz, 1H), 6.47 (d, J = 3.2 Hz, 
1H), 6.45 (dd, J = 1.8, 3.1 Hz, 1H), 5.59 (dd, J = 7.2, 36.0 Hz, 1H), 4.75 (s, 1H), 4.60 (d, J = 2.4 
Hz, 1H), 3.64 (s, 3H), 3.31- 3.25 (m, 1H), 2.97-2.93 (m, 1H), 2.59 (d, J = 3.3 Hz, 1H), 1.82-1.75 
(m, 1H), 1.61 and 1.50 (s, 9H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 170.4, 155.7, 153.7, 142.4, 139.7, 133.3, 128.5, 127.8, 
126.1, 125.4, 122.9, 119.8, 117.5, 110.5, 106.5, 80.2, 63.6, 51.7, 45.1, 44.3, 35.0, 28.4. 
FT-IR (neat): 3120, 3050, 2975, 2826, 1789, 1686, 1574, 1515, 1454, 1436, 1388, 1296, 1259, 
1191, 1164, 1116, 1020, 1032, 877, 858, 794, 748, 663, 616, 5075, 507 cm-1. 
HR-EIMS (C27H28N2O5): calculated: 460.2, found: 460.1996. 
HN
N
H H
CO2Me
H
H
Boc
O
Experimental	Part		 							2012	
 
112 
 
Compound 10v: Synthesized according to General Procedure A3 using 5-phenylfuran-2-carbal- 
dehyde 7j (143 mg), aniline 8a (76 μL) and tert-butyl methyl 2-aza-
bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The product was 
purified by column chromatography (4% to 16% EtOAc/hexanes) to 
afford 107 mg (Yield: 66%) of a white solid 10v, mp = 94 oC. 
1H NMR (600 MHz, CDCl3, ppm, signal doubling because of rotamers) δ: 7.65 (d, J = 7.6 Hz, 
2H), 7.60 and 7.53 (d, J = 5.5 Hz, and d, J = 6.7 Hz, 1H), 7.39 (t, J = 7.6 Hz, 2H), 7.27 (d, J = 
7.3 Hz, 1H), 7.11 (t, J = 7.4 Hz, 1H), 6.85 (t, J = 7.4 Hz, 1H), 6.68 (d, J = 7.9 Hz, 1H), 6.64 (d, J 
= 3.2 Hz, 1H), 6.45 (d, J = 3.1 Hz, 1H), 5.45-5.34 (m, 1H), 4.57 (d, J = 2.0 Hz, 1H), 4.04 (br s, 
1H), 3.63 (s, 3H), 3.42-3.36 (m, 1H), 2.92 (d, J = 7.1 Hz, 1H), 2.65 (s, 1H), 1.80 and 1.72 (br s, 
1H), 1.58 and 1.49 (s, 9H).  
13C NMR (150 MHz, CDCl3, ppm) δ: 170.3, 155.5, 153.6, 144.8, 130.4, 128.6, 127.5, 123.6, 
120.1, 115.3, 108.6, 105.6, 80.1, 62.9, 51.6, 45.6, 44.3, 35.8, 28.4 and 28.3. 
FT-IR (neat): 3012, 2978, 1721, 1691, 1609, 1480, 1439, 1391, 1367, 1248, 1166, 1121, 1021, 
789, 754, 692, 667 cm-1. 
HR-ESMS exact mass calculated for C29H30N2O5: m/z 487.2227  [M+H]+, found: m/z 487.2232 
[M+H]+. 
 
Compound 10w: Synthesized according to General Procedure A3 using 5-phenylfuran-2-carbal- 
dehyde 7j (143 mg), 3,4-dimethylaniline 8m (94 μL) and tert-butyl 
methyl 2-aza-bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The 
product was purified by column chromatography (2% to 15% 
EtOAc/hexanes) to afford 102 mg (Yield: 60%) of a white solid 10w, 
mp = 92-94 oC. 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.66-7.65 (m, 2H), 7.39 (t, J = 7.2 Hz, 2H), 7.30-7.25 (m, 
1H), 6.93 (d, J = 8.2 Hz, 1H), 6.63 (d, J = 3.3 Hz, 1H), 6.50 (d, J = 8.1 Hz, 1H), 6.43 (d, J = 3.75 
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Hz, 1H), 5.56 (d, J = 5.7 Hz, 1H), 4.51 (s, 1H), 3.94 (br s, 1H), 3.65 (s, 3H), 3.27 (d, J = 6.6 Hz, 
1H), 2.87-2.83 (m, 2H), 2.26 (s, 3H), 2.22 (s, 3H), 1.74 (d, J = 1.6 Hz, 1H), 1.51 (s, 9H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 170.4, 156.3, 153.6, 144.2, 138.6, 130.5, 130.3, 129.8, 
128.7, 128.2, 127.5, 123.7, 120.5, 116.9, 113.1, 112.6, 108.4, 105.6, 80.2, 51.7, 46.6, 44.8, 28.3, 
20.1, 16.3 
FT-IR (neat): 3014, 2973, 1722, 1690, 1604, 1485, 1439, 1356, 1257, 1162, 1115, 1065, 1023, 
896, 812, 760, 692, 667 cm-1. 
HR-ESI-MS exact mass calculated for C31H34N2O5: m/z 515.2540 [M+H]+, found: m/z 515.2551 
[M+H]+. 
Compound 10x: Synthesized according to General Procedure A3 using 5-phenylfuran-2-carbal- 
dehyde 7j (143 mg), 4-methoxyaniline 8h (103 mg) and tert-butyl 
methyl 2-aza-bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). 
The product was purified by column chromatography (5% to 20% 
EtOAc/hexanes) to afford 118 mg (Yield: 69%) of a white sticky 
solid 10x. 
1H NMR (300 MHz, CDCl3, ppm, signal doubling because of rotamers) δ: 7.66 (d, J = 7.2 Hz, 
2H), 7.38 (t, J = 7.3 Hz, 2H), 7.29-7.24 (m, 2H), 6.73 (dd, J = 2.7, 8.7 Hz, 1H), 6.64 (s, 1H), 6.63 
(d, J = 5.9 Hz, 1H), 6.44 (d, J = 3.2 Hz, 1H), 5.40 (dd, J = 7.3, 32.1 Hz, 1H), 4.50 (d, J = 2.4 Hz, 
1H), 3.84 (s, 1H), 3.74 (s, 3H), 3.62 (s, 3H), 3.41-3.35 (m, 1H), 2.93-2.9 (m, 1H), 2.64-2.62 (m, 
1H), 1.79-1.72 (m, 1H), 1.58 and 1.48 (s, 9H). 
13C NMR (300 MHz, CDCl3, ppm) δ: 170.4, 155.5, 153.6, 138.7, 130.5, 128.7,127.5, 124.3, 
123.7, 116.8, 116.6, 115.9, 115.8, 113.7, 108.6, 105.7, 80.2, 63.2, 55.6, 52.5, 51.7, 45.6, 44.3, 
35.7, 28.4 
FT-IR (neat): 3358, 2949, 2835, 1721, 1693, 1616, 1504, 1473, 1441, 1390, 1331, 1243, 1664, 
1116, 1037, 1022, 969, 921, 866, 759 cm-1. 
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HR-ESI-MS exact mass calculated for C30H32N2O6: m/z 517.2333 [M+H]+, found: m/z 517.2336 
[M+H]+. 
 
7.5 General Procedure for Stereoselective Synthesis of Cis-4,5-Disubstituted 
Pyrrolidinones 38.  
 
7.5a General Procedure A4 
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rt to 125 oC
R1
R1
Sc(OTf)3 (5 mol%)
 
A solution of furan-2-carbaldehyde 7i (0.40 mmol), aniline 8a (0.40 mmol) and tert-butyl methyl 
2-aza-bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (0.334 mmol) in 4 mL acetonitrile was placed 
in a microwave vial, the solution was degassed by sparging with nitrogen. Sc(OTf)3 (0.016 
mmol, 5 mol%) was added to the solution and the capped vial containing the reaction mixture 
was stirred at room temperature for 1.5 h and then at 125 oC under microwave irradiation for 3-5 
h until 6 disappeared. The reaction mixture was concentrated; the residue was dissolved in 
ethylacetate and extracted. The organic layer was dried, concentrated and purified on silica to 
afford the desired pyrrolidinone 38. 
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7.6 Characterization Data of Compound 38. 
(4S,5S)-5-(furan-2-yl)-4-(quinoline-3-yl)pyrrolidine-2-one (38a). Synthesized according to the   
General Procedure A4 using furan-2-carbaldehyde 7i (33 μL), aniline 
8a (36 μL) and tert-butyl methyl 2-aza-bicyclo[3.1.0]hex-3-ene-2,6-
dicarboxylate 6 (80 mg). The product was purified by column 
chromatography (50% to 100% EtOAc/hexanes) to afford 76 mg of a 
pale yellow solid 38a (Yield: 82%). Mp = 186-187 oC.  
1H NMR (300 MHz, CDCl3, ppm) δ: 8.54 (d, J = 2.08, 1H), 8.01 (d, J = 8.30 Hz, 1H), 7.67 (d, J 
= 8.71 Hz, 3H), 7.50 (td, J = 0.9, 8.2 Hz, 1H), 7.5 (d, J = 1.1 Hz, 1H), 6.83 (s, 1H), 6.09 (dd, J = 
1.8, 3.1 Hz, 1H), 6.05 (d, J = 3.2 Hz, 1H), 5.15 (d, J = 7.6 Hz, 1H), 4.22 (dt, J = 10.5, 8.1 Hz, 
1H), 3.05 (dd, J = 10.6, 16.6 Hz, 1H), 2.75 (dd, J = 8.4, 16.6 Hz, 1H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 177.0, 151.0, 150.6, 147.2, 142.7, 134.1, 130.5, 129.4, 
129.0, 127.6, 127.5, 126.8, 110.4, 108.6, 56.5, 43.5, 34.5. 
FT-IR (neat): 2984, 1737, 1440, 1373, 1233, 1043, 938, 847, 608 cm-1. 
HR-EI-MS (C17H14N2O2): calculated: 278.1055, found: 278.1056. 
 
(4S,5S)-4-(6-fluoroquinoline-3-yl)-5-(furan-2-yl)pyrrolidine-2-one (38b). Synthesized  
according to the General Procedure A4 using furan-2-carbaldehyde 
7i (33 μL), 4-fluouroaniline 8b (38 μL) and tert-butyl methyl 2-aza-
bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The product  
was purified by column chromatography (50% to 100% EtOAc/hexanes) to afford 75 mg (Yield: 
76%) of a pale yellow sticky solid 38b.  
1H NMR (300 MHz, CDCl3, ppm) δ: 8.52 (bs, 1H), 8.01 (dd, J = 5.3, 9.1 Hz, 1H), 7.64 (s, 1H), 
7.42 (td, J = 2.7, 11.3 Hz, 1H), 7.29 (dd, J = 2.5, 8.8 Hz, 1H), 7.12 (d, J = 1.2, 1H), 6.25 (bs, 
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1H), 6.11 (dd, J = 1.8, 3.1 Hz, 1H), 6.06 (d, J = 3.2 Hz, 1H), 4.27-4.18 (m, 1H), 3.04 (dd, J = 
10.5, 16.6 Hz, 1H), 2.81 (dd, J = 8.4, 16.6 Hz, 1H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 176.5, 162.2, 150.9, 142.8, 133.4, 133.3, 131.7, 131.6, 
131.3, 130.4, 119.8, 119.5, 110.4, 108.6, 56.4, 43.4, 34.3. 
19F NMR (282 MHz, CDCl3, ppm) δ: -113.2 to -113.3 (m, 1F). 
FT-IR (neat): 2925, 2853, 1698, 1629, 1502, 1445, 1422, 1220, 1146, 1011, 912, 832, 751, 598 
cm-1. 
HR-EI-MS (C17H13FN2O2): calculated: 296.0961, found: 296.0962. 
 
(4S,5S)-5-(furan-2-yl)-4-(6-methoxyquinoline-3-yl)pyrrolidine-2-one (38c). Synthesized  
according to the General Procedure A4 using furan-2-
carbaldehyde 7i (33 μL), 4-methoxyaniline 8h (50 mg) and tert-
butyl methyl 2-aza-bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 
(80 mg). The product was purified by column chromatography (60% to 100% EtOAc/hexanes) to 
afford 77 mg (Yield: 75%) of a pale yellow sticky solid 38c.  
1H NMR (300 MHz, CDCl3, ppm) δ: 8.38 (d, J = 2.1 Hz, 1H), 7.87 (d, J = 9.1 Hz, 1H), 7.60 (d, J 
= 1.9 Hz, 1H), 7.30 (dd, J = 2.7, 9.1 Hz, 1H), 7.12 (d, J = 1.2 Hz, 1H), 6.93 (d, J = 2.7 Hz, 1H), 
6.52 (s, 1H), 6.09 (dd, J = 1.8, 3.2 Hz, 1H), 6.04 (d, J = 3.2 Hz, 1H), 5.12 (d. J = 7.6 Hz, 1H), 
4.23-4.14 (m, 1H), 3.89 (s, 3H), 3.04 (dd, J = 10.5, 16.6 Hz, 1H), 2.75 (dd, J = 8.3, 16.6 Hz, 1H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 177.0, 157.9, 151.0, 148.0, 143.3, 142.6, 132.8, 130.8, 
130.4, 128.6, 122.1, 110.3, 108.5, 104.9, 56.5, 55.5, 43.4, 34.5. 
FT-IR (neat): 2927, 2857, 1695, 1604, 1578, 1498, 1472, 1331, 1268, 1208, 1093, 1010, 815, 
746 cm-1. 
HR-ESI-MS exact mass calculated for C18H16N2O3: m/z 309.1234 [M+H]+, found: m/z 309.1236 
[M+H]+. 
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(4S,5S)-5-(furan-2-yl)-4-(6-nitroquinoline-3-yl)pyrrolidine-2-one (38d). Synthesized  
according to the General Procedure A4 using furan-2-carbaldehyde 
7i (33 μL), 4-nitroaniline 8i (55 mg) and tert-butyl methyl 2-aza-
bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The product 
was purified by column chromatography (70% to 100% EtOAc/ 
hexanes) to afford 89 mg (Yield: 83%) of a red-yellow solid 38d. Mp = 94-96 oC.  
1H NMR (300 MHz, CDCl3, ppm) δ: 8.73 (d, J = 2.2 Hz, 1H), 8.64 (d, J = 2.4 Hz, 1H), 8.40 (dd, 
J = 2.4, 6.7 Hz, 1H), 8.16 (d, J = 9.2 Hz, 1H), 7.88 (d, J = 2.0 Hz, 1H), 7.11 (s, 1H), 6.70 (bs, 
1H), 6.12-6.09 (m, 2H), 5.17 (d, J = 7.6 Hz, 1H), 4.33-4.24 (m, 1H), 3.05 (dd, J = 7.6, 10.3 Hz, 
1H), 2.83 (dd, J = 8.4, 16.6 Hz, 1H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 176.4, 154.1, 150.6, 149.1, 145.7, 142.9, 135.6, 132.9, 
131.0, 126.4, 124.3, 122.8, 110.5, 108.8, 56.3, 43.3, 34.4. 
FT-IR (neat): 2923, 2857, 1688, 1623, 1526, 1491, 1434, 1349, 1259, 1169, 1031, 1011, 928, 
840, 735, 641, 592, 573, 520, 476. 
HR-ESI-MS exact mass calculated for C17H13N3O4: m/z 324.0979 [M+H]+, found: m/z 324.0982 
[M+H]+. 
 
(4S,5S)-5-(furan-2-yl)-4-(7-methoxyquinoline-3-yl)pyrrolidine-2-one (38e). Synthesized  
according to the General Procedure A4 using furan-2-carbaldehyde 
7i (33 μL), 3-methoxyaniline 8j (50 mg) and tert-butyl methyl 2-
aza-bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The  
product was purified by column chromatography (50% to 100% EtOAc/hexanes) as a mixture of 
two diastereomers to afford 66 mg of a sticky yellow solid 38e.  
1H NMR (600 MHz, CDCl3, ppm) δ: 8.50 (d. J = 2.2 Hz, 1H), 8.19 (d, J = 2.0 Hz, 1H), 7.60-7.59 
(m, 1H), 7.55 (t, J = 7.5 Hz, 1H), 7.13 (s, 1H), 6.82 (d, J = 7.5 Hz, 1H), 6.09-6.08 (m, 1H), 6.04 
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(d, J = 3.3 Hz, 1H), 5.1 (d, J = 7.7 Hz, 1H), 4.25-4.19 (m, 1H), 3.97 (s, 3H), 3.11 (dd, J = 10.8, 
16.6 Hz, 1H), 2.76 (dd, J = 8.3, 16.6 Hz, 1H).  
13C NMR (150 MHz, CDCl3, ppm) δ: 176.7, 160.6, 154.9, 150.6, 147.9, 142.7, 133.8, 129.2, 
129.0, 121.1, 120.0, 119.9, 110.2, 108.6, 104.4, 56.4, 55.7, 43.6, 34.3. 
FT-IR (neat): 2929, 2856, 1698, 1604, 1578, 1498, 1472, 1331, 1268, 1208, 1096, 1012, 815, 
747 cm-1. 
HR-ESI-MS exact mass calculated for C18H16N2O3: m/z 309.1234 [M+H]+, found: m/z 309.1236 
[M+H]+. 
 
(4S,5S)-5-(furan-2-yl)-4-(5,7-dimethylquinoline-3-yl)pyrrolidine-2-one (38f). Synthesized  
according to the General Procedure A4 using furan-2-carbaldehyde 
7i (33 μL), 3,5-dimetahylaniline 8f (50 μL) and tert-butyl methyl 2-
aza-bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The  
product was purified by column chromatography (40% to 90% EtOAc/hexanes) to afford 38 mg 
(Yield: 38%) of a dark yellow sticky solid 38f.  
1H NMR (300 MHz, CDCl3, ppm) δ: 8.54 (d, J = 2.0 Hz, 1H), 7.79 (d, J = 1.9 Hz,1H), 7.67 
(s,1H), 7.19 (s, 1H), 7.15 (dd, J = 0.7, 1.7 Hz, 1H), 6.13 (dd, J = 1.8, 3.2 Hz, 1H), 6.11 (s, 1H), 
6.07 (d, J = 3.3 Hz, 1H), 5.07 (d, J = 7.7 Hz, 1H), 4.26-4.21 (m, 1H), 3.06 (dd, 11.1, 16.6 Hz, 
1H), 2.77 (dd, 8.4, 16.6 Hz, 1H), 2.53 (s, 3H), 2.49 (s, 3H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 176.6, 151.1, 149.5, 147.2, 142.7, 139.9, 133.9, 131.1, 
129.9, 129.1, 125.7, 125.0, 110.4, 108.7, 56.5, 43.6, 34.7, 21.8, 18.4. 
FT-IR (neat): 2887, 1688, 1680, 1651, 1618, 1576, 1482, 1473, 1458, 1379, 1252, 1153, 1070, 
950. 
HR-ESI-MS exact mass calculated for C19H18N2O2: m/z 307.1441 [M+H]+, found: m/z 307.1442 
[M+H]+. 
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(4S,5S)-4-(7-fluoro-6-methylquinoline-3-yl)-5-(furan-2-yl)pyrrolidine-2-one (38g).  
Synthesized according to the General Procedure A4 using furan-2-
carbaldehyde 7i (33 μL), 3-fluoro-4-metahylaniline 8k (50 mg) and 
tert-butyl methyl 2-aza-bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 
(86 mg). The product was purified by column chromatography (50% to 100% EtOAc/hexanes) to 
afford 86 mg (Yield: 84%) of a dirty white solid 38g. Mp = 214-215 oC.  
1H NMR (300 MHz, CDCl3, ppm) δ: 8.48 (s, 1H), 7.59 (d, J = 10.1 Hz, 2H), 7.46 (d, J = 7.6 Hz, 
1H), 7.11 (s, 1H), 6.62 (s, 1H), 6.06 (d, J = 34.3, 2H), 5.1 (d, J = 6.5 Hz, 1H), 4.19 (d, J = 7.9, 
1H), 3.01 (dd, J = 10.7, 16.1 Hz, 1H), 2.76 (dd J = 7.8, 16.2 Hz, 1H), 2.42 (s, 3H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 176.8, 163.1, 161.4, 151.0 (d), 146.9 (d), 142.6, 133.1, 
129.7 (d), 128.9 (d), 127.4 (d), 124.6, 112.1 (d), 110.3, 108.5, 56.5, 43.3, 34.5, 15.2 (d). 
FT-IR (neat): 2931, 2859, 1698, 1575, 1500, 1431, 1349, 1248, 1149, 1112, 1011, 919, 746, 666, 
597 cm-1. 
HR-ESI-MS exact mass calculated for C18H15FN2O2: m/z 311.1190  [M+H]+, found: m/z 
311.1195 [M+H]+. 
 
 (4S,5S)-4-(benzo[h]quinolin-3-yl)-5-(furan-2-yl)pyrrolidine-2-one (38h). Synthesized  
according to the General Procedure A4 using furan-2-carbaldehyde 
7i (33 μL), 1-napthyl amine 8l (57 mg) and tert-butyl methyl 2-aza-
bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The product 
was purified by column chromatography (40% to 90% EtOAc/ 
hexanes) to afford 84 mg (Yield: 77%) of a pale yellow solid 38h. Mp = 97-98 oC.  
1H NMR (300 MHz, CDCl3, ppm) δ: 8.68 (d, J = 2.2 Hz, 1H), 7.87 (d, J = 7.1 Hz, 1H), 7.75 (d, J 
= 8.8 Hz, 1H), 7.71-7.67 (m, 3H), 7.54 (d, J = 8.8 Hz, 1H), 7.10 (s, 1H), 6.73 (s, 1H), 6.08-6.04 
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(m, 1H), 5.12 (d, J = 7.7 Hz, 1H), 4.31-4.22 (m, 1H), 3.11 (dd, J = 10.6, 16.6 Hz, 1H), 2.79 (dd, 
J = 8.4, 16.6 Hz, 1H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 177.1, 151.1, 148.9, 145.6, 142.6, 134.0, 133.5, 131.2, 
131.2, 128.2, 128.0, 127.8, 127.1, 125.7, 125.1, 124.2, 110.4, 108.5, 56.7, 43.4, 34.6. 
FT-IR (neat): 2918, 1699, 1623, 1504, 1452, 1406, 1331, 1230, 1186, 1145, 1072, 1011, 912, 
803, 746, 720 cm-1. 
HR-EI-MS (C21H16N2O2): calculated: 328.1212, found: 328.1210. 
 
(4S,5S)-5-(5-phenylfuran-2-yl)-4-(quinoline-3-yl)pyrrolidine-2-one (38i). Synthesized  
according to the General Procedure A4 using 5-phenylfuran-2-
carbaldehyde 7j (69 mg),aniline 8a (36 μL) and tert-butyl methyl 2-
aza-bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (80 mg). The product 
was purified by column chromatography (40% to 90% EtOAc/ 
hexanes) to afford 83 mg (Yield: 71%) of a yellow sticky solid 38i.  
1H NMR (300 MHz, CDCl3, ppm) δ: 8.66 (d, J = 1.9 Hz, 1H), 7.95 (d, J = 8.4 Hz, 1H), 7.77 (d, J 
= 1.5 Hz, 1H), 7.61 (t, J = 7.7 Hz, 1H), 7.43 (t, J = 6.9 Hz, 1H), 7.23-7.18 (m, 5H), 6.30 (d, J = 
3.2 Hz, 1H), 6.18 (s, 1H), 6.12 (d, J = 3.3 Hz, 1H), 5.16 (d, J = 7.5 Hz, 1H), 4.33-4.24 (m, 1H), 
3.14 (dd, J = 10.5, 16.6 Hz, 1H), 2.82, (dd, J = 8.2, 16.5 Hz, 1H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 175.7, 154.6, 151.3, 150.2, 147.6, 133.5, 133.3, 130.2, 
129.6, 129.2, 128.8, 127.8, 127.8, 127.6, 127.2, 123.8, 110.0, 105.6, 59.0, 44.3, 37.3. 
FT-IR (neat): 2929, 2856, 1699, 1573, 1496, 1430, 1276, 1021, 911, 789, 758, 693 cm-1. 
HR-ESI-MS exact mass calculated for C23H18N2O2: m/z 355.1441 [M+H]+, found: m/z 355.1443 
[M+H]+. 
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(4S,5S)-4-(6,7-dimethylquinoline-3-yl)-5-(5-phenylfuran-2-yl)pyrrolidine-2-one (38j).  
Synthesized according to the General Procedure A4 using 5-
phenylfuran-2-carbaldehyde 7j (69 mg), 3,4-dimethylaniline 8m 
(48 mg) and tert-butyl methyl 2-aza-bicyclo[3.1.0]hex-3-ene-2,6-
dicarboxylate 3 (80 mg). The product was purified by column 
chromatography (40% to 90% EtOAc/hexanes) to afford 88 mg (Yield: 69%) of a yellow sticky 
solid 38j.  
1H NMR (300 MHz, CDCl3, ppm) δ: 8.54 (d, J = 2.2 Hz, 1H), 7.7 (s, 1H), 7.63 (d, J = 2.0 Hz, 
1H), 7.30-7.19 (m, 5H), 6.28 (d, J = 3.3 Hz, 1H), 6.08 (d, J = 3.3 Hz, 1H), 5.12 (d, J = 7.5 Hz, 
1H), 4.28-4.20 (m, 1H), 3.12 (dd, J = 10.6, 16.5 Hz, 1H), 2.79 (dd, J = 8.3, 16.6 Hz, 1H), 2.38 (s, 
3H), 2.33 (s, 3H). 
13C NMR (300 MHz, CDCl3, ppm) δ: 176.9, 154.2, 150.3, 149.7, 146.5, 139.6, 136.7, 132.9, 
129.9, 129.4, 128.5, 128.3, 127.4, 126.7, 126.1, 123.5, 110.6, 105.4, 56.7, 43.5, 34.1, 20.3, 19.9. 
FT-IR (neat): 2918, 2849, 1698, 1491, 1448, 1215, 1023, 920, 757, 667 cm-1. 
HR-EI-MS (C25H22N2O2): calculated: 382.1681, found: 382.1678. 
 
(4S,5S)-4-(7-methoxyquinoline-3-yl)-5-(5-phenylfuran-2-yl)pyrrolidine-2-one (38k).  
Synthesized according to the General Procedure A4 using 5-
phenylfuran-2-carbaldehyde 7j (69 mg), 3-methoxyaniline 8j (49 
mg) and tert-butyl methyl 2-aza-bicyclo[3.1.0]hex-3-ene-2,6-
dicarboxylate 3 (80 mg). The product was purified by column 
chromatography (50% to 100% EtOAc/hexanes) to afford 94 mg (Yield: 74%) of a pale yellow 
sticky solid 38k.  
1H NMR (300 MHz, CDCl3, ppm) δ: 8.49 (d, J = 2.2 Hz, 1H), 7.84 (d, J = 9.1 Hz, 1H), 7.27-7.16 
(m, 6H), 6.81 (d, J = 2.7 Hz, 1H), 6.32 (s, 1H), 6.30 (d, J = 3.34 Hz, 1H), 6.10 (d, J = 3.34 Hz, 
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1H), 5.14 (d, J = 7.5 Hz, 1H), 4.29-4.20 (m, 1H), 3.79 (s, 3H), 3.12 (dd, J = 10.4, 16.6, Hz, 1H), 
2.80 (dd, J = 8.3, 16.6 Hz, 1H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 176.8, 157.9, 154.2, 150.3, 132.8, 130.3, 129.9, 128.5, 
127.5, 123.5, 122.2, 110.6, 105.4, 104.8, 56.7, 55.4, 43.4, 34.2. 
FT-IR (neat): 2949, 2835, 1721, 1693, 1616, 1504, 1473, 1441, 1390, 1331, 1243, 1664, 1116, 
1037, 1022, 969, 921, 866, 759. 
HR-EIMS (C24H20N2O3): calculated: 384.1474, found: 384.1468. 
 
7.7 General Procedure for Synthesis of Chiral Cis-4,5-Disubstituted  
Pyrrolidinones (+)-38. 
 
7.7a General Procedure A5 
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N
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CO2Me O
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O O
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7 8
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rt to 125 oC
R1
R1
Sc(OTf)3 (5 mol%)
 
A mixture of furan-2-carbaldehyde 7i (0.40 mmol), aniline 8a (0.40 mmol) and (+)-(1R,5R,6R)-
tert-butyl methyl 2-aza-bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate (+)-6 (0.334 mmol) in 4 mL 
acetonitrile was placed in a microwave vial and the solution was degassed by sparging with 
nitrogen. Sc(OTf)3 (0.016 mmol) was added, the vial capped the reaction mixture was 
microwaved initially at room temperature for 1.5 h and then at 125 oC for 3-5 h until the starting 
materials disappear. The reaction mixture was concentrated in vacuo, extracted with ethylacetate 
and washed with distilled water. The organic layer was dried over anhydrous sodiumsulphate, 
concentrated in vacuo and purified using column chromatography (50-90% ethylacetate in 
hexane) to yield the desired chiral pyrrolidinones (+)-38. 
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(4S,5S)-5-(furan-2-yl)-4-(quinoline-3-yl)pyrrolidine-2-one (38a). 97% ee. HPLC Phenomenex 
Lux Cellulose-1, 4.6×250 nm, 5μm, n-heptane/2-propanol = 70/30, flow rate = 0.5 mL/min, λ = 
215 nm, retention time: 29.41 min and 36.68 min.  
 
(4S,5S)-5-(furan-2-yl)-4-(6-nitroquinoline-3-yl)pyrrolidine-2-one (38d). 97% ee. HPLC 
Phenomenex Lux Cellulose-1, 4.6×250 nm, 5μm, n-heptane/2-propanol = 50/50, flow rate = 0.5 
mL/min, λ = 215 nm, retention time: 27.45 min and 32.70 min.  
 
(4S,5S)-4-(benzo[h]quinolin-3-yl)-5-(furan-2-yl)pyrrolidine-2-one (38h). 95% ee. HPLC 
Phenomenex Lux Cellulose-1, 4.6×250 nm, 5μm, n-heptane/2-propanol = 50/50, flow rate = 0.5 
mL/min, λ = 215 nm, retention time: 23.76 min and 33.75 min.  
 
7.8 Experimental Procedure for the Sc(OTf)3-Catalyzed Synthesis of endo-10n 
and exo-11n. 
 
7.8a General Procedure A6 
HN
N Boc
CO2Me
O H
H
H H
N
Boc
CO2Me
H
H
HN
N Boc
CO2Me
O H
H
H H
N
H
O
Sc(OTf)3
5 mol%
MeCN, MS 4 Å
9i 6 endo-10n exo-11n
rt
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A mixture of aldimine3 9i (0.833 mmol) and tert-butyl methyl 2-aza-bicyclo[3.1.0]hex-3-ene-
2,6-dicarboxylate 6 (0.334 mmol) in 4 mL acetonitrile was placed in a dry Schlenck tube and the 
mixture was degassed by sparging with nitrogen. Sc(OTf)3 (0.016 mmol) was added at room 
temperature under N2 and the tube was sealed with a Teflon lined cap at once and the reaction 
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mixture was allowed to stir for 8-24 h until the starting materials disappear. The reaction mixture 
was concentrated in vacuo, extracted with chloroform and washed with distilled water. The 
organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure. The crude 
product was purified using column chromatography (2 -15% ethylacetate in hexane) to yield the 
desired products endo-10n and exo-11n. 
 
Compound endo-10n: Synthesized according to the General Procedure A6 using aldimine 9i  
(143 mg) and tert-butyl methyl 2-aza-bicyclo[3.1.0]hex-3-ene-2,6-
dicarboxylate 6 (80 mg). The product was purified by column 
chromatography (2% to 10% EtOAc/hexane; Rf = 0.4) to afford 98 mg 
(Yield: 77%) of a white solid 10n. Mp = 73-75 oC. 
1H NMR (600 MHz, CDCl3, ppm, signal doubling because of rotamers) δ: 7.59 (dd, J = 6.2, 3.2 
Hz, 1H), 7.42 (d, J = 1.0 Hz, 1H), 7.10 (t, J = 7.4 Hz, 1H), 6.83 (t, J = 7.4 Hz, 1H), 6.65 (d, J = 
7.9 Hz, 1H), 6.36 (dd, J = 1.7, 3.1 Hz, 2H), 5.42 (d, J = 6.2 Hz) and 5.30 (s)[1H], 4.50 (d, J = 2.3 
Hz, 1H), 4.02 (br s, 1H), 3.38 (s) and 3.33 (d, J = 5.4 Hz)[1H], 2.88 (dd, J = 2.4, 4.8 Hz, 1H), 
2.50 (s, 1H), 1.69 (d, J = 14.5, 1H), 1.57 and 1.48 (s, 9H), 1.28 (d, J = 17.3 Hz, 1H). 
13C NMR (150 MHz, CDCl3, ppm, signal doubling because of rotamers) δ: 170.4 and 170.3, 
155.5, 153.6, 144.8, 142.1, 130.6, 128.3 and 128.3, 128.2, 123.5, 120.1, 115.3, 110.4, 106.2, 
80.1, 62.8, 51.9 and 51.6, 45.4, 44.4, 35.7, 31.3, 30.2 and 30.1, 28.3. 
FT-IR (neat): 3367, 3116, 3059, 2975, 2927, 2852, 1726, 1695, 1605, 1480, 1441, 1390, 1366, 
1335, 1289, 1250, 1167, 1121, 1068, 1009, 978, 945, 880, 851, 750, 595 cm-1. 
HR-EIMS (C23H26N2O5): calculated: 410.1842, found: 410.1835. 
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Compound exo-10n: Synthesized according to the General Procedure A6; Yield: 22%; Yellow 
sticky solid; Rf = 0.33 
1H NMR (600 MHz, CDCl3, ppm) δ: 7.45 (d, J = 7.6 Hz, 1H), 7.29 (d, J 
= 1.0 Hz, 1H), 7.07 (J = 8.0 Hz, 1H), 6.76 (t, J = 7.8 Hz, 1H), 6.60 (d, J 
= 7.8 Hz, 1H), 6.22 (dd, J= 1.8, 3.1 Hz, 1H), 6.05 (d, J = 3.2 Hz, 1H), 
5.05 (d, J = 7.5 Hz, 1H), 4.48 (d, J = 3.8 Hz, 1H), 4.15 (s, 1H), 3.67 (s, 
3H), 3.46 (dd, J = 1.3, 6.9 Hz, 1H), 3.00-2.97 (m, 1H), 2.40-2.38 (m,  
1H), 1.81 (dd, J = 1.3, 3.4 Hz, 1H), 1.50 (s, 9H). 
13C NMR (150 MHz, CDCl3, ppm) δ: 170.4, 155.0, 143.1, 141.9, 129.9, 128.2, 122.7, 119.4, 
114.9, 110.2, 106.4, 80.4, 60.2, 52.0, 51.7, 44.6, 44.2, 35.1, 31.4, 31.0, 30.1, 29.6, 28.4,22.6. 
FT-IR (neat): 3377, 2963, 2926, 1727, 1696, 1606, 1494, 1441, 1393, 1317, 1254, 1165, 1125, 
1009, 750, 596 cm-1. 
HR-ESI-MS exact mass calculated for C23H26N2O5: m/z 411.1914 [M+H]+, found: m/z 411.1922 
[M+H]+. 
 
Compound 38nʹ: Synthesized by heating a solution of exo-11n (0.089 mmol) in 3ml acetonitrile  
and Sc(OTf)3 (5 mol%) under reflux condition for 2h. The reaction mixture 
was concentrated in vacuo, extracted with chloroform and washed with 
distilled water. The organic layer was dried over anhydrous Na2SO4, 
concentrated under reduced pressure. The crude product was purified using 
column chromatography (2-5% methanol in chloroform) to give a pale- 
yellow sticky solid of 38nʹ in 72% yield. 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.61 (d, J = 8.5 Hz, 2H), 7.40 (d, J = 1.1 Hz, 1H), 7.07 (t, J 
= 15.2, 1H), 6.85 (t, J = 14.8 Hz, 1H), 6.62 (d, J = 7.9 Hz, 1H), 6.36 (dd, J = 1.8, 3.2 Hz, 1H), 
6.29 (d, J = 3.2 Hz, 1H), 5.13 (d, J = 7.2 Hz, 1H), 3.9 (br s, 1H), 3.83 (d, J = 9.6 Hz, 1H), 3.64 
(s, 3H), 3.20 (t, J = 15.2 Hz, 1H), 2.70-2.63 (m, 1H), 2.56-2.41 (m, 2H). 
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13C NMR (75 MHz, CDCl3, ppm) δ: 171.5, 167.0, 154.3, 144.4, 142.5, 130.7, 127.8, 121.8, 
119.5, 115.3, 110.3, 107.7, 69.7, 52.0, 51.2, 50.3, 45.5, 35.0. 
FT-IR (neat): 3367, 3261, 3107, 2949, 2923, 2857, 1732, 1612, 1592, 1489, 1434, 1366, 1331, 
1305, 1256, 1195, 1167, 1125, 1070, 1011, 926, 884, 752, 669 cm-1. 
HR-ESI-MS exact mass calculated for C18H18N2O3: m/z 311.139 [M+H]+, found: m/z 311.1389 
[M+H]+. 
 
7.9 General Procedure for the Sc(OTf)3-Catalyzed Synthesis of Substituted 
Polycyclic Imines 43. 
 
7.9a General Procedure A7 
N
O
OH
H
43
HN
Ar
N
Boc
CO2Me
H
H
6
NH2
7 8a
MW
rt to 125 oC
Sc(OTf)3 (5 mol%)
ArCHO
 
A mixture of aromatic aldehyde 7 (0.40 mmol), aniline 8a (0.40 mmol) and tert-butyl methyl 2-
aza-bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6  (0.334 mmol) in 4 mL acetonitrile was placed 
in a microwave vial and the solution was degassed by sparging with nitrogen. Sc(OTf)3 (0.016 
mmol) was added, the vial capped the reaction mixture was microwaved initially at room 
temperature for 1.5 h and then at 125 oC for 2-4 h until the starting materials disappear. The 
reaction mixture was concentrated in vacuo, extracted with ethylacetate and washed with 
distilled water. The organic layer was dried over anhydrous Na2SO4, concentrated in vacuo and 
purified using column chromatography (20-60% ethylacetate in hexane) to yield the polycyclic 
imine 43. 
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7.10 Characterization Data of the Polycyclic Imines 43. 
Compound 43a (major diastereomer): Synthesized according to the General Procedure 
A7; Yield: 64%, White sticky solid; Rf = 0.2. 
                                                                                     1H NMR (300 MHz, CDCl3, ppm) δ: 7.44 (d, J = 7.2 Hz, 2H), 7.41-7.36 (m, 
4H), 7.31-7.28 (m, 2H), 7.00 (t, J = 7.1 Hz, 1H), 6.78 (d, J = 8.8 Hz, 2H), 
5.50 (d, J = 9.1 Hz, 1H), 4.67 (d, J = 3.1 Hz, 1H), 3.52 (s, 3H), 3.46-3.43 (m, 
1H), 2.68 (td, J = 3.4, 12.5 Hz, 1H), 2.48-2.39 (m, 1H), 2.30 (dd, J = 8.2, 
15.2 Hz, 1H): 
13C NMR (75 MHz, CDCl3, ppm) δ: 171.9, 170.0, 148.0, 143.0, 131.1, 129.9, 129.7, 129.6, 
128.8, 128.7, 127.4, 123.8, 120.1, 117.3, 73.4, 58.6, 52.1, 49.8, 46.2, 35.9. 
FT-IR (neat): 3362, 3255, 3029, 2948, 2848, 1734, 1612, 1483, 1455, 1436, 1352, 1307, 1256, 
1198, 1164, 1109, 1067, 1020, 982, 878, 850, 755, 703, 631, 540 cm-1. 
HR-EIMS (C20H20N2O2): calculated: 320.1525, found: 320.1521. 
 
Compound 43b (major diastereomer): Synthesized according to the General Procedure 
A7; Yield: 69%, Pale yellow solid; Rf = 0.22; Mp = 190-193 oC.  
 1H NMR (400 MHz, CDCl3, ppm) δ: 7.44 (d, J = 7.0 Hz, 1H), 7.38 (d, J = 1.2 Hz, 4H), 
7.08-7.04 (m, 1H), 6.86-6.82 (m, 1H), 6.64 (d, J = 8.6 Hz, 1H), 5.60 (d, J = 8.9 Hz, 1H),  
4.73 (d, J = 3.0 Hz, 1H), 3.72 (br s, 1H), 3.59 (s, 3H), 3.54-
3.48 (m, 1H), 2.63-2.58 (m, 1H), 1.76 (dd, J = 9.4, 16.3 Hz, 
1H), 1.65 (dd, J = 4.1, 16.3 Hz, 1H). 
 
13C NMR (100 MHz, CDCl3, ppm) δ: 171.7, 168.9, 145.0, 139.9, 133.6, 130.4, 129.2, 127.8, 
127.4, 120.1, 115.9, 72.3, 57.1, 51.6, 49.0, 44.7, 35.7. 
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FT-IR (neat): 3165, 3059, 2993, 2918, 2848, 1732, 1693, 1629, 1605, 1592, 1487, 1434, 1408, 
1370, 1307, 1265, 1228, 1195, 1169, 1088, 1013, 985, 941, 820, 757, 684, 508 cm-1. 
HR-EIMS (C20H19ClN2O2): calculated: 354.1125, found: 354.1132. 
 
Compound 43c (major diastereomer): Synthesized according to the General Procedure 
A7; Yield: 61%, White sticky solid; Rf = 0.2. 
                                                           1H NMR (300 MHz, CDCl3, ppm) δ: 7.45 (d, J = 6.3 Hz, 2H), 7.31 (d, 
J = 8.0 Hz, 2H), 7.21 (d, J = 7.9 Hz, 2H), 7.05 (t, J = 7.6 Hz, 1H), 6.82 
(t, J = 7.4 Hz, 1H), 6.64 (d, J = 7.9 Hz, 1H), 5.59 (d, J = 8.9 Hz, 1H), 
4.73 (d, J = 2.9 Hz, 1H), 3.75 (s, 1H), 3.58 (s, 3H), 3.57-3.50 (m, 1H), 
2.63-2.56 (m, 1H), 2.36 (s, 3H), 1.73 (dd, J = 10.0, 16.4 Hz, 1H), 1.63 
(dd, J = 4.3, 11.9 Hz, 1H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 172.0, 169.2, 145.5, 138.3, 137.6, 130.4, 129.6, 127.7, 
125.8, 123.1, 119.7, 116.5, 115.8, 72.4, 57.3, 51.6, 49.2, 44.8, 35.8, 21.1. 
FT-IR (neat): 3151, 2953, 2923, 2870, 2839, 2725, 1632, 1682, 1607, 1480, 1458, 1375, 1272, 
1217, 1164, 1123, 1070, 1040, 996, 974, 840, 807, 755, 505 cm-1. 
HR-EIMS (C21H22N2O2): calcd: 334.1681, found: 334.1680. 
 
Compound 43d (major diastereomer): Synthesized according to the General Procedure 
A7; Yield: 60%, Pale yellow sticky solid; Rf = 0.15 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.67 (d, J = 5.1 Hz, 1H), 7.12 
(d, J = 7.4 Hz, 1H), 7.03-7.00 (m, 1H), 6.67-6.64 (m, 1H), 6.50 (d, J 
= 4.9 Hz, 1H), 4.57 (dd, J = 12.57, 18.14 Hz, 2H), 4.20 (s, 1H), 3.75-
3.71 (m, 1H), 3.50-3.46 (m, 1H), 3.36 (s, 3H), 3.33 (s, 3H), 2.87-
2.80 (m, 1H), 2.33-2.27 (m, 1H). 
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13C NMR (75 MHz, CDCl3, ppm) δ: 157.09, 143.30, 126.75, 125.36, 121.92, 120.93, 118.87, 
88.40, 71.70, 71.68, 58.70, 56.20, 49.14, 49.11. 
FT-IR (neat): 3447, 3261, 3110, 3076, 3011, 2953, 2921, 2851, 2817, 1734, 1631, 1608, 1522, 
1487, 1436, 1350, 1320, 1261, 1198, 1169, 1110, 1018, 981, 860, 758, 705, 523 cm-1. 
HR-ESI-MS (C14H18N2O2): calculated: 246.14, found: 246.1416. 
 
Compound 43e (major diastereomer): Synthesized according to the General Procedure 
A7; Yield: 65%, Pale yellow sticky solid; Rf = 0.1. 
 1H NMR (300 MHz, CDCl3, ppm) δ: 8.30 (d, J = 8.7 Hz, 2H), 7.68 
(d, J = 8.6 Hz, 2H), 7.47 (d, J = 11.1 Hz, 2H), 7.12-7.06 (m, 1H), 
6.91-6.86 (m, 1H), 6.69 (d, J = 7.3 Hz, 1H), 5.65 (d, J = 8.9 Hz, 1H), 
4.88 (d, J = 3.1 Hz, 1H), 3.79 (s, 1H), 3.58 (s, 3H), 3.55-3.47 (m, 
1H), 2.71-2.64 (m, 1H), 1.74 (dd, J = 9.8, 16.3 Hz, 1H), 1.57 (dd. J = 
4.1, 16.4 Hz, 1H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 171.4, 168.6, 148.8, 147.5, 144.¸130.4, 127.9, 127.0, 124.3, 
122.9, 120.5, 116.1, 72.4, 57.4, 51.8, 48.7, 44.6, 35.7. 
FT-IR (neat): 3447, 3261, 3110, 3076, 3011, 2953, 2921, 2851, 2817, 1734, 1631, 1608, 1522, 
1487, 1436, 1350, 1320, 1261, 1198, 1169, 1110, 1018, 981, 860, 758, 705, 523 cm-1. 
HR-ESI-MS (C20H19N3O4): calculated: 366.1448, found: 366.1456. 
 
Compound 43f (major diastereomer): Synthesized according to the General Procedure 
A7; Yield: 70%, White sticky solid; Rf = 0.3. 
                                                            1H NMR (300 MHz, CDCl3, ppm) δ: 8.04 (d, J = 9.2 Hz, 1H), 7.94-7.90 
(m, 1H), 7.86 (t, J = 6.5 Hz, 1H), 7.57-7.50 (m, 4H), 7.45 (br s, 1H), 
7.10 (td, J = 1.4, 8.8 Hz, 1H), 6.88 (td, J = 1.0, 8.4 Hz, 1H), 6.72 (d, J =  
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7.8 Hz, 1H), 5.72 (d, J = 9.0 Hz, 1H), 5.54 (d, J = 2.4 Hz, 1H), 3.78 (br s, 1H), 3.62-3.55 (m, 
1H), 3.43 (s, 3H), 2.96-2.89 (m, 1H), 1.46 (dd, J = 10.3, 16.4 Hz, 1H), 1.24 (t, J = 4.2 Hz, 1H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 171.7, 169.2, 145.9, 136.9, 133.7, 130.5, 130.0, 129.3, 
128.4, 127.8, 126.6, 126.0, 125.6, 123.3, 122.3, 122.0, 120.0, 116.1, 72.3, 53.5, 51.5, 46.8, 45.3, 
35.4. 
FT-IR (neat): 3050, 3010, 2945, 2918, 2848, 1730, 1623, 1592, 1605, 1592, 1480, 1434, 1377, 
1351, 1324, 1289, 1254, 1224, 1197, 1169, 1083, 1033, 993, 904, 884, 860, 779, 750, 660, 634, 
461 cm-1. 
HR-EIMS (C24H22N2O2): calculated: 370.1681, found: 370.1684. 
 
Compound 43g (major diastereomer): Synthesized according to the General Procedure 
A7; Yield: 53%, White sticky solid; Rf = 0.15 
                                                 1H NMR (300 MHz, CD3OD, ppm) δ: 7.47 (s, 1H), 7.31 (dd, J = 1.1, 5.0 Hz, 
1H), 7.29 (s, 1H), 7.12 (d, J = 3.4 Hz, 1H), 7.04-7.01 (m, 1H), 7.00 (dd, J = 
1.2, 7.6 Hz, 1H), 6.75 (t, J = 7.2 Hz, 1H), 5.49 (d, J  = 9.1 Hz, 1H), 4.93 (d.  
J = 3.5 Hz, 1H), 3.58 (s, 3H), 3.48 (d, J = 8.3 Hz, 1H), 2.74-2.67 (m, 1H), 
1.84 (d, 1H), 1.81 (s, 1H). 
13C NMR (75 MHz, CD3OD, ppm) δ: 173.7, 172.2, 147.3, 146.5, 131.1, 128.8, 128.0, 125.0, 
124.7, 123.7, 120.5, 117.4, 72.8, 55.0, 52.1, 50.0, 46.8, 35.9. 
FT-IR (neat): 3313, 3061, 2935, 2847, 1716, 1623, 1588, 1559, 1532, 1500, 1432, 1406, 1374, 
1352, 1273, 1202, 1147, 1103, 1039, 995, 952, 911, 846, 829, 768, 738, 706, 659, 610, 573, 472 
cm-1. 
HR-EIMS (C18H18SN2O2): calculated: 326.1089, found: 326.1092. 
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7.11 Plausible Mechanism for the Synthesis of Imine Derivatives. 
HN
N
O
O
O O
H
H H
H H
H
Sc(OTf)3
HN
N
O
O
O O
H
H H
H
HH
Sc(OTf)3
HN
N
O
O
O
O
H
H H
H
H
H
H2O:
HN
N
CO2Me
H
H H
H
Sc(OTf)3
 
 
7.12 Experimental Procedure for the Sc(OTf)3-Catalyzed Functionalization of 
43 via Intermolecular Trapping of Iminium Ion. 
 
7.12a General Procedure A8 
reflux
N
H
46
MeCN, MS 4 Å
Sc(OTf)3
(20 mol%)N
Boc
CO2Me
H
H
6
NH2
7a 8a
PhCHO
45
HN
NH
CO2Me
H
H
NH
 
A mixture of benzaldehyde 7a (0.40 mmol), aniline 8a (0.40 mmol) and tert-butyl methyl 2-aza-
bicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate 6 (0.334 mmol) in pyrrole 45 (excess or as solvent) 
was placed in a microwave vial and the solution was degassed by sparging with nitrogen. 
Sc(OTf)3 (0.032 mmol) was added, the vial capped the reaction mixture was microwaved initially 
at room temperature for 1.5 h and then at 125 oC for 2 h until the starting materials disappear. 
The reaction can also be done under reflux condition using molecular sieves and 20 mol% 
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Sc(OTf)3 to produce similar product. The reaction mixture was concentrated in vacuo, extracted 
with ethylacetate and washed with distilled water. The organic layer was dried over anhydrous 
Na2SO4, concentrated in vacuo and the major diastereomer was separated using column 
chromatography (30-70% ethylacetate in hexane) to yield 46. 
 
7.13 Characterization Data of Compound 46. 
Compound 46 (major diastereomer): Synthesized according to the General Procedure A8; 
Yield: 42%, Yellow sticky solid; Rf = 0.45. 
1H NMR (600 MHz, CD3OD, ppm) δ: 7.51 (d, J = 7.4 Hz, 2H), 7.36 
(t, J = 7.5 Hz, 2H), 7.27 (t, J = 7.3 Hz, 1H), 7.22(dd, J = 1.2, 7.5 Hz, 
1H), 7.09 (td, J = 1.4, 7.9 Hz, 1H), 6.89 (dd, J = 0.8, 8.0 Hz, 1H), 
6.78 (td, J = 1.1, 7.4 Hz, 1H), 5.88 (t, J = 3.1 Hz, 1H), 5.79 (dd, J =  
1.4, 3.3 Hz, 1H), 4.51 (d, J = 3.7 Hz, 1H), 4.50 (br s, 1H), 3.87 (d, J = 10.1 Hz, 1H), 3.33 (s, 1H), 
3.24 (s, 3H), 2.82-2.78 (m, 1H), 2.72- 
2.66 (m, 1H), 1.50 (dd, J = 8.3, 15.5 Hz, 1H), 1.41 (dd, J = 3.2, 15.5 Hz, 1H), 1.28 (br s, 1H). 
13C NMR (150 MHz, CD3OD, ppm) δ: 172.9, 148.0, 141.0, 129.6, 129.0, 128.7, 128.2, 127.5, 
127.0, 124.8, 119.7, 117.7, 116.3, 107.4, 106.6, 62.1, 58.1, 50.9, 50.7, 42.7, 35.5. 
HR-EIMS (C24H25N3O2): calculated: 387.19, found: 387.1000.    
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7.14 General Procedure and Characterization Data for Cu(OTf)2-Catalyzed, 
Multicomponent Syntheses of Substituted Tetrahydro Pyrazoles 74. 
 
7.14a General Procedure A9 
DCM, rt, air
Cu(OTf)2 (20 mol%)
R1
O
R2
H
N
R1
NHN
XX
n
[X = N-Boc, O]
n
NH2
[n = 1, 2]
R2
7
69
71
74
 
To a 20 mL glass vial equipped with a magnetic stir bar, was sequentially added aldehyde 7 
(0.90 mmol), CH2Cl2 (5 mL) and Cu(OTf)2 (0.09 mmol, 20 mol%). The resulting mixture was 
stirred for 15 minutes and then hydrazine 69 (0.45 mmol) and olefin 71 (0.45 mmol) were added 
drop wise in a sequential manner. The reaction mixture was stirred at room temperature initially 
under aerial atmosphere for 1.0 h and then the vial was capped, fitted with small needles, kept for 
stirring and monitored periodically by TLC. Upon consumption of the olefin 71 (6 – 12 h), the 
reaction mixture was concentrated; the residue was dissolved in ethylacetate, washed with 
distilled water and extracted in ethylacetate. The organic layer was dried, concentrated and 
subjected to silica gel chromatography (hexanes/ethylacetate) to give the desired products 74. 
 
(3R,3aR,6aS)-Tert-butyl hexahydro-2-methyl-3-phenylpyrrolo[2,3-c]pyrazole-6(6aH)-
carboxylate (74a). Synthesized according to the Synthesized according to the General Procedure  
A9 using benzaldehyde 7a (92 μL), methylhydrazine 69a (24 μL) and 
tert-butyl 2,3-dihydropyrrole-1-carboxylate 71a (73 μL). The product  
was purified by column chromatography (0 to 25% EtOAc/hexanes) to afford 88 mg (Yield: 
65%) of a white gummy solid 74a. Rf = 0.4 (30% EtOAc/hexanes), mp = 105-108 oC. 
NHN
N
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H
H
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1H NMR (300 MHz, CDCl3, ppm) δ: 7.52 (d, J = 28.1 Hz, 2H), 7.27 (d, J = 8.4 Hz, 3H), 4.93 (s, 
1H), 3.62 (d, J = 6.6 Hz, 1H), 3.12 (dd, J = 15.7, 10.8 Hz, 1H), 3.04 (dd, J = 11.9, 3.6 Hz, 1H), 
2.96 (s, 3H), 2.74 (d, J = 8.8 Hz, 1H), 2.09 – 1.99 (m, 2H), 1.42 (dd, J = 8.9, 5.7 Hz, 1H), 1.30 
(s, 9H).  
13C NMR (75 MHz, CDCl3, ppm) δ: 163.27, 141.20, 127.81, 127.60, 127.10, 79.66, 71.15, 
46.42, 44.84, 28.18, 27.38. 
FT-IR (neat) cm-1: 3370, 3322, 3276, 2976, 2931, 2866, 1706, 1517, 1457, 1388, 1364, 1273, 
1253, 1169, 995, 910, 785, 760, 726, 701, 472, 442, 417. 
HR-ESI-MS exact mass calculated for C17H25N3O2: m/z 303.19, found: m/z 304.2010 [M+H]+. 
 
 (3R,3aR,6aS)-Tert-butyl hexahydro-2-methyl-3-phenyl-1H-pyrazolo[3,4-c]pyridine-
6(7aH)-carboxylate (74b). Synthesized according to the General Procedure A9 using benzalde- 
hyde 7a (92 μL), methylhydrazine 69a (24 μL) and tert-butyl 3,4-
dihydropyridine-1(2H)-carboxylate 71b (80 μL). The product was 
purified by column chromatography (0 to 15% EtOAc/hexanes) to afford  
115 mg (Yield: 81%) of a pale yellow gummy solid 74b. Rf = 0.5 (20% EtOAc/hexanes) 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.45 (d, J = 6.8 Hz, 2H), 7.37 – 7.33 (m, 2H), 7.13 (d, J = 
3.8 Hz, 1H), 4.14 – 4.04 (m, 1H), 3.38 (d, J = 13.5 Hz, 1H), 3.11 (td, J = 12.4, 3.1 Hz, 1H), 2.96 
– 2.80 (m, 1H), 2.68 (s, 3H), 1.98 (dd, J = 13.9, 7.7 Hz, 1H), 1.86 – 1.78 (m, 1H), 1.52 (s, 9H), 
1.40 (dt, J = 10.1, 5.0 Hz, 4H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 151.77, 128.66, 128.00, 127.72, 81.27, 79.67, 77.46, 77.03, 
76.61, 51.92, 45.55, 42.56, 28.26, 27.11, 23.17. 
FT-IR (neat) cm-1: 3026, 2980, 2951, 2936, 2866, 2781, 1702, 1602, 1507, 1452, 1408, 1363, 
1343, 1293, 1253, 1213, 1159, 905, 751, 726, 701, 671, 432. 
HR-ESI-MS exact mass calculated for C18H27N3O2: m/z 317.21, found: m/z 318.2186 [M+H]+. 
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(3R,3aR,7aR)-Octahydro-2-methyl-3-phenylpyrano[2,3-c]pyrazole (74c). Synthesized 
according to the General Procedure A9 using 2-methoxy benzaldehyde 7n (123 mg),  
methylhydrazine 69a (24 μL) and 3,4-dihydro-2H-pyran 71e (41 μL). 
The product was purified by column chromatography (0 to 40% 
EtOAc/hexanes) to afford 60 mg (Yield: 62%) of a pale yellow gummy 
solid 74c. Rf = 0.25 (40% EtOAc/hexanes) 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.48 – 7.43 (m, 1H), 7.40 (dd, J = 5.0, 2.0 Hz, 1H), 7.35 
(dd, J = 5.3, 3.0 Hz, 2H), 4.25 (t, 2H) (two doublets immerging with each other), 3.70 (s, 3H), 
2.58 (s, 1H), 2.54 (t, J = 6.3 Hz, 2H), 1.92 (dt, J = 10.5, 6.3 Hz, 2H), 1.82 – 1.73 (m, 1H), 1.73 – 
1.63 (m, 1H), 1.59 – 1.42 (m, 1H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 139.99, 130.29, 128.93, 128.69, 128.29, 98.32, 69.85, 
68.01, 48.58, 36.86, 22.97, 18.51. 
FT-IR (neat) cm-1: 2980, 2946, 2926, 2851, 2781, 1716, 1677, 1637, 1507, 1492, 1463, 1402, 
1353, 1333, 1288, 1213, 1089, 1064, 1014, 995, 930, 905, 840, 825, 666, 481, 422. 
HR-ESI-MS exact mass calculated for C13H18N2O: m/z 218.14, found: m/z 219.1491 [M+H]+. 
 
(3R,3aR,6aS)-tert-butyl hexahydro-2-methyl-3-(4-nitrophenyl)pyrrolo[2,3-c]pyrazole-
6(6aH)-carboxylate (74d): Synthesized according to the General Procedure A9 using 4-nitro  
benzaldehyde 7e (136 mg), methylhydrazine 69a (24 μL) and tert-
butyl 2,3-dihydropyrrole-1-carboxylate 71a (73 μL). The product 
was purified by column chromatography (0 to 50% EtOAc/ 
hexanes) to afford 119 mg (Yield: 76%) of a white gummy solid 74d. Rf = 0.1 (40% 
EtOAc/hexane) 
1H NMR (400 MHz, CDCl3, ppm) δ: 8.22 (d, J = 8.8 Hz, 2H), 7.46 (d, J = 8.7 Hz, 2H), 4.78 (d, J 
= 9.1 Hz, 1H), 4.27 (dt, J = 18.8, 9.4 Hz, 1H), 4.01 (dd, J = 10.8, 8.8 Hz, 1H), 3.92 – 3.84 (m, 
1H), 2.86 (s, 3H), 1.84 – 1.74 (m, 2H), 1.57 (d, J = 11.1 Hz, 1H), 1.53 (s, 9H). 
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13C NMR (101 MHz, CDCl3, ppm) δ: 161.19, 149.51, 147.75, 129.47, 123.93, 82.76, 70.25, 
53.60, 40.62, 29.21, 27.97, 21.99. 
FT-IR (neat) cm-1: 3021, 2981, 2926, 2892, 2845, 1731, 1704, 1514, 1405, 1344, 1188, 855, 556, 
474. 
HR-ESI-MS exact mass calculated for C17H14N2O4: m/z 348.18, found: m/z 348.1911 [M+H]+. 
 
(3R,3aR,6aS)-tert-butyl hexahydro-2-methyl-3-p-tolylpyrrolo[2,3-c]pyrazole-6(6aH)-
carboxylate (74e): Synthesized according to the General Procedure A9 using 4-methyl  
benzaldehyde 7k (106 μL), methylhydrazine 69a (24 μL) and tert-
butyl 2,3-dihydropyrrole-1-carboxylate 71a (73 μL). The product was 
purified by column chromatography (0 to 20% EtOAc/ hexanes) to 
afford 107 mg (Yield: 75%) of a white gummy solid 74e. Rf = 0.45 (30% EtOAc/ hexanes) 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.66 – 7.33 (m, 2H), 7.09 (d, J = 8.0 Hz, 2H), 4.90 (d, 1H), 
3.62 (d, J = 6.7 Hz, 1H), 3.12 (dd, J = 9.7, 5.0 Hz, 1H), 3.03 (dd, J = 11.8, 3.4 Hz, 1H), 2.95 (s, 
3H), 2.72 (s, 1H), 2.31 (s, 3H), 2.10 – 1.93 (m, 2H), 1.41 (t, J = 7.3 Hz, 1H), 1.32 (s, 9H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 159.15, 128.50, 126.98, 80.06, 70.69, 46.45, 44.96, 28.19, 
21.20. 
FT-IR (neat) cm-1: 3359, 3021, 2976, 2951, 2926, 2856, 1711, 1512, 1448, 1388, 1363, 1248, 
1174, 1034, 980, 905, 815, 751, 527, 462, 427. 
HR-ESI-MS exact mass calculated for C18H27N3O2: m/z 317.21, found: m/z 317.2208 [M+H]+. 
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(3R,3aR,7aS)-Tert-butyl hexahydro-3-(2-methoxyphenyl) -2-methyl-1H-pyrazolo[3,4-
b]pyridine-7(7aH)-carboxylate (74h). Synthesized according to the General Procedure A9  
using 2-methoxybenzaldehyde 7n (123 mg), methylhydrazine 69a (24 
μL) and tert-butyl 3,4-dihydropyridine-1(2H)-carboxylate 71b (80 
μL). The product was purified by column chromatography 
(0 to 30% EtOAc/hexanes) to afford 100 mg (Yield: 64%) of a pale yellow gummy solid 74h. Rf 
= 0.3 (40% EtOAc/hexanes) 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.22 (t, J = 7.8 Hz, 2H), 6.88 (td, J = 7.4, 0.7 Hz, 1H), 6.78 
(d, J = 8.2 Hz, 1H), 5.53 (d, J = 5.8 Hz, 1H), 3.77 (s, 3H), 3.59 (d, J = 13.7 Hz, 1H), 3.19 (dd, J 
= 12.0, 2.3 Hz, 1H), 2.96 (s, 3H), 2.31 (t, J = 13.2 Hz, 1H), 2.03 (s, 2H), 1.78 (dd, J = 10.0, 3.4 
Hz, 2H), 1.59 – 1.50 (m, 2H), 1.39 (s, 3H), 1.31 (s, 6H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 157.52, 130.99, 129.40, 128.99, 120.01, 109.82, 79.26, 
75.53, 55.14, 49.40, 45.79, 41.23, 40.02, 29.83, 28.22, 25.81, 25.00. 
FT-IR (neat) cm-1: 3384, 3364, 3319, 2961, 2936, 2926, 2856, 2836, 2787, 1711, 1602, 1522, 
1492, 1463, 1283, 1243, 1174, 1104, 1049, 1029, 905, 756, 731, 651, 512, 407. 
HR-ESI-MS exact mass calculated for C19H29N3O3: m/z 347.22, found: m/z 348.2306 [M+H]+. 
 
(3R,3aR,7aR)-3-(4-chlorophenyl)-Octahydro-2-methylpyrano[2,3-c]pyrazole (74i). 
Synthesized according to the General Procedure A9 using 4-chlorobenzaldehyde 7b (126 mg),  
methylhydrazine 69a (24 μL) and 3,4-dihydro-2H-pyran 71e (41 μL). 
The product was purified by column chromatography (0 to 40% 
EtOAc/hexanes) to afford 78 mg (Yield: 69%) of a pale white gummy 
solid 74i. Rf = 0.28 (40% EtOAc/hexanes) 
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1H NMR (300 MHz, CDCl3, ppm) δ: 7.43 – 7.30 (m, 4H), 4.35 (d, J = 9.7 Hz, 1H), 3.99 – 3.89 
(m, 1H), 3.42 (d, J = 13.4 Hz, 1H), 2.79 (dt, J = 16.6, 11.1 Hz, 1H), 2.58 (s, 3H), 2.04 (dd, J = 
6.3, 4.4 Hz, 1H), 1.79 (dd, J = 11.0, 7.3 Hz, 2H), 1.56 (ddd, J = 20.3, 15.4, 9.0 Hz, 2H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 146.13, 133.84, 128.95, 127.78, 125.77, 80.38, 77.46, 77.04, 
76.62, 70.07, 62.11, 48.46, 43.03, 25.60, 23.07. 
FT-IR (neat) cm-1: 3397, 3063, 2987, 2946, 2857, 2782, 1691, 1636, 1596, 1493, 1452, 1404, 
1350, 1336, 1288, 1179, 1090, 1064, 1016, 981, 927, 824, 722, 668, 524, 476, 415. 
HR-ESI-MS exact mass calculated for C13H17ClN2O: m/z 252.10, found: m/z 252.1099 [M+H]+. 
 
(3R,3aR,7aR)-Octahydro-2-methyl-3-(4-nitrophenyl)pyrano[2,3-c]pyrazole (74k): 
Synthesized according to the General Procedure A9 using 4-nitrobenzaldehyde 7e (136 mg),  
methylhydrazine 69a (24 μL) and 3,4-dihydro-2H-pyran 71e (41 μL). 
The product was purified by column chromatography (0 to 50% 
EtOAc/hexanes) to afford 82 mg (Yield: 70%) of a pale white gummy 
solid 74k. Rf = 0.10 (50% EtOAc/hexanes) 
1H NMR (300 MHz, CDCl3) δ: 8.23 (d, J = 8.7 Hz, 2H), 7.63 (d, J = 8.6 Hz, 2H), 4.37 (d, J = 
10.9 Hz, 1H), 3.96 (td, J = 11.0, 4.7 Hz, 1H), 3.74 – 3.64 (m, 1H), 3.56 (d, J = 13.5 Hz, 1H), 
2.90 – 2.72 (m, 1H), 2.59 (s, 3H), 2.04 (s, 1H), 1.84 – 1.77 (m, 2H), 1.66 – 1.58 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ: 160.77, 147.75, 145.74, 128.56, 124.04, 80.08, 70.27, 62.52, 
49.00, 43.35, 25.39, 22.86. 
FT-IR (neat) cm-1: 3020, 2926, 2901, 2856, 1512, 1348, 1213, 905, 751, 731, 666, 651, 502, 437. 
HR-ESI-MS exact mass calculated for C13H17N3O3: m/z 263.12, found: m/z 264.1339 [M+H]+. 
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(3R,5R)-3-ethoxy-5-(2-fluorophenyl)-1-methylpyrazolidine (74l): Synthesized according to  
the General Procedure A9 using 2-fluorobenzaldehyde 7q (0.90 mmol), 
methylhydrazine 66a (0.45 mmol) and ethyl-vinyl ether 71f (0.45 mmol). 
The product was purified by column chromatography (0 to 30% EtOAc/ 
hexanes) to afford 59 mg (Yield: 59%) of a pale white gummy solid 74l. Rf = 0.32 (35% 
EtOAc/hexane) 
1H NMR (300 MHz, CDCl3) δ: 7.69 – 7.61 (m, 1H), 7.17 (d, J = 6.7 Hz, 1H), 7.12 (d, J = 10.3 
Hz, 1H), 7.04 (t, 1H), 4.21 (t, J = 5.9 Hz, 1H), 4.19 – 4.13 (m, 1H), 3.73 – 3.50 (m, 2H), 3.08 (s, 
1H), 3.01 – 2.95 (m, 1H), 2.81 – 2.74 (m, 1H), 2.62 (s, 3H), 1.34 (t, J = 7.1 Hz, 3H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 158.33, 128.59, 128.18, 124.43, 115.47, 103.67, 88.24, 
77.45, 77.03, 76.60, 66.53, 64.53, 44.15, 39.60, 14.28. 
19F NMR (282 MHz, CDCl3) δ: -119.62. 
FT-IR (neat) cm-1: 2926, 2856, 2801, 1731, 1622, 1592, 1567, 1487, 1457, 1363, 1278, 1250, 
1164, 1114, 1089, 1059, 984, 756, 577, 502, 442. 
HR-ESI-MS exact mass calculated for C12H17FN2O: m/z 224.13, found: m/z 224.1411 [M+H]+. 
 
7.15 General Procedure and Characterization Data for Cu(OTf)2-Catalyzed, 
Multicomponent Syntheses of Dihydro- and 1H-Pyrazoles 74-76. 
7.15a General Procedure A10 
DCM, rt, air
Cu(OTf)2 (20 mol%)
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To a 20 ml glass vial equipped with a magnetic stir bar, was sequentially added aldehyde 7 (0.90 
mmol), CH2Cl2 (5 mL) and Cu(OTf)2 (0.09 mmol, 20 mol%). The resulting mixture was stirred 
for 15 minutes and then hydrazine 69 (0.45 mmol) and olefin 71 (0.45 mmol) were added drop 
wise in a sequential manner. The reaction mixture was stirred at room temperature initially under 
air for 1.0 h and then the vial was capped, fitted with small needles, kept for stirring and 
monitored periodically by TLC. After consumption of the olefin 71 (6 – 12 h), the reaction 
mixture was kept for stirring for longer time (12 – 24 h) under air until the preformed 74 
disappear and a new spot of 75 and 76 form successively in different reaction vials depending on 
the reaction time. The reaction mixture was then concentrated; the residue was dissolved in 
ethylacetate, washed with distilled water and extracted in ethylacetate. The organic layer was 
dried, concentrated and subjected to silica gel chromatography (hexanes/ethylacetate) to give the 
desired products 75 and 76 in separate reactions. 
 
tert-butyl 3,3a,4,5-tetrahydro-2-methyl-3-phenylpyrrolo[2,3-c]pyrazole-6(2H)-carboxylate 
(75a): Synthesized according to the General Procedure A10 using  benzaldehyde 7a (92 μL),  
methylhydrazine 69a (24 μL) and tert-butyl 2,3-dihydropyrrole-1-
carboxylate 71a (73 μL). The product was purified by column  
chromatography (0 to 25% EtOAc/hexanes) to afford 83 mg (Yield:  
65%) of a pale yellow gummy solid 75a. Rf = 0.45 (30% EtOAc/hexanes) 
1H NMR (400 MHz, CDCl3) δ: 7.47 – 7.42 (m, 2H), 7.40 – 7.39 (m, 1H), 7.38 – 7.35 (m, 2H), 
4.24 (t, J = 7.9 Hz, 2H), 3.79 (s, 3H), 2.92 (t, J = 2.9 Hz, 2H), 1.56 (s, 9H), 1.42 (dd, J = 9.1, 5.5 
Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ: 164.82, 156.28, 138.01, 130.23, 128.75, 128.42, 128.29, 127.53, 
80.38, 53.17, 45.81, 37.84, 29.68, 28.35, 28.12, 28.00. 
FT-IR (neat) cm-1: 3076, 3056, 2966, 2921, 2851, 2831, 1696, 1531, 1506, 1476, 1446, 1371, 
1337, 1247, 1148, 1048, 764, 739, 699, 539, 520, 460. 
HR-ESI-MS exact mass calculated for C16H20N3O2: m/z 286.16, found: m/z 286.1723 [M+H]+. 
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(3R,3aR)-tert-butyl 2,3,3a,4,5,6-hexahydro-2-methyl-3-phenylpyrazolo[3,4-b]pyridine-7-
carboxylate (75b): Synthesized according to the General Procedure A10 using  benzaldehyde 7a  
(92 μL), methylhydrazine 69a (24 μL) and tert-butyl 3,4-
dihydropyridine-1(2H)-carboxylate 71b (80 μL). The product was   
purified by column chromatography (0 to 15% EtOAc/hexanes) to afford 113 mg (Yield: 80%) 
of a pale yellow gummy solid 75b. Rf = 0.48 (20% EtOAc/hexanes) 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.54 – 7.42 (m, 2H), 7.30 – 7.24 (m, 2H), 7.20 (dd, J = 6.5, 
1.4 Hz, 1H), 5.52 – 5.20 (m, 1H), 3.70 (dd, 1H), 3.14 (dd, J = 11.8, 2.1 Hz, 1H), 2.99 (s, 4H), 
2.20 – 2.02 (m, 2H), 1.85 – 1.67 (m, 2H), 1.54 (s, 3H), 1.41 (s, 6H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 155.05, 143.00, 137.28, 127.79, 127.32, 126.36, 79.76, 
55.14, 47.74, 46.02, 40.57, 29.98, 28.59, 28.40, 26.09, 24.59. 
FT-IR (neat) cm-1: 3026, 2980, 2951, 2936, 2866, 2781, 1702, 1602, 1507, 1452, 1408, 1363, 
1343, 1293, 1253, 1213, 1159, 905, 751, 726, 701, 671, 432. 
HR-ESI-MS exact mass calculated for C18H25N3O2: m/z 315.19, found: m/z 316.2018 [M+H]+. 
 
1-(4,5-dihydro-1-methyl-5-phenyl-1H-pyrazol-3-yl)pyrrolidin-2-one (75c): Synthesized  
according to the General Procedure A10 using  benzaldehyde 7a (92 μL), 
methylhydrazine 69a (24 μL) and vinylpyrrolidin-2-one 71c (48 μL). 
The product was purified by column chromatography (0 to 45% EtOAc/ 
hexanes) to afford 93 mg (Yield: 85%) of a pale yellow gummy solid 75c. Rf = 0.3 (50% 
EtOAc/hexane) 
1H NMR (300 MHz, CDCl3) δ: 7.57 (d, J = 7.5 Hz, 2H), 7.34 (t, J = 7.4 Hz, 2H), 7.24 (d, J = 7.2 
Hz, 1H), 3.97 (t, J = 3.9 Hz, 1H), 3.43 (t, J = 3.4 Hz, 2H), 2.90 (s, 3H), 2.62 – 2.47 (m, 1H), 2.39 
(t, J = 8.1 Hz, 2H), 2.16 (td, J = 14.6, 7.0 Hz, 1H), 2.02 – 1.90 (m, 2H). 
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13C NMR (75 MHz, CDCl3) δ: 175.91, 147.35, 133.08, 128.56, 127.71, 125.73, 77.46, 77.04, 
76.61, 65.16, 47.20, 37.17, 35.54, 30.98, 18.07. 
FT-IR (neat) cm-1: 2894, 2831, 2782, 1702, 1604, 1492, 1407, 1372, 1260, 1197, 1127, 1092, 
1036, 994, 917, 861, 749, 735, 700, 643, 601, 581, 525, 554, 421 
HR-ESI-MS exact mass calculated for C14H17N3O: m/z 243.14, found: m/z 244.1446 [M+H]+. 
 
2-(4,5-dihydro-1-methyl-5-phenyl-1H-pyrazol-4-yl)ethanol (75d): Synthesized according to 
the General Procedure A10 using  benzaldehyde 7a (92 μL), methylhydrazine 69a (24 μL) and 
2,3-dihydrofuran 71d (34 μL). The product was purified by column 
chromatography (0 to 50% EtOAc/hexanes) to afford 61 mg (Yield: 
67%) of a white gummy solid 75d. Rf = 0.1 (50% EtOAc/hexanes) 
1H NMR (300 MHz, CDCl3, ppm) δ (Diastereomer 1): 7.44 – 7.39 (m, 2H), 7.34 – 7.28 (m, 3H), 
6.94 (s, 1H), 4.01 (d, J = 9.8 Hz, 1H), 3.73 – 3.60 (m, 2H), 3.43 (dd, J = 7.2, 2.9 Hz, 1H), 3.19 
(dd, J = 9.6, 5.5 Hz, 1H), 2.74 (s, 3H), 1.86 (dd, J = 13.8, 6.9 Hz, 1H), 1.41 (ddt, J = 13.9, 9.9, 
6.2 Hz, 1H). 
1H NMR (300 MHz, CDCl3, ppm) δ (Diastereomer 2): 7.35 (d, J = 4.4 Hz, 5H), 6.80 (s, 1H), 
4.01 (d, J = 9.8 Hz, 1H), 3.73 – 3.60 (m, 2H), 3.38 (dd, J = 7.3, 3.4 Hz, 1H), 3.10 (dd, J = 13.2, 
6.5 Hz, 1H), 2.67 (s, 3H), 1.81 – 1.73 (m, 1H), 1.27 – 1.12 (m, 1H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 146.15, 145.34, 139.71, 136.33, 128.73, 128.50, 128.04, 
127.92, 127.64, 60.76, 60.71, 54.43, 48.67, 41.67, 41.21, 33.40, 31.05. 
FT-IR (neat) cm-1: 3365, 2921, 2862, 2787, 1585, 1448, 1046, 744, 703, 636, 535, 443. 
HR-ESI-MS exact mass calculated for C12H16N2O: m/z 204.13, found: m/z 205.1335 [M+H]+. 
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Tert-butyl 3,3a,4,5-tetrahydro-2-methyl-3-p-tolylpyrrolo[2,3-c]pyrazole-6(2H)-carboxylate 
(75h): Synthesized according to the General Procedure A10 using  4-methylbenzaldehyde 7k  
(106 μL), methylhydrazine 69a (24 μL) and tert-butyl 2,3-
dihydropyrrole-1-carboxylate 71a (73 μL). The product was purified 
by column chromatography (0 to 30% EtOAc/hexanes) to afford 106  
mg (Yield: 75%) of a pale yellow gummy solid 75h. Rf = 0.48 (40% EtOAc/hexanes)) 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.21 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 7.0 Hz, 2H), 4.33 (d, J 
= 14.9 Hz, 1H), 4.08 (d, J = 14.9 Hz, 1H), 2.72 (s, 3H), 2.42 (dd, J = 8.4, 5.1 Hz, 1H), 2.34 (s, 
3H), 1.57 – 1.48 (m, 1H), 1.43 (d, J = 6.8 Hz, 2H), 1.37 (s, 9H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 155.50, 138.75, 137.55, 129.30, 129.25, 127.93, 80.06, 
57.57, 48.60, 41.23, 38.43, 28.35, 21.31, 21.15. 
FT-IR (neat) cm-1: 3349, 2976, 2926, 2851, 1706, 1691, 1527, 1512, 1393, 1363, 1253, 1213, 
1169, 905, 751, 726, 671, 421. 
HR-ESI-MS exact mass calculated for C18H25N3O2: m/z 315.19, found: m/z 316.2020 [M+H]+. 
 
(3R,3aR)-tert-butyl 2,3,3a,4,5,6-hexahydro-3-(2-methoxyphenyl)-2-methylpyrazolo[3,4-
b]pyridine-7-carboxylate (75i): Synthesized according to the General Procedure A10 using  2- 
methoxybenzaldehyde 7n (123 mg), methylhydrazine 69a (24 μL) and 
tert-butyl 3,4-dihydropyridine-1(2H)-carboxylate 71b (80 μL). The 
product was purified by column chromatography (0 to 40% EtOAc/ 
hexanes) to afford 93 mg (Yield: 60%) of a pale yellow gummy solid 75i. Rf = 0.3 (40% 
EtOAc/hexane) 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.31 (d, J = 7.4 Hz, 1H), 7.22 (t, J = 7.8 Hz, 1H), 6.88 (td, J 
= 7.4, 0.7 Hz, 1H), 6.78 (d, J = 8.2 Hz, 1H), 3.78 (d, J = 9.8 Hz, 3H), 3.59 (d, J = 13.7 Hz, 1H), 
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3.19 (dd, J = 12.0, 2.3 Hz, 1H), 2.96 (s, 3H), 2.31 (t, J = 13.2 Hz, 1H), 2.03 (s, 1H), 1.77 (dd, J = 
10.2, 3.6 Hz, 2H), 1.59 – 1.49 (m, 1H), 1.39 (s, 3H), 1.31 (s, 6H), 0.94 – 0.76 (m, 1H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 157.52, 154.72, 130.99, 129.40, 128.56, 120.01, 110.22, 
78.74, 77.46, 77.03, 76.61, 55.14, 49.40, 45.79, 41.23, 29.83, 28.27, 26.20, 24.59. 
FT-IR (neat) cm-1: 3085, 2976, 2936, 2931, 2856, 1716, 1691, 1688, 1602, 1502, 1463, 1368, 
1333, 1288, 1253, 1159, 1119, 1054, 1020, 760, 666, 527, 477. 
HR-ESI-MS exact mass calculated for C19H27N3O3: m/z 345.21, found: m/z 345.2199 [M+H]+. 
 
(3S,3aR)-tert-butyl 2,3,3a,4,5,6-hexahydro-3-isobutyl-2-methylpyrazolo[3,4-b]pyridine-7-
carboxylate (75j): Synthesized according to the General Procedure A10 using  3-methylbutanal  
7o (94 μL), methylhydrazine 69a (24 μL) and tert-butyl 3,4-
dihydropyridine-1(2H)-carboxylate 71b (80 μL). The product was 
purified by column chromatography (0 to 12% EtOAc/hexanes) to  
afford 73 mg (Yield: 55%) of a pale yellow gummy solid 75j. Rf = 0.55 (20% EtOAc/hexanes) 
1H NMR (300 MHz, CDCl3) δ: 4.01 (dt, J = 7.0, 5.9 Hz, 1H), 3.03 (t, J = 10.7 Hz, 1H), 2.71 (s, 
3H), 2.39 – 2.29 (m, 1H), 2.16 – 2.02 (m, 1H), 1.82 – 1.72 (m, 1H), 1.67 (dd, J = 10.7, 4.8 Hz, 
1H), 1.65 – 1.57 (m, 2H), 1.49 (d, J = 4.7 Hz, 2H), 1.42 (s, 9H), 1.21 (t, 1H), 0.88 (dd, J = 12.3, 
6.2 Hz, 6H). 
13C NMR (75 MHz, CDCl3) δ: 152.18, 150.17, 81.67, 49.36, 45.20, 42.96, 41.21, 28.41, 28.20, 
25.39, 23.82, 23.08, 22.19. 
FT-IR (neat, cm-1): 3095, 2951, 2926, 2866, 1702, 1627, 1507, 1457, 1406, 1388, 1368, 1343, 
1293, 1268, 1253, 1213, 1154, 905, 850, 751, 731, 666, 567, 457. 
HR-ESI-MS exact mass calculated for C16H29N3O2: m/z 295.23, found: m/z 296.2337 [M+H]+. 
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1-(5-(4-chlorophenyl)-4,5-dihydro-1-methyl-1H-pyrazol-3yl)pyrrolidin-2-one (75m): 
Synthesized according to the General Procedure A10  4-chlorobenzaldehyde 7b (126 mg),  
methylhydrazine 69a (24 μL) and vinylpyrrolidin-2-one 71c (48 μL). 
The product was purified by column chromatography (0 to 46% 
EtOAc/hexanes) to afford 107 mg (Yield: 86%) of a dirty white 
gummy solid 75m. Rf = 0.32 (50% EtOAc/hexanes) 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.39 – 7.29 (m, 4H), 3.88 (d, 2H), 3.81 (dt, 2H), 3.03 (dd, J 
= 19.5, 17.4 Hz, 1H), 2.61 (s, 3H), 2.50 (t, J = 8.1 Hz, 2H), 2.11 (dt, J = 15.6, 8.0 Hz, 2H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 174.26, 174.14, 148.09, 138.20, 137.99, 133.56, 133.31, 
130.02, 128.97, 128.90, 128.78, 46.89, 46.82, 42.66, 42.15, 32.14, 18.25, 17.97. 
FT-IR (neat) cm-1: 3069, 3027, 2985, 2956, 2894, 2831, 2782, 1702, 1604, 1492, 1407, 1372, 
1260, 1197, 1127, 1092, 1036, 994, 917, 861, 749, 735, 700, 643, 601, 581, 525, 554, 421. 
HR-ESI-MS exact mass calculated for C14H16ClN3O: m/z 277.1, found: m/z 278.1099 [M+H]+. 
 
2-((R)-5-(2-fluorophenyl)-4,5-dihydro-1-methyl-1H-pyrazol-4-yl)ethanol (75o): Synthesized 
according to the General Procedure A10  using  2-fluorobenzaldehyde 7q (95 μL), methylhydra-  
zine 69a (24 μL) and 2,3-dihydrofuran 71d (34 μL). The product was 
purified by column chromatography (0 to 50% EtOAc/hexanes) to 
afford 65 mg (Yield: 65%) of a white gummy solid 75o. Rf = 0.15  
(50% EtOAc/hexane) 
1H NMR (300 MHz, CDCl3) δ: 7.58 (td, J = 7.5, 1.8 Hz, 1H), 7.16 – 7.08 (m, 2H), 7.06 – 6.97 
(m, 2H), 6.75 (s, 1H), 3.90 (d, J = 13.4 Hz, 1H), 3.74 – 3.57 (m, 3H), 3.20 – 3.08 (m, 1H), 2.67 
(s, 3H), 1.88 – 1.80 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ: 157.13, 136.75, 128.99, 128.59, 124.45, 115.96, 115.46, 100.85, 
70.28, 60.89, 53.53, 41.64, 33.54, 29.84. 
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19F NMR (282 MHz, CDCl3) δ: -119.58. 
HR-ESI-MS exact mass calculated for C12H15FN2O: m/z 222.12, found: m/z 223.1241 [M+H]+. 
 
(3R,3aR)-3-(4-chlorophenyl)-2,3,3a,4,5,6-hexahydro-2-methylpyrano[2,3-c]pyrazole (75q): 
Synthesized according to the General Procedure A10  4-chlorobenzaldehyde 7b (126 mg),  
methylhydrazine 69a (24 μL) and 3,4-dihydro-2H-pyran 71e (41 
μL). The product was purified by column chromatography (0 to 44% 
EtOAc/hexanes) to afford 80 mg (Yield: 71%) of a white gummy  
solid 75q. Rf = 0.25 (50% EtOAc/hexanes) 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.41 – 7.30 (m, 4H), 4.35 (d, J = 10.7 Hz, 1H), 4.00 – 3.88 
(m, 1H), 3.41 (d, J = 13.5 Hz, 1H), 2.79 (dt, J = 12.0, 6.6 Hz, 1H), 2.57 (s, 3H), 2.08 – 1.96 (m, 
1H), 1.86 – 1.70 (m, 2H), 1.61 – 1.47 (m, 1H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 161.15, 146.13, 133.84, 128.95, 127.78, 126.16, 70.07, 
54.73, 48.46, 43.03, 25.60, 23.07. 
FT-IR (neat) cm-1: 2851, 2781, 1716, 1677, 1637, 1507, 1492, 1463, 1402, 1353, 1333, 1288, 
1213, 1089, 1064, 1014, 995, 930, 905, 840, 825, 751, 721, 666, 481, 422. 
HR-ESI-MS exact mass calculated for C13H15ClN2O: m/z 250.09, found: m/z 251.0946 [M+H]+. 
 
(3R,3aR)-3-(2-fluorophenyl)-2,3,3a,4,5,6-hexahydro-2-methylpyrano[2,3-c]pyrazole (75r): 
Synthesized according to the General Procedure A10  using 2-fluorobenzaldehyde 7q (95 μL),  
methylhydrazine 69a (24 μL) and 3,4-dihydro-2H-pyran 71e (41 μL). 
The product was purified by column chromatography (0 to 40% 
EtOAc/hexanes) to afford 76 mg (Yield: 73%) of a white gummy solid 
75r. Rf = 0.30 (50% EtOAc/hexanes) 
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1H NMR (300 MHz, CDCl3, ppm) δ: 7.55 (td, J = 7.5, 1.7 Hz, 1H), 7.16 (td, J = 7.5, 1.0 Hz, 1H), 
7.09 – 7.02 (m, 1H), 6.91 (s, 1H), 4.22 (d, J = 7.5 Hz, 1H), 3.44 (t, J = 6.4 Hz, 2H), 3.26 – 3.17 
(m, 1H), 2.78 (s, 3H), 1.54 – 1.39 (m, 2H), 1.39 – 1.27 (m, 2H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 159.44, 146.11, 129.02, 128.96, 128.91, 124.24, 124.19, 
123.92, 115.20, 114.92, 68.05, 62.54, 49.76, 41.54, 30.31, 24.44. 
19F NMR (282 MHz, CDCl3) δ: -118.62. 
FT-IR (neat) cm-1: 3419, 2951, 2926, 2856, 2801, 1731, 1622, 1592, 1567, 1487, 1457, 1363, 
1278, 1224, 1114, 1089, 1059, 984, 756, 577, 502, 442. 
HR-ESI-MS exact mass calculated for C13H15FN2O: m/z 234.12, found: m/z 235.1244 [M+H]+. 
 
(3R,3aR)-2,3,3a,4,5,6-hexahydro-3-(4-methoxyphenyl)-2-methylcyclopenta[c]pyrazole 
(75u): Synthesized according to the General Procedure A10  using 4-methoxy benzaldehyde 7l  
(103 μL), methylhydrazine 69a (24 μL) and 
(cyclopentenyloxy)trimethylsilane 71g (160 μL). The product was  
purified by column chromatography (0 to 15% EtOAc/hexanes) to  
afford 86 mg (Yield: 83%) of a yellow gummy solid 75u. Rf = 0.60 (20% EtOAc/hexanes) 
1H NMR (300 MHz, CDCl3) δ: 7.38 – 7.32 (m, 2H), 6.90 – 6.86 (m, 2H), 3.80 (s, 3H), 3.55 (d, J 
= 12.5 Hz, 1H), 2.83 (dd, J = 9.0, 4.3 Hz, 1H), 2.64 (s, 3H), 2.45 – 2.32 (m, 2H), 2.22 – 2.11 (m, 
1H), 2.05 – 1.91 (m, 2H), 1.48 (tdd, J = 11.7, 11.2, 7.8 Hz, 1H). 
13C NMR (75 MHz, CDCl3) δ: 158.13, 157.72, 130.37, 127.54, 125.53, 112.91, 59.85, 54.14, 
41.49, 36.17, 27.57, 25.96. 
FT-IR (neat) cm-1: 3064, 3064, 2953, 2863, 2835, 2773, 1733, 1643, 1616, 1511, 1456, 1435, 
1366, 1290, 1242, 1172, 1109, 1026, 832, 735, 686, 604, 575, 542, 527, 458, 437, 417. 
HR-ESI-MS exact mass calcd for C14H18N2O: m/z 230.14, found: m/z 231.1492 [M+H]+. 
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Tert-butyl 4,5-dihydro-2-methyl-3-phenylpyrrolo[2,3-c]pyrazole-6(2H)-carboxylate (76a). 
Synthesized according to the General Procedure A10 using benzaldehyde 7a (92 μL), methyl  
hydrazine 69a (24 μL) and tert-butyl 2,3-dihydropyrrole-1-carboxylate 
71a (73 μL). The product was purified by column chromatography (0 to 
30% EtOAc/hexanes) to afford 111 mg (Yield: 83%) of a yellow gummy  
solid 76a. Rf = 0.40 (40% EtOAc/hexanes), mp = 187-190 oC. 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.53 – 7.47 (m, 3H), 7.33 – 7.30 (m, 1H), 7.29 (d, J = 1.8 
Hz, 1H), 3.84 (s, 3H), 3.22 (t, J = 6.3 Hz, 2H), 2.59 (t, J = 6.8 Hz, 2H), 1.41 (s, 9H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 155.77, 153.50, 141.20, 138.20, 130.09, 129.75, 128.80, 
128.69, 116.51, 79.12, 41.23, 37.25, 28.39, 24.57. 
FT-IR (neat) cm-1: 2851, 2831, 1696, 1531, 1506, 1476, 1446, 1371, 1337, 1247, 1148, 1048, 
764, 739, 699, 539, 520, 460. 
HR-ESI-MS exact mass calculated for C17H21N3O2: m/z 299.16, found: m/z 300.1707 [M+H]+. 
 
1-(1-methyl-5-phenyl-1H-pyrazol-3-yl)pyrrolidin-2-one  (76b): Synthesized according to the 
General Procedure A10 using benzaldehyde 7a (92 μL), methylhydrazine 69a (24 μL) and 1- 
vinylpyrrolidin-2-one 71c (48 μL). The product was purified by column 
chromatography (0 to 40% EtOAc/hexanes) to afford 81 mg (Yield: 
88%) of a white gummy solid 76b. Rf = 0.20 (50% EtOAc/hexanes) 
1H NMR (300 MHz, CDCl3) δ: 7.44 – 7.34 (m, 5H), 6.89 (s, 1H), 3.96 – 3.89 (m, 2H), 3.77 (s, 
3H), 2.54 (dd, J = 10.1, 6.1 Hz, 2H), 2.18 – 2.06 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ: 173.49, 146.98, 144.63, 135.95, 130.45, 128.78, 128.67, 128.61, 
127.38, 125.75, 96.77, 77.50, 77.08, 76.65, 46.86, 37.17, 32.10, 18.27. 
FT-IR (neat) cm-1: 2950, 2891, 1698, 1547, 1512, 1477, 1458, 1438, 1370, 1286, 1266, 1105, 
1021, 795, 765, 697, 589. 
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HR-ESI-MS exact mass calculated for C14H15N3O: m/z 241.12, found: m/z 242.1292 [M+H]+. 
 
2-(1-methyl-5-phenyl-1H-pyrazol-4-yl)ethanol (76c): Synthesized according to the General 
Procedure A10 using benzaldehyde 7a (92 μL), methylhydrazine 69a (24 μL) and 2,3-dihydro- 
furan 71d (34 μL). The product was purified by column chromatography 
(0 to 46% EtOAc/hexanes) to afford 58 mg (Yield: 67%) of a white 
gummy solid 76c. Rf = 0.2 (50% EtOAc/hexanes) 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.47 (d, J = 7.7 Hz, 3H), 7.42 (d, J = 8.1 Hz, 1H), 7.35 (d, J 
= 4.2 Hz, 1H), 7.34 – 7.29 (m, 2H), 3.75 (s, 3H), 3.69 (t, J = 6.7 Hz, 2H), 2.65 (t, J = 6.6 Hz, 
2H). 
13C NMR (75 MHz, CDCl3, ppm) δ:  138.31, 137.21, 133.50, 129.83, 128.80, 128.75, 128.38, 
127.84, 117.33, 63.12, 37.27, 27.47. 
FT-IR (neat) cm-1: 3382, 3058, 2955, 2920, 2865, 2790, 1586, 1496, 1454, 1262, 1166, 1048, 
973, 732, 704, 415. 
HR-ESI-MS exact mass calculated for C12H14N2O: m/z 202.11, found: m/z 203.1183 [M+H]+. 
 
1-methyl-3,5-diphenyl-1H-pyrazole (76e): Synthesized according to 
the General Procedure A10 7a (92 μL), methylhydrazine 69a (24 μL) 
and (1-phenylvinyloxy)trimethylsilane 71h (173 mg). The product was  
purified by column chromatography (0 to 15% EtOAc/hexanes) to afford 94 mg (Yield: 90%) of 
a white gummy solid 76e. Rf = 0.4 (20% EtOAc/hexanes) 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.80 (dt, J = 3.1, 1.8 Hz, 2H), 7.45 – 7.40 (m, 5H), 7.39 (t, 
J = 1.6 Hz, 1H), 7.36 (dd, J = 6.3, 1.3 Hz, 2H), 6.58 (s, 1H), 3.91 (s, 3H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 150.16, 144.92, 133.02, 130.61, 128.78, 128.69, 128.16, 
127.80, 125.62, 103.29, 77.46, 77.04, 76.62, 37.58. 
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FT-IR (neat) cm-1: 3059, 3025, 2963, 2929, 2860, 1683, 1600, 1572, 1469, 1448, 1393, 1338, 
1304, 1263, 1173, 1097, 1077, 1042, 1022, 801, 760, 726, 691, 601, 512, 430. 
 
Tert-butyl 4,5-dihydro-2-methyl-3-p-tolylpyrrolo[2,3-c]pyrazole-6(2H)-carboxylate (76f): 
Synthesized according to the General Procedure A10 4-methylbenzaldehyde 7k (106 μL), methyl  
hydrazine 69a (24 μL) and tert-butyl 2,3-dihydropyrrole-1-carboxylate 
71a (73 μL). The product was purified by column chromatography (0 
to 30% EtOAc/hexanes) to afford 111 mg (Yield: 79%) of a yellow  
gummy solid 76f. Rf = 0.42 (40% EtOAc/hexanes) 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.43 (s, 1H), 7.29 (s, 1H), 7.17 (d, J = 8.0 Hz, 2H), 3.74 (s, 
3H), 3.20 (dd, J = 6.2 Hz, 2H), 2.55 (t, J = 6.8 Hz, 2H), 2.42 (s, 3H), 1.40 (s, 9H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 156.72, 155.52, 141.59, 138.78, 137.56, 129.39, 128.17, 
126.57, 116.38, 80.05, 57.57, 37.18, 28.19, 24.19, 21.25. 
FT-IR (neat) cm-1: 3349, 2976, 2926, 2851, 1706, 1691, 1527, 1512, 1393, 1363, 1253, 1213, 
1169, 905, 751, 726, 671, 421. 
HR-ESI-MS exact mass calculated for C18H23N3O2: m/z 313.18, found: m/z 314.1873 [M+H]+. 
 
Tert-butyl 4,5-dihydro-3-(2-methocyphenyl)-2- phenylpyrrolo[2,3-c]pyrazole-6(2H)-
carboxylate (76g): Synthesized according to the General Procedure A10 using 2-methoxy  
benzaldehyde 7n (123 μL), phenylhydrazine 69b (24 μL) and tert-
butyl 2,3-dihydropyrrole-1-carboxylate 71a (73 μL). The product was 
purified by column chromatography (0 to 35% EtOAc/hexanes) to  
afford 123 mg (Yield: 70%) of a yellow gummy solid 76g. Rf = 0.3 (40% EtOAc/hexanes) 
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1H NMR (300 MHz, CDCl3, ppm) δ: 7.73 (d, 2H), 7.43 (t, J = 5.9 Hz, 3H), 7.38 (dd, J = 9.7, 1.8 
Hz, 1H), 7.23 (d, J = 7.4 Hz, 1H), 7.05 (d, J = 7.4 Hz, 1H), 6.99 (d, J = 8.3 Hz, 1H), 3.84 (s, 3H), 
3.31 (d, J = 7.8 Hz, 2H), 2.65 (t, J = 6.8 Hz, 2H), 1.41 (s, 9H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 157.21, 140.08, 131.82, 129.94, 129.32, 126.02, 125.64, 
122.42, 120.88, 118.75, 110.95, 79.24, 77.46, 77.04, 76.61, 55.49, 40.82, 28.41, 24.58. 
HR-ESI-MS exact mass calculated for C23H25N3O3: m/z 391.19, found: m/z 392.2001 [M+H]+. 
 
1-(5-(4-chlorophenyl)-1-methyl-1H-pyrazol-3-yl)pyrrolidin-2-one (76h): Synthesized 
according to the General Procedure A10 4-chlorobenzaldehyde 7b (126 μL), methylhydrazine  
69a (24 μL) and 1-vinylpyrrolidin-2-one 68c (48 μL). The product 
was purified by column chromatography (0 to 40% EtOAc/hexanes) 
to afford 68 mg (Yield: 85%) of a brown-yellow gummy solid 76h. 
Rf = 0.40 (50% EtOAc/hexanes) 
1H NMR (300 MHz, CDCl3) δ: 7.48 – 7.30 (m, 4H), 6.92 (s, 1H), 4.00 – 3.90 (m, 2H), 3.78 (s, 
3H), 2.57 (t, J = 8.1 Hz, 2H), 2.24 – 2.10 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ: 173.54, 147.02, 143.43, 134.80, 130.02, 128.98, 128.85, 96.95, 
46.83, 37.17, 32.07, 18.26. 
FT-IR (neat) cm-1: 2950, 2920, 2895, 1701, 1545, 1510, 1479, 1454, 1389, 1363, 1288, 1262, 
1096, 1016, 996, 834, 789, 588. 
HR-ESI-MS exact mass calculated for C14H14ClN3O: m/z 275.08, found: m/z 276.0891 [M+H]+. 
 
1-(5-isobutyl-1-methyl-1H-pyrazol-3-yl)pyrrolidin-2-one (76i): Synthesized according to the  
General Procedure A10 using 3-methylbutanal 7o (94 μL), methyl 
hydrazine 69a (24 μL) and 1-vinylpyrrolidin-2-one 71c (48 μL). The 
product was purified by column chromatography (0 to 25% EtOAc/ 
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hexanes) to afford 58 mg (Yield: 59%) of a brown-yellow gummy solid 76i. Rf = 0.50 (50% 
EtOAc/hexanes) 
1H NMR (300 MHz, CDCl3, ppm) δ: 6.62 (s, 1H), 3.90 (t, J = 7.1 Hz, 2H), 3.70 (s, 3H), 2.54 (t, J 
= 8.1 Hz, 2H), 2.44 (d, J = 7.2 Hz, 2H), 2.21 – 2.06 (m, 2H), 1.92 (dt, J = 13.5, 6.8 Hz, 1H), 0.95 
(d, J = 6.6 Hz, 6H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 173.08, 146.54, 143.31, 96.01, 46.82, 35.86, 34.92, 32.16, 
28.38, 22.48, 18.24. 
FT-IR (neat) cm-1: 2956, 2926, 2971, 1702, 1542, 1492, 1463, 1373, 1288, 1268, 1009, 905, 756, 
732. 
HR-ESI-MS exact mass calculated for C12H19N3O: m/z 221.15, found: m/z 222.1606 [M+H]+. 
 
1-(5-(2-fluorophenyl)-1-methyl-1H-pyrazol-3-yl)pyrrolidin-2-one (76j): Synthesized 
according to the General Procedure A10 using 2-fluorobenzaldehyde 7q (95 μL), methyl  
hydrazine 69a (24 μL) and 1-vinylpyrrolidin-2-one 71c (48 μL). The 
product was purified by column chromatography (0 to 40% 
EtOAc/hexanes) to afford 103 mg (Yield: 89%) of a white gummy  
solid 76j. Rf = 0.32 (50% EtOAc/hexanes) 
1H NMR (300 MHz, CDCl3) δ (Two rotamars are present): 7.48 – 7.34 (m, 4H), 6.94 (d, J = 2.6 
Hz, 1H), 3.97 (dd, J = 8.4, 5.9 Hz, 2H), 3.82 (s, 1H), 3.73 (dd, J = 4.2, 1.5 Hz, 2H), 2.58 (t, J = 
8.1 Hz, 2H), 2.25 – 2.11 (m, 12H). 
13C NMR (75 MHz, CDCl3) δ: 173.47, 146.94, 131.41, 131.04, 128.79, 128.70, 124.42, 115.95, 
97.99, 96.31, 46.86, 36.81, 32.08, 18.28. 
19F NMR (282 MHz, CDCl3) δ:  -113.49. 
HR-ESI-MS exact mass calculated for C14H14FN3O: m/z 259.11, found: m/z 260.1195 [M+H]+. 
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1-(5-(4-methoxyphenyl)-1-methyl-1H-pyrazol-3-yl)pyrrolidin-2-one (76k): Synthesized 
according to the General Procedure A10 using 4-methoxybenzaldehyde 7l (110 μL), methyl  
hydrazine 69a (24 μL) and 1-vinylpyrrolidin-2-one 71c (48 μL). 
The product was purified by column chromatography (0 to 45% 
EtOAc/hexanes) to afford 97 mg (Yield: 80%) of a pale-yellow  
gummy solid 76k. Rf = 0.20 (50% EtOAc/hexanes) 
1H NMR (300 MHz, CDCl3) δ: 7.40 – 7.32 (m, 2H), 7.01 – 6.94 (m, 2H), 6.89 (s, 1H), 4.03 – 
3.93 (t, J = 7.0 Hz, 2H), 3.86 (s, 3H), 3.81 (s, 3H), 2.62 – 2.54 (m, 2H), 2.18 (dt, J = 15.5, 7.7 
Hz, 2H). 
13C NMR (75 MHz, CDCl3) δ: 173.48, 160.35, 159.95, 129.79, 119.60, 114.27, 96.30, 55.14, 
46.97, 36.76, 31.85, 18.03. 
HR-ESI-MS exact mass calculated for C15H17N3O2: m/z 271.13, found: m/z 272.1393 [M+H]+. 
 
2-(5-(2-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)ethanol (76l): Synthesized according to the 
General Procedure A10 using 2-fluorobenzaldehyde 7q (95 μL), methylhydrazine 69a (24 μL)  
and 2,3-dihydrofuran 71d (34 μL). The product was purified by column 
chromatography (0 to 44% EtOAc/hexanes) to afford 76 mg (Yield: 
69%) of a pale yellow gummy solid 76l. Rf = 0.3 (50% EtOAc/hexanes) 
1H NMR (300 MHz, CDCl3) δ: 7.51 – 7.39 (m, 2H), 7.26 (dd, J = 6.2, 2.8 Hz, 1H), 7.19 (t, J = 
11.7 Hz, 1H), 3.70 (s, 3H), 3.66 (d, J = 6.7 Hz, 2H), 2.60 (t, J = 6.7 Hz, 2H), 2.02 – 1.80 (m, 
1H). 
13C NMR (75 MHz, CDCl3) δ: 161.66, 158.34, 138.43, 135.13, 132.13, 131.02, 124.48, 116.36, 
115.44, 62.91, 37.16, 27.39. 
19F NMR (282 MHz, CDCl3) δ: -113.19. 
NN
OH
F
NN
N
OO
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FT-IR (neat) cm-1: 3423, 3337, 2950, 2867, 2791, 1616, 1581, 1491, 1450, 1353, 1256, 1227, 
1172, 1095, 1061, 970, 922, 811, 755, 533, 470, 429. 
HR-ESI-MS exact mass calculated for C12H13FN2O: m/z 220.1, found: m/z 221.1084 [M+H]+. 
 
2-(5-isopropyl-1-methyl-1H-pyrazol-4-yl)ethanol (76m): Synthesized according to the General 
Procedure A10 using isobutyraldehyde 7r (82 μL), methylhydrazine 69a (24 μL) and 2,3- 
dihydrofuran 71d (34 μL). The product was purified by column 
chromatography (0 to 30% EtOAc/hexanes) to afford 58 mg (Yield: 47%) 
of a pale yellow gummy solid 76m. Rf = 0.4 (40) 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.51 (s, 1H), 5.05 (s, 3H), 3.77 (t, J = 8.5, 4.4 Hz, 2H), 2.69 
(t, J = 6.5 Hz, 2H), 2.57 (d, J = 7.3 Hz, 1H), 1.98 (dt, J = 13.5, 6.8 Hz, 1H), 0.95 (s, 3H), 0.92 (s, 
3H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 152.69, 138.36, 136.34, 121.62, 62.52, 41.23, 28.62, 22.06. 
FT-IR (neat) cm-1: 3423, 3020, 2955, 2916, 2871, 2791, 1448, 1213, 1039, 905, 756, 726, 666, 
651, 422. 
HR-ESI-MS exact mass calculated for C9H16N2O: m/z 168.13, found: m/z 169.1335 [M+H]+. 
 
2,4,5,6-tetrahydro-3-(4-methoxyphenyl)-2-methylcyclopenta[c]pyrazole (76n): Synthesized 
according to the General Procedure A10 using 4-methoxybenzaldehyde 7l (110 μL), methyl  
hydrazine 69a (24 μL) and (cyclopentenyloxy)trimethylsilane 71h (141 
mg). The product was purified by column chromatography (0 to 20% 
EtOAc/hexanes) to afford 90 mg (Yield: 88%) of a white gummy solid 
76n. Rf = 0.3 (25% EtOAc/hexanes) 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.76 (d, J = 8.7 Hz, 2H), 6.94 (d, J = 8.8 Hz, 2H), 3.91 (s, 
3H), 3.83 (s, 3H), 2.87 (d, J = 7.0 Hz, 2H), 2.75 (t, 2H), 2.66 (d, J = 7.3 Hz, 2H). 
NN
OH
NN
O
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13C NMR (75 MHz, CDCl3, ppm) δ: 144.53, 139.18, 129.38, 126.98, 126.57, 114.22, 55.15, 
52.72, 45.35, 39.62, 29.42, 24.97, 23.27. 
FT-IR (neat) cm-1: 2773, 1733, 1643, 1616, 1511, 1456, 1435, 1366, 1290, 1242, 1172, 1109, 
1026, 832, 735, 686, 604, 575, 542, 527, 458, 437, 417. 
HR-ESI-MS exact mass calculated for C14H16N2O: m/z 228.13, found: m/z 229.1337 [M+H]+. 
 
7.16 Characterization Data of the Reactive Intermediate 73a and 
Corresponding Amide 81a. 
 
O
N
HN
R1
+
OH
N
N
Ph
Ph
R1
O
N
N
Ph
R1FeCl3 (5 mol%)
rt, air
2 h
Isolated and
Characterized
Isolated, readily 
gets oxidised
[O]
N
N
Ph
R1
Presence of this Cation was Determined
from the Peak at 223.1235 Mass Spectroscopy
7a 70a 73
80a
81a
rt
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Compound 73a: 
OH
N
N
Ph
 
1H NMR (300 MHz, CDCl3) δ: 8.68 (s, 1H), 7.88 – 7.83 (m, 1H), 7.58 (d, J = 7.4 Hz, 2H), 7.46 
(dd, J = 5.1, 1.8 Hz, 2H), 7.35 (d, J = 7.1 Hz, 3H), 7.30 (d, J = 8.7 Hz, 2H), 5.30 (s, 1H), 4.98 (s, 
1H), 2.96 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ: 141.53, 134.42, 128.74, 128.53, 128.19, 127.42, 127.09, 126.42, 
125.70, 125.52, 99.19, 35.51. 
HR-ESI-MS exact mass calcd for C15H16N2O: m/z 223.123, found as C15H15N2 (-H2O): m/z 
223.1235 [M]+. 
 
(E)-N'-benzylidene-N-methylbenzohydrazide (81a): 
O
N
N
Ph
 
1H NMR (300 MHz, CDCl3, ppm) δ: 7.76 (s, 1H), 7.75 – 7.71 (m, 2H), 7.52 – 7.48 (m, 2H), 7.46 
– 7.40 (m, 3H), 7.36 – 7.30 (m, 3H), 3.57 (s, 3H). 
13C NMR (75 MHz, CDCl3, ppm) δ: 171.03, 140.78, 138.78, 135.15, 134.33, 129.79, 128.59, 
126.97, 28.62. 
FT-IR (neat) cm-1: 1685, 1653, 1605, 1573, 1489, 1471, 1444, 1395, 1337, 1306, 1388, 1252, 
1177, 1048, 1025, 938, 879, 789, 754, 714, 696, 665, 603, 567, 513, 420, 402. 
HR-ESI-MS exact mass calcd for C15H14N2O: m/z 238.11, found: m/z 239.1185 [M+H]+. 
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7.17 Mechanistic Proof: Search for Plausible Mechanism-Stepwise Reaction 
Sequences with Two Equivalents of Same and Different Aldehydes. 
O
H
N
NH2 N
H
N
N
H
N
DCM, rt, air
Cu(OTf)2 (20 mol%) No Reaction
DCM or neat
N
O
NN
N
O
O
N
H
N
DCM, rt, air
Cu(OTf)2 (20 mol%)
OH
N
N
-PhCHO
O O O
Product obtained
instead of 76b
7a 69a 73a
73a 71c
7l 73a
76l (26 h, 80 %)7a
NN
N
O
O
N
H
N
DCM, rt, air
Cu(OTf)2 (20 mol%)
OH
N
N
-PhCHO
Product obtained
7a 73a
76b (24 h, 88%)
7a
1.5 h, reflux
DCM, rt
DCM, rt
 
 
7.17a Procedure for Cu(OTf)2-Catalyzed Syntheses of Pyrazoles 76 in a 
Sequential Manner with Two Equivalents of Same Aldehyde. 
 
7.17a General Procedure A11 
To a 10 mL round bottom flask equipped with a magnetic stir bar, was sequentially added 
benzaldehyde 7a (0.45 mmol), CH2Cl2 (0.5 mL) and methylhydrazine 69a (0.45 mmol). The 
resulting mixture was stirred for 1.5 h under refluxing condition. To this, a pre-stirred (30 mints) 
solution of another equivalent of benzaldehyde 7a (0.45 mmol) and Cu(OTf)2 (0.09 mmol, 20 
mol%) in CH2Cl2 (1.5 mL) and a solution of the olefin 71c (0.45 mmol) in CH2Cl2 (0.5 mL) were 
added drop wise in a sequential manner. The resulting reaction mixture was stirred at room 
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temperature in air and monitored periodically by TLC. Upon consumption of the olefin 71c (24 
h), the reaction mixture was concentrated; the residue was dissolved in ethylacetate, washed with 
distilled water and extracted in ethylacetate. The organic layer was dried, concentrated and 
subjected to silica gel chromatography (hexanes/ethylacetate) to give the desired products 76b as 
a single diastereomer in 88 % yield. 
 
7.17b Procedure for Cu(OTf)2-Catalyzed Syntheses of Pyrazoles 76 in a 
Sequential Manner with Two Equivalents of Different Aldehydes. 
 
7.17b General Procedure A12 
To a 10 mL round bottom flask equipped with a magnetic stir bar, was sequentially added 
benzaldehyde 7a (0.45 mmol), CH2Cl2 (0.5 mL) and methylhydrazine 69a (0.45 mmol). The 
resulting mixture was stirred for 1.5 h under refluxing condition. To this, a pre-stirred (30 mints) 
solution of 4-methoxybenzaldehyde 7l (0.45 mmol) and Cu(OTf)2 (0.09 mmol, 20 mol%) in 
CH2Cl2 (1.5 mL) and a solution of the olefin 71c (0.45 mmol) in CH2Cl2 (0.5 mL) were added 
drop wise in a sequential manner. The resulting reaction mixture was stirred at room temperature 
in air and monitored periodically by TLC. Upon consumption of the olefin 71c (22 h), the 
reaction mixture was concentrated; the residue was dissolved in ethylacetate, washed thoroughly 
with distilled water to remove the catalyst and extracted in ethylacetate. The organic layer was 
dried, concentrated and purified on silica to afford a pale yellow gummy solid product as a single 
diastereomer in 80% yield (using hexanes/ethylacetate as the eluants). Characterization of the 
product via NMR and Mass spectroscopy confirmed it as the desired cross-aldehyde product 76l. 
Absence of the product 76b indicated that only the second molecule of the aldehyde (7l here), 
used during the reaction course gave rise to the product. Initial one equivalent of aldehyde (7a 
here) was involved only to produce the active intermediate and at the end of the reaction it gets 
removed from the reaction system. 
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7.17c Mechanistic Proof: IR Studies Showing the Consumption and 
Regeneration of Benzaldehydea  
 
7.17c General Procedure A13 
DCM, rt, air
Cu(OTf)2 (20 mol%)
O
H
N
NH2
NHN
H
H
(2 equiv)
O
O
7a 69a 71e 74c
 
To a 5 mL glass vial equipped with a magnetic stir bar, was sequentially added benzaldehyde 7a 
(0.40 mmol), CH2Cl2 (0.5 mL) and Cu(OTf)2 (0.04 mmol, 20 mol%). The resulting mixture was 
stirred for 15 minutes and the IR spectrum was recorded, showing a sharp band at 1699 cm-1 
corresponding to the carbonyl stretching of the aldehyde (Chapter 4, Figure 3, A). 
Methylhydrazine 69a (0.235 mmol) was then added to the reaction mixture and the IR spectrum 
was recorded, showing a decrease in the relative intensity of the previous carbonyl stretching 
(Chapter 4, Figure 3, B), after 1 h of addition of 69a the sharp band at 1699 cm-1 was found to be 
almost disappeared (Chapter 4, Figure 3, C). Olefin 71e (0.40 mmol) was then added drop wise 
to the reaction mixture and stirred at room temperature in air for 2.0 h and IR spectrum was 
recorded again, showing the reappearance of the peak at 1699 cm-1 (Chapter 4, Figure 3, D). 
After 6 h, again the IS spectrum of the reaction mixture was recorded showing the large increase 
in the relative intensity of the aldehyde peak (Chapter 4, Figure 3, E) and hence supporting the 
removal of aldehyde. 
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8. Appendix 
 
8.1 X-Ray Diffraction Structures 
The data were collected at 123 K using an Oxford Diffraction Cryojet Cooler. The structure was 
solved by direct methods (SIR97) and refined by full-matrix anisotropic least squares 
(SHELXL97). Most of the H-atoms were calculated geometrically and a riding model was used 
during refinement process; the remaining ones were located by difference Fourier syntheses and 
refined isotropically. 
Refinement: Refinement of F2 against ALL reflections. The weighted R-factor wR and goodness 
of fit S are based on F2, conventional R-factors R are based on F, with F set to zero for negative 
F2. The threshold expression of F2 > 2 sigma (F2) is used only for calculating R-factors (gt) etc. 
and is not relevant to the choice of reflections for refinement. R-factors based on F2 are 
statistically about twice as large as those based on F, and R– factors based on ALL data will be 
even larger. 
8.1A Crystal Structure of Compound 10a. 
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Table S1. Crystallographic data and structure refinement parameters for compound 10a.  
Compound 10a V [Å3] 1351.97 (11) 
Formula C25H28N2O4·CHCl3 Ζ 2 
Mr 540.19 ρcalcd [g cm-3] 1.327 
Cryst size[mm] 0.32 × 0.22 × 0.05 µ(Cu Kα) [mm-1] 3.36 
Cryst colour Colourless F(000) 564 
Cryst description Plate reflns collected 9102 
Cryst System Triclinic unique reflns 5060 
Space group P-1 Rint 0.015 
T[K] 123 reflns with I > 2σ(I) 4664 
a [Å] 9.2264 (4) parameters/restraints 339/0 
b [Å] 10.1560 (5) GOF on F 2 1.07 
c [Å] 14.9764 (7) R1 [I > 2σ(I)] 0.049 
α [deg] 82.805 (4) wR2 (all data) 0.133 
β [deg] 76.505 (4) Largest difference 
peak/hole [e Å-3] 
+0.93/-0.69 
γ [deg] 85.408 (4) CCDC number  
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8.1B Crystal Structure of Compound 10b. 
 
Table S2. Crystallographic data and structure refinement parameters for compound 10b 
Compound 10b V [Å3] 1264.82 (11) 
Formula C25H27FN2O4 Ζ 2 
Mr 438.49 ρcalcd [g cm-3] 1.279 
Cryst size[mm] 0.19 × 0.15 × 0.04 µ(Cu Kα) [mm-1] 0.79 
Cryst colour Colourless F(000) 513 
Cryst description Flat prism reflns collected 24718 
Cryst System Triclinic unique reflns 4806 
Space group P-1 Rint 0.019 
T[K] 123 reflns with I > 2σ(I) 4401 
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a [Å] 10.2350 (4) parameters/restraints 299/2 
b [Å] 11.4890 (6) GOF on F 2 1.09 
c [Å] 12.0711 (5) R1 [I > 2σ(I)] 0.037 
α [deg] 102.210 (4) wR2 (all data) 0.099 
β [deg] 112.650 (4) Largest difference 
peak/hole [e Å-3] 
+0.21/-0.18 
γ [deg] 93.355 (4) CCDC number  
 
 
 
8.1C Crystal Structure of Compound 10k. 
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Table S3. Crystallographic data and structure refinement parameters for compound 10k.  
Compound 10k V [Å3] 3148.93 (10) 
Formula C25H27N3O6·2(CHCl3) Ζ 4 
Mr 704.23 ρcalcd [g cm-3] 1.485 
Cryst size[mm] 0.32 × 0.08 × 0.06 µ(Cu Kα) [mm-1] 5.36 
Cryst colour Colourless F(000) 1448 
Cryst description Stick reflns collected 45266 
Cryst System Monoclinic unique reflns 6024 
Space group P21/c Rint 0.063 
T[K] 123 reflns with I > 2σ(I) 5408 
a [Å] 12.1149 (2) parameters/restraints 388/0 
b [Å] 14.3143 (3) GOF on F 2 1.04 
c [Å] 18.2524 (3) R1 [I > 2σ(I)] 0.040 
α [deg] 90.00 wR2 (all data) 0.107 
β [deg] 95.8232 (17) Largest difference 
peak/hole [e Å-3] 
+0.70/-0.77 
γ [deg] 90.00 CCDC number  
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8.1D Crystal Structure of Compound 10n. 
 
Table S4. Crystallographic data and structure refinement parameters for compound 10n.  
Compound 10n V [Å3] 1150.94 (11) 
Formula C23H26N2O5·C2H3N Ζ 2 
Mr 451.51 ρcalcd [g cm-3] 1.303 
Cryst size[mm] 0.62 × 0.12 × 0.09 µ(Cu Kα) [mm-1] 0.75 
Cryst colour Colourless F(000) 480 
Cr st description Stick reflns collected 7492 
Cryst System Triclinic unique reflns 4107 
Space group P-1 Rint 0.023 
T[K] 123 reflns with I > 2σ(I) 3714 
a [Å] 9.7271 (6) parameters/restraints 302/0 
b [Å] 11.1563 (6) GOF on F 2 1.06 
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c [Å] 11.4379 (5) R1 [I > 2σ(I)] 0.045 
α [deg] 101.815 (4) wR2 (all data) 0.127 
β [deg] 103.484 (4) Largest difference 
peak/hole [e Å-3] 
+0.52/-0.56 
γ [deg] 99.621 (5) CCDC number  
 
 
8.1E Crystal Structure of Compound 38a. 
 
Table S5. Crystallographic data and structure refinement parameters for compounds 38a.  
Compound 38a V [Å3] 1376.21 (5) 
Formula C17H14N2O2 Ζ 4 
Mr 278.30 ρcalcd [g cm-3] 1.343 
Cryst size[mm] 0.17 × 0.15 × 0.03 µ(Cu Kα) [mm-1] 0.72 
Cryst colour Colourless F(000) 584 
Cryst description Prism reflns collected 10062 
Cryst System Orthorhombic unique reflns 2673 
Space group P212121 Rint 0.019 
T[K] 123 reflns with I > 2σ(I) 2655 
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a [Å] 5.67652 (13) parameters/restraints 193/0 
b [Å] 7.84185 (14) GOF on F 2 1.11 
c [Å] 30.9161 (5) R1 [I > 2σ(I)] 0.028 
α [deg] 90 wR2 (all data) 0.071 
β [deg] 90 Largest difference 
peak/hole [e Å-3] 
+0.16/-0.23 
γ [deg] 90 CCDC number  
 
 
 
8.1F Crystal Structure of Compound 38j. 
 
Table S6. Crystallographic data and structure refinement parameters for compounds 38j.  
Compound  38j V [Å3] 1006.78 (4) 
Formula C25H22N2O2 Ζ 2 
Mr 382.45 ρcalcd [g cm-3] 1.262 
Cryst size[mm] 0.7676 x 0.1181 x 
0.0883 mm 
µ(Cu Kα) [mm-1] 0.64 
Cryst colour faint yellow F(000) 404 
Cryst description stick Reflns collected 4069 
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Cryst System Monoclinic Unique reflns 2758 
Space group P21 Rint 0.018 
T[K] 123 Reflns with I > 2σ(I) 2640 
a [Å] 12.3990 (3) Parameters/restraints 268/1 
b [Å] 6.6618 (1) GOF on F 2 0.90 
c [Å] 13.1194 (3) R1 [I > 2σ(I)] 0.031 
α [deg] 90 wR2 (all data) 0.088 
β [deg] 111.712 (3) Largest difference 
peak/hole [e Å-3] 
+0.16/−0.15 
γ [deg] 90 CCDC number  
 
 
8.1G Crystal Structure of Compound 75c. 
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Table S7. Crystallographic data and structure refinement parameters for compounds 75c.  
 
Compound 75c V [Å3] 1245.75 (4) 
Formula C14H17N3O Ζ 4 
Mr 243.31 ρcalcd [g cm-3] 1.297 
Cryst size[mm] 0.32 × 0.24 × 0.12 µ(Cu Kα) [mm-1] 0.67 
Cryst colour Colourless F(000) 520 
Cryst description Block reflns collected 6795 
Cryst System Monoclinic unique reflns 2452 
Space group P21/n Rint 0.063 
T[K] 123 reflns with I > 2σ(I) 2149 
a [Å] 11.1353 (2) parameters/restraints 164/0 
b [Å] 7.3686 (1) GOF on F 2 1.11 
c [Å] 15.4910 (3) R1 [I > 2σ(I)] 0.039 
α [deg] 90.00 wR2 (all data) 0.116 
β [deg] 101.454 (2) Largest difference 
peak/hole [e Å-3] 
+0.26/-0.19 
γ [deg] 90.00 CCDC number  
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8.1H Crystal structure of compound 75d. 
 
Table S8. Crystallographic data and structure refinement parameters for compounds 75d.  
 
Compound 75d V [Å3] 1106.4 (2) 
Formula C12H16N2O Ζ 4 
Mr 204.27 ρcalcd [g cm-3] 1.226 
Cryst size[mm] 0.24 × 0.19 × 0.15 µ(Cu Kα) [mm-1] 0.63 
Cryst colour Colourless F(000) 440 
Cryst description Prism reflns collected 4748 
Cryst System Monoclinic unique reflns 2098 
Space group P21/c Rint 0.023 
T[K] 123 reflns with I > 2σ(I) 1756 
a [Å] 10.7781 (13) parameters/restraints 188/2 
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b [Å] 7.3422 (8) GOF on F 2 1.07 
c [Å] 14.0343 (15) R1 [I > 2σ(I)] 0.075 
α [deg] 90.00 wR2 (all data) 0.185 
β [deg] 94.988 (11) Largest difference 
peak/hole [e Å-3] 
+0.29/-0.25 
γ [deg] 90.00 CCDC number  
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8.2 Copies of 1H and 13C NMR spectra 
Compound 10a 
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Compound 10b 
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Compound 10d  
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Compound 10g 
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Compound 10h 
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Compound 10i 
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Compound 10j 
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Compound 10k 
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HN
N
H H
MeO2C
H
H
Boc
S
Appendix	 2012	
 
186 
 
Compound 10m 
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Compound 10p 
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Compound 10r 
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Compound 10s 
 
 
 
HN
N
H H
MeO2C
H
H
Boc
O
Appendix	 2012	
 
193 
 
Compound 11s 
 
 
 
HN
N
H H
MeO2C
H
H
Boc
O
Appendix	 2012	
 
194 
 
Compound 10t 
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Compound 10u 
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Compound 10w 
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Compound 38a 
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Compound 38b 
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Compound 38c 
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Compound 38d 
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Compound 38e  
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Compound 38f 
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Compound 38h 
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Compound 38k 
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Compound 11n 
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Compound 43a (major diastereomer) 
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Compound 43b (major diastereomer) 
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Compound 43c (major diastereomer) 
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Compound 43e (major diastereomer) 
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Compound 43f (major diastereomer) 
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Compound 43g (major diastereomer) 
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Compound 46 (major diastereomer) 
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Compound 74a  
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Compound 75a  
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NN
N
Boc
H
Appendix	 2012	
 
227 
 
Compound 75c  
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Compound 75q  
 
 
 
NN
O
Cl
Appendix	 2012	
 
235 
 
Compound 75r  
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8.3 HPLC data 
8.3A HPLC data for racemic and (+)-38a. 
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8.3B HPLC data for racemic and (+)-38d. 
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8.3C HPLC data for racemic and (+)-38h. 
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Abbreviations 
abs  absolute 
Ar  aryl 
atm.  atmosphere 
BA  Brønsted acid 
Bn  benzyl 
Boc  tert-butyloxycarbonyl 
Bz  benzoyl 
Cbz  carboxybenzyloxy 
dr  diastereomeric ratio 
D-A  donor-acceptor 
DBU 1,8-diazabicyclo[4.4.0] undec-
7-ene 
DCM  dichloromethane 
DMF  dimethyl formamide 
DOS  diversity-oriented synthesis 
ee  enantiomeric excess 
EE  ethylacetate 
EI  electron impact (MS) 
equiv  equivalents 
ESI  electronspray ionization (MS) 
EtOH  ethanol 
Et  ethyl 
etc.  etcetera 
H  hour (s) 
HPLC high performance liquid 
chromatography 
HRMS high resolution mass 
spectrometry 
LA  Lewis acid 
iPr  iso-propyl 
IR  infrared spectroscopy 
M  metal 
MCR  multicomponent reaction 
Me  methyl 
MeCN  acetonitril 
min  minutes 
MS  molecular sieves 
nBu  n-butyl 
NHC  N-heterocyclic carbene 
NMR  nuclear magnetic resonance 
Nu  nucleophile 
nPr  n-propyl 
o-  ortho- 
OAc  acetate 
OTf  triflate 
p-  para 
Ph  phenyl 
quant.  quantitative 
rac  racemic 
rt  room temperature 
tBu  tert-butyl 
TEMPO (2,2,6,6-Tetramethylpiperidin-1-
yl)oxyl 
Tf  trifluormethanesulfonate 
TLC  thin layer chromatography 
TMS  trimethylsilyl 
Ts  tosyl 
UV  ultraviolet 
x  arbitrary number 
X  arbitrary anion 
 
Acknowledgements	 						2012
	
259 
 
Acknowledgements 
 
First, I would like to express my deep and sincere gratitude to my research 
supervisor, Prof. Dr. Oliver Reiser for giving me the opportunity to explore my scientific 
research career. He provided me everything, what I needed to become a well trained 
organic chemist. It was an immense pleasure for me to work under his captivative 
guidance which I will preserve in my heart forever. His vast knowledge and experience, 
helpful suggestions, constructive criticisms and constant encouragement have inspired me 
at every stage of my Ph.D tenure.  
I am very much thankful to Prof. Dr. Axel Jacobi von Wangelin and Prof. Dr. 
Manfred Scheer for being the doctoral committee members and referring my thesis. I also 
thank Prof. Dr. Armin Buschauer for being the Chairman during my Ph.D defense. 
I am also thankful to Prof. Dr. Burkhard König for his several recommendation 
letters, which helped me a lot to extend my DAAD fellowship.  
I deeply acknowledge Prof. Dr. S. Chandrasekaran, I.I.Sc, Bangalore (India), for 
introducing me to the exciting chemistry of D-A substituted cyclopropanes. I am very 
much grateful to Prof. Dr. G. Mugesh, IPC, I.I.Sc, Bangalore (India), for giving me an 
opportunity to carry out my first research career in his laboratory during my M.Sc. 
studies. I would also like to thank Ms. Gunasundari and Dr. S. D. Haveli for their 
constant encouragement and for providing me the practical knowledge of basic organic 
chemistry throughout my research stay at the laboratory of Prof. Dr. S. Chandrasekaran. 
A very warm thank to Dr. Peter Kreitmeier for his constant help and support in all 
the technical aspects and computer problems.  
I thank Dr. Burgermeister, Mr. Kastner, Ms. Schramm, and Ms. Stühler for 
recording NMR spectra; Dr. Manfred Zabel, Dr. Michael Bodensteiner and Mrs. Sabine 
Stempfhuber for recording X-ray crystal data; Mr. Kiermaier, Mr. Söllner and Ms. Prockl 
for recording mass spectra, Ms. Helena Konkel for carrying out the HPLC measurements. 
Without their constant help and support it was impossible for me to carry out my research 
in a successful way. 
 
Acknowledgements	 						2012
	
260 
 
I thank Mr. George Adolin and Mr. Klaus Döring for their technical help. I would 
also like to thank Mrs. Rothermund, Mrs. Weigert and Ms. Ohli for helping me all the 
time in official work. 
I would like to thank Dr. Kartik Mondal, Dr. Georgii Kachkovskyi and Mr. Suva 
Paria not only for bearing the pain of correcting my thesis several times but also for 
giving me valuable suggestions and different perspectives regarding my work. 
I thank all of my friends and the group members of Prof. Reiser for keeping 
friendly atmosphere inside and outside the laboratory. My heartiest thank to Kathrine, 
Suva, Corina, Hana, Andreas Kreuzer, Ludwig, Michael Pirtsch and Thomas for their all 
time support and help during my whole stay in Regensburg. Sometimes, I feel really 
lucky to have friends like Kathrine, Munmun, Iti and Suva; I will be always missing them 
throughout my life. I specially thank all of my Indian friends I have met during my stay at 
Regensburg. We had a lot of fun together with Anu, Selvi, Suva, Ananta, Arpita, Tapan, 
Mouchumi, Maloy, Durga, Senthil, Sunil, Deepak, Datta, Nanaji and Supratim.  
Finally, it’s time to thank my family once again, first of all, I pay my due respect 
and sincere regards to my parents, whose love, blessings and believe are always with me 
for all the accomplishments, I had so far and going to have in future. My mother has been 
protecting me for years like a covering of a bud during the most difficult part of my life 
which no doubt has enabled me to blossom into where I am and what I am today. My 
father always inspired me to proceed along the right tract of my life. He supported me in 
every respect of my life in a distinct way. I feel myself on the top of the world, being able 
to bring their dreams on the earth. I always feel proud of my little sister for her innocence 
and thankful to her for bringing sweet moments all the time in my life. I would like to 
thank my husband and of course the dearest friend Kartik, for all of his support, love and 
encouragement. You are the one who always keeps me grounded and without your 
support and love, it would not have been possible for me to overcome every trial or 
tribulations that have been thrown at me. I am also thankful to my extended family, 
particularly my parents-in-law and Rupali who have looked after me as their dearest one. 
 
Acknowledgements	 						2012
	
261 
 
I am very much grateful to the DAAD (German Academic Exchange Service) for 
the financial assistance throughout my Ph.D period. I thank my refarat Mr. Benedikt V. 
Romberg, Mrs. Anna Wornowski and Mrs. Elisabeth Janzen, for their kind help. 
Last but not the least; to anyone who has supported me on this road, I would like 
to thank you as well. There have been too many names and faces that have passed 
through my life and all of you have helped me to grow just not as a chemist but also as a 
person.  
At the end, I thank you in advance for going through my thesis. It’s an amazing 
feeling, how a three-year long hard work and pain and excitement of new discoveries 
ultimately transform into a doctoral thesis. 
 
Curriculum Vitae       2012
 
262 
 
Curriculum Vitae of Mrs. Sudipta Roy 
 
 
Educational Qualifications: 
 
10/2009 – 12/2012: Ph.D under supervision of  
Prof. Dr. Oliver Reiser 
Institut für Organische Chemie, 
Universität Regensburg, Germany. 
 
06/2009 – 09/2009: German courses at the Goethe-Institut Mannheim 
   Language school German. 
 
04/2009 – 05/2009: German courses at the Goethe-Institut Maxmueller Bhavan 
   New Delhi. 
 
11/2007 - 03/2009: Research project under supervision of 
Prof. Dr. S. Chandrasekaran 
Dept. of Organic Chemistry, 
Indian Institute of Science (IISc), 
Bangalore, India. 
Project Title: ‘Synthetic studies on cyclopropane carboxylate 
derivatives’ 
 
08/2007 – 10/2007: Research project under supervision of 
Dr. Debasish Paul, 
Govt. College of Engineering and Leather Technology, 
Kolkata, India. 
Project Title: ‘Isolation and characterization of 
Proteins and nucleic acids of Halophilic Bacteria’ 
 
Academic Achievements: 
 
• PhD fellowship from DAAD 2009 (Deutscher Akademischer Austausch 
Dienst). 
• GATE 2007 (Graduate Aptitude Test Examination): Qualified (92.00 
percentile) 
 
Scientific Publications: 
 
1. Sudipta Roy and Oliver Reiser*, A Catalytic Multicomponent Approach for 
the Stereoselective Synthesis of Cis-4,5-Disubstituted Pyrrolidinones and 
Tetrahydro-3H-pyrrolo[3,2-c]quinolines, Angew. Chem., Int. Ed. 2012, 51, 
4722. 
DOI: 10.1002/anie.201107831 
 
2. Sudipta Roy and Oliver Reiser*, Highly Regioselective Synthesis of Cis-4,5-
Disubstituted Pyrrolidinones via a Microwave-Assisted Povarov-
Cyclopropane Ring-Opening-Intramolecular Furan Ring Migration Reaction, 
Curriculum Vitae       2012
 
263 
 
Abstracts of Papers, 242nd ACS National Meeting, Denver, Colorado, United 
States, August 28 to September 1st, 2011. 
 
3. Shrutisagar Dattatraya Haveli, Sudipta Roy and Srinivasan Chandrasekaran*, 
Synthesis of Unnatural C-2 Amino Acid Nucleosides Using NIS-Mediated 
Ring  Opening of 1,2-Cyclopropane Carboxylated Sugar Derivatives, Synlett, 
2009, 451. 
DOI: 10.1055/s-0028-1087545 
 
4. Sudipta Roy and Oliver Reiser*, A Regio- and Stereoselective Catalytic 
Multicomponent Approach for Syntheses of Functionalized Tetrahydro-, 
Dihydro- and 1H-Pyrazoles (Manuscript under process). 
        
5. Sudipta Roy and Oliver Reiser*, Recent Developments of Povarov Reaction 
(Review article under process). 
 
 
Presentations: 
 
1. A Catalytic Multicomponent Approach for the Efficient Synthesis 
of Pyrrolidinones and Pyrazolidines (Short Lecture & Poster Presentation) - 
ORCHEM 2012, Weimar, Germany. 
 
2. Catalytic Multicomponent Approaches for the Efficient Syntheses    of 
Pyrrolidinones and Pyrazolidines (Poster Presentation) – A thematic mini-
symposium, June 4-6, 2012, University of Regensburg, Germany. 
 
3. Stereoselective Syntheses of Cis-4,5-Disubstituted Pyrrolidinones: A 
Multicomponent Approach (Oral Presentation), 2011 Weihnachtskolloquium 
der OC, Institut für Organische Chemie, Universität Regensburg, Germany. 
 
4. Highly regioselective synthesis of cis-4,5-disubstituted pyrrolidinones via a     
microwave-assisted Povarov-cyclopropane ring opening-intramolecular furan 
ring migration reaction (Oral Presentation) - 242nd ACS National Meeting, 
Denver, Colorado, United States, August 30th, 2011. 
 
5. Lewis Acid Catalyzed, Microwave-Assisted, One-Pot Rearrangement of β-
Aminocyclopropylcarboxylate Ester: Stereoselective Synthesis of Cis-4,5-
Disubstituted Pyrrolidinones (Poster Presentation) - 6th Heidelberg Forum of 
Molecular Catalysis (2011), Heidelberg, Germany. 
 
 
REFERENCE: Prof. Dr. Oliver Reiser 
Institut für Organische Chemie 
Universität Regensburg 
Universitätsstr. 31 
D‐93053 Regensburg, 
Germany. 
E mail: Oliver.Reiser@chemie.uniregensburg.de 
 
Curriculum Vitae       2012
 
264 
 
Personal Details: Female 
   Marrital status: Married  
   Nationality: Indian 
 
Current Address: C/O Prof. Dr. Oliver Reiser                          
Institut für Organische Chemie,                   
Universität Regensburg,                               
  D-93053 Regensburg, Germany. 
  Universitätsstr. 31,                                  
  E-mail: roy.sudipta12345@gmail.com 
                                                 sudipta.roy@chemie.uni-regensburg.de 
 
Permanent Address: 144 E/1G South Sinthee Road, 
Kolkata-700050, 
West Bengal, India.
Curriculum Vitae       2012 
 
265 
 
 
